UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  November 15, 2017

 

Diplomat Pharmacy, Inc.

(Exact Name of Registrant as Specified in its Charter)

 


 

Michigan
(State or Other Jurisdiction
of Incorporation)

 

001-36677
(Commission File Number)

 

38-2063100
(IRS Employer
Identification No.)

 

4100 S. Saginaw St.

Flint, Michigan 48507

(Address of Principal Executive Offices)  (Zip Code)

 

(888) 720-4450

(Registrant’s Telephone Number, Including Area Code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see  General Instruction A.2. below):

 

o             Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o             Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o             Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o             Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  o

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o  

 

 

 



 

Item 1.01                                            Entry into a Material Definitive Agreement.

 

Purchase Agreement

 

On November 15, 2017 Diplomat Pharmacy, Inc., a Michigan corporation (the “Company”), entered into a Securities Purchase Agreement and Plan of Merger (the “Purchase Agreement”) with LDI Holding Company, LLC, a Delaware limited liability company (“LDI”) and certain indirect equityholders of LDI (the “Sellers”) and Nautic Capital VIII, L.P., a Delaware limited partnership, solely in its capacity as Securityholder Representative (the “Securityholder Representative”).  The Purchase Agreement provides that, upon the terms and conditions set forth therein, the Company will acquire, directly and indirectly, all of the outstanding equity interests of LDI (the “Acquisition”).

 

The purchase price consists of $515 million in cash (the “Closing Cash Consideration”) and approximately $80 million (based on the Company’s current trading price) in shares of the Company’s common stock, no par value (the “Closing Stock Consideration”), to be paid at closing .

 

The Closing Cash Consideration is subject to adjustment at closing for estimated net working capital, indebtedness, cash and Sellers’ expenses, with a final true-up following closing.  In addition, $7.5 million of the Closing Cash Consideration will be held in escrow as security for certain Closing Cash Consideration adjustments.

 

Each recipient of the Closing Stock Consideration will enter into a subscription agreement with the Company. In addition to any restrictions under applicable law, each subscription agreement provides that a holder of the Closing Stock Consideration will be restricted from selling or otherwise transferring (with limited exceptions) the common stock owned by such holder as follows: no sales or transfers for three months following the closing of the Acquisition (“Closing”); sales or transfers of up to 50% of such holder’s Closing Stock Consideration between three and six months following the Closing; and no restrictions after six months following the Closing, in each case subject to limited exceptions.

 

The Purchase Agreement also requires the Company to file a registration statement with the Securities and Exchange Commission for the benefit of the Sellers with respect to the resale of the Closing Stock Consideration.

 

Consummation of the Acquisition by the parties is subject to customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.

 

The Company has obtained buy-side “representation and warranty” insurance, which provides coverage of up to $57 million for certain breaches of representations and warranties of LDI and the Sellers contained in the Purchase Agreement, subject to exclusions, deductibles, and other terms and conditions.  This representations and warranties insurance policy will be the sole recourse of the Company for any breaches of representations and warranties of LDI and Sellers in the Purchase Agreement.

 

The Purchase Agreement also contains specified termination rights for the parties, including if the Acquisition fails to close by December 31, 2017 (provided, that such date may be extended to January 14, 2018 by either party in its sole discretion, except that the Company cannot exercise such extension unless certain Sellers have notified the Company that such extension would not have a specified adverse effect on such Sellers).

 

The foregoing summary of the Purchase Agreement and the transactions contemplated thereby is qualified in its entirety by reference to the Purchase Agreement attached hereto as Exhibit 2.1 and incorporated herein by reference.

 

The representations and warranties in the Purchase Agreement were made for the purposes of allocating contractual risk between the parties to the Purchase Agreement and as of the specified dates noted therein.  Furthermore, such representations and warranties may have been qualified by certain disclosures between the parties and a contractual standard of materiality different from those generally applicable to shareholders, among other limitations. The Company’s shareholders are not third party beneficiaries under the Purchase Agreement and should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or conditions of the Company or of LDI.

 

2



 

Financing of the Acquisition

 

The Company intends to finance the Acquisition with debt financing consisting of a term loan and a revolving loan, together with cash on hand. In connection with entering into the Purchase Agreement, the Company entered into a commitment letter (the “Commitment Letter”), dated as of November 15, 2017, with JPMorgan Chase Bank, N.A. (“JPMorgan”) and Capital One, National Association (“Capital One” and together with JPMorgan, the “Commitment Parties”), pursuant to which, subject to the terms and conditions set forth therein, the Commitment Parties have committed to provide a seven-year senior secured term loan facility and a five-year senior secured revolving credit facility in an aggregate principal amount of up to $795 million (together, the “Facilities”), to fund the consideration for the Acquisition and to pay related fees and expenses, to repay in full any outstanding principal and interest under the Company’s existing credit facility (including the line of credit, Term Loan A and a deferred draw term loan, with an aggregate principal amount outstanding of $127.3 million as of October 31, 2017) and for general corporate purposes. The Facilities also include an incremental facility of $125 million upon the satisfaction of specified conditions.  The Facilities would be guaranteed by substantially all of the Company’s subsidiaries and would be collateralized by substantially all of the Company’s and its subsidiaries’ respective assets, with certain exceptions. In addition, under the Facilities, the Company would pledge the equity of substantially all of its subsidiaries as security for the obligations under the Facilities.

 

The funding of the Facilities provided for in the Commitment Letter is contingent on the satisfaction of customary conditions, including (i) the execution and delivery of definitive documentation with respect to the Facilities in accordance with the terms sets forth in the Commitment Letter, and (ii) the consummation of the Acquisition in accordance with the Purchase Agreement.  The Commitment Letter will terminate upon the earliest of (x) January 14, 2018, (y) if and when the Purchase Agreement is terminated without consummation of the Acquisition and the funding of the Facilities, and (z) if and when the consummation of the Acquisition occurs with or without use of the Facilities.

 

The foregoing description of the Commitment Letter and the transactions contemplated thereby is qualified in its entirety by reference to the Commitment Letter attached hereto as Exhibit 10.1 and incorporated herein by reference.

 

Item 3.02                                            Unregistered Sales of Equity Securities.

 

The information regarding the Acquisition set forth under “Purchase Agreement” in Item 1.01 is incorporated herein by reference.

 

The Closing Stock Consideration (approximately 4.2 million shares) will be issued and sold in connection with the Acquisition pursuant to exemptions from registration under Section 4(a)(2) of the Securities Act of 1933, as amended, and/or Rule 506 of Regulation D promulgated thereunder by the Securities and Exchange Commission.  The issuance and sale of securities as described above will not involve a public offering and will be made without general solicitation or advertising.  Furthermore, the Sellers’ have represented, or will represent, among other things, that such persons are accredited investors (as defined under Rule 501 of Regulation D).

 

Item 7.01                                            Regulation FD Disclosure.

 

On November 15, 2017 the Company issued a press release announcing that it had executed the Purchase Agreement and related matters, which press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The press release includes a link to additional information regarding the Acquisition, which information is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

 

The information contained in this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

3



 

Item 9.01                                            Financial Statements and Exhibits.

 

(d)                                  Exhibits

 

No.

 

Description

2.1

 

Securities Purchase Agreement and Plan of Merger by and among Diplomat Pharmacy, Inc., LDI Holding Company, LLC and the other parties named therein, dated November 15, 2017*

 

 

 

10.1

 

Commitment Letter by and among Diplomat Pharmacy, Inc., JPMorgan Chase Bank, N.A., and Capital One, National Association dated November 15, 2017

 

 

 

99.1

 

Company press release dated November 15, 2017

 

 

 

99.2

 

Additional information regarding the pending acquisition of LDI

 


* Certain exhibits and schedules to this agreement have been omitted in accordance with Item 601(b)(2) of Regulation S-K. A copy of any omitted exhibits and schedules will be furnished to the Securities and Exchange Commission upon request.

 

4



 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Diplomat Pharmacy, Inc.

 

 

 

 

 

 

 

By:

/s/ Philip R. Hagerman

 

 

Philip R. Hagerman

 

 

Chief Executive Officer

 

Date: November 16, 2017

 

5


Exhibit 2.1

 

EXECUTION VERSION

 

SECURITIES PURCHASE AGREEMENT AND PLAN OF MERGER

 

BY AND AMONG

 

DIPLOMAT PHARMACY, INC.,

 

AS THE PURCHASER,

 

LEEWARD MERGER SUB LLC,

 

AS MERGER SUB,

 

LDI HOLDING COMPANY, LLC,

 

AS THE COMPANY,

 

NAUTIC PARTNERS VII, L.P.,

 

NAUTIC PARTNERS VII-A, L.P.,

 

NAUTIC PARTNERS VIII-A, L.P.,

 

OAK HC/FT PARTNERS L.P.,

 

AS THE BLOCKER SELLERS,

 

NAUTIC VIII, L.P.,

 

AND

 

NAUTIC CAPITAL VIII, L.P.,

 

AS SECURITYHOLDER REPRESENTATIVE

 

Dated as of November 15, 2017

 



 

TABLE OF CONTENTS

 

 

 

 

PAGE

 

 

ARTICLE I THE SECURITIES PURCHASE AND THE MERGER

6

 

 

1.1

 

Sale and Purchase of Blockers’ Equity

6

1.2

 

The Merger

6

1.3

 

Certificate of Merger

6

1.4

 

Effect of Merger

7

1.5

 

Certificate of Formation

7

1.6

 

Limited Liability Company Agreement

7

1.7

 

Closing

7

1.8

 

Deliveries at Closing

7

1.9

 

Managers

10

1.10

 

Effect on Capital Structure; Transaction Consideration

10

 

 

 

 

ARTICLE II PAYMENTS FOR SECURITIES

10

 

 

 

 

2.1

 

Payments at the Closing

10

2.2

 

Delivery of Funds Procedures

12

2.3

 

Estimated Closing Statement; Post-Closing Purchase Price Adjustment

12

2.4

 

Escrow Account; Securityholder Expense Amount Holdback

17

2.5

 

Payment of Additional Payments

18

2.6

 

Allocation of Purchase Price

18

 

 

 

 

ARTICLE III REPRESENTATIONS AND WARRANTIES OF THE COMPANY

19

 

 

 

 

3.1

 

Status; Authority; Conflicts

19

3.2

 

Capitalization of the Company

20

3.3

 

Subsidiaries

20

3.4

 

Financial Statements

21

3.5

 

Title to Assets

22

3.6

 

Real Property

22

3.7

 

Absence of Certain Changes and Events

23

3.8

 

Taxes

25

3.9

 

Employees and Employee Benefits

28

3.10

 

Compliance with Laws; Permits

30

3.11

 

Legal Proceedings; Orders

30

3.12

 

No Undisclosed Liabilities

31

3.13

 

Accounts Receivable and Payable

31

3.14

 

Contracts

31

3.15

 

Environmental Matters

33

3.16

 

Employment and Labor Matters

34

3.17

 

Intellectual Property

36

3.18

 

Customers and Suppliers

39

3.19

 

Healthcare Regulatory Compliance

40

 



 

3.20

 

Related Party Transactions

41

3.21

 

Brokers and Finders

41

3.22

 

Insurance

41

3.23

 

Service Liability Claims

42

3.24

 

Officers and Managers; Bank Accounts

42

3.25

 

Books and Records

42

3.26

 

No Other Representations and Warranties

42

 

 

 

 

ARTICLE IV REPRESENTATIONS AND WARRANTIES OF BLOCKER SELLERS

43

 

 

 

 

4.1

 

Status; Authority; Conflicts

43

4.2

 

Title

44

4.3

 

Blocker Capitalization

44

4.4

 

Brokers or Finders

45

4.5

 

Blockers

45

4.6

 

No Other Representations and Warranties

48

 

 

 

 

ARTICLE V REPRESENTATIONS AND WARRANTIES OF THE PURCHASER

49

 

 

 

 

5.1

 

Organization

49

5.2

 

Authority and Validity

49

5.3

 

No Violation

49

5.4

 

Litigation

50

5.5

 

Brokers or Finders

50

5.6

 

Financing

50

5.7

 

Solvency

51

5.8

 

SEC Filings; Financial Statements

51

5.9

 

Legal Compliance; NYSE Requirements

52

5.10

 

Absence of Certain Changes or Events

52

5.11

 

S-3 Eligibility; Registration Statement

52

5.12

 

Capitalization and Related Matters

53

5.13

 

No Other Representations

53

5.14

 

Due Diligence Investigation; No Other Representations

54

 

 

 

 

ARTICLE VI ADDITIONAL AGREEMENTS

54

 

 

 

 

6.1

 

Publicity

54

6.2

 

Commercially Reasonable Efforts; Notices and Consents

55

6.3

 

Conduct of Business

56

6.4

 

Non-Solicit; Confidentiality

58

6.5

 

Exclusivity

61

6.6

 

Liquidity of Purchaser Common Stock

61

6.7

 

Employee Related Matters

62

6.8

 

Director and Officer Indemnification and Insurance

64

6.9

 

Access to Information

64

6.10

 

Preservation of Records

65

 

2



 

6.11

 

Dissolution of Nautic VIII-A Splitter

66

6.12

 

Financing Cooperation

66

6.13

 

Registration Statement

67

6.14

 

Audited Financial Statements

68

6.15

 

Other Seller Agreements

69

 

 

 

 

ARTICLE VII CONDITIONS TO CLOSING

69

 

 

 

 

7.1

 

Conditions to Obligations of Each Party

69

7.2

 

Conditions to Obligations of the Purchaser

69

7.3

 

Conditions to Obligations of the Company

71

 

 

 

 

ARTICLE VIII CERTAIN TAX MATTERS

71

 

 

 

 

8.1

 

Tax Matters

71

 

 

 

 

ARTICLE IX TERMINATION

73

 

 

 

 

9.1

 

Termination Events

73

9.2

 

Effect of Termination

75

 

 

 

 

ARTICLE X MISCELLANEOUS

76

 

 

 

 

10.1

 

Defined Terms

76

10.2

 

Nonsurvival of Representations, Warranties and Agreements

92

10.3

 

Notices

93

10.4

 

Titles; References

94

10.5

 

Supplement to Disclosure Schedules

94

10.6

 

Entire Agreement; Mutual Drafting

95

10.7

 

Assignment

95

10.8

 

Amendment or Modification

96

10.9

 

Waiver

96

10.10

 

Securityholder Representative

96

10.11

 

Severability

99

10.12

 

Governing Law

99

10.13

 

Waiver of Trial by Jury

99

10.14

 

Consent to Jurisdiction

99

10.15

 

Specific Performance

100

10.16

 

Non-Recourse

101

10.17

 

No Third Party Beneficiaries

101

10.18

 

Cumulative Remedies

102

10.19

 

Expenses

102

10.20

 

Waiver of Conflicts; Privilege

102

 

3



 

10.21

 

Time of the Essence

104

10.22

 

Counterparts

104

 

4



 

SCHEDULES

Schedule I

-

 

Disclosure Schedules

 

 

 

 

EXHIBITS

Exhibit A

-

 

Form of Certificate of Merger

Exhibit B

-

 

Escrow Agreement

Exhibit C

-

 

Form of Letter of Transmittal

Exhibit D

-

 

Form of Restrictive Covenant Agreement

Exhibit E

-

 

Financing Letters

Exhibit F

-

 

Form of Other Seller Agreement

Exhibit G

-

 

Form of Subscription Agreement

Exhibit H

-

 

Form of Paying Agent Agreement

 

5



 

SECURITIES PURCHASE AGREEMENT AND PLAN OF MERGER

 

This SECURITIES PURCHASE AGREEMENT AND PLAN OF MERGER, dated as of November 15, 2017 (this “ Agreement ”), is by and among by and among (i) Diplomat Pharmacy, Inc., a Michigan corporation (the “ Purchaser ”), (ii) Leeward Merger Sub LLC, a Delaware limited liability company and a wholly-owned subsidiary of the Purchaser (“ Merger Sub ”), (iii) LDI Holding Company, LLC, a Delaware limited liability company (the “ Company ”), (iv) Nautic Partners VII, L.P., a Delaware limited partnership, (v) Nautic Partners VII-A, L.P., a Delaware limited partnership, (vi) Nautic Partners VIII-A, L.P., a Delaware limited partnership,  and (vii) Oak HC/FT Partners L.P., a Delaware limited partnership (each of (iv), (v), (vi), and (vii), a “ Blocker Seller ”, and together, the “ Blocker Sellers ”), (viii) Nautic Capital VIII, L.P., a Delaware limited partnership, solely in its capacity as the Securityholder Representative (the “ Securityholder Representative ”) and (ix) Nautic Partners VIII, L.P., a Delaware limited partnership, solely for purposes of its obligations under Section 6.4 .  The Purchaser, Merger Sub, the Company, the Blocker Sellers and the Securityholder Representative are each referred to herein as a “Party” and collectively as the “Parties”.

 

RECITALS

 

WHEREAS , the Purchaser desires to acquire (i) all of the issued and outstanding limited liability company interests of the Company (other than the Blockers’ Units) through a merger of Merger Sub with and into the Company, with the Company continuing as the surviving limited liability company, and (ii) the remaining issued and outstanding limited liability company interests of the Company indirectly through the purchase of the Blockers’ Equity from the Blocker Sellers;

 

WHEREAS , (i) the board of managers of the Company (the “ Company Board ”) has, in accordance with the Delaware Limited Liability Company Act (as amended from time to time, the “ DLLCA ”) and the Company LLC Agreement, approved, (ii) the general partner, board of managers or board of directors, as applicable, of each Blocker Seller has approved, and (iii) the members of the Company representing at least a majority in voting interest of the Company have, in accordance with the DLLCA and the Company LLC Agreement, approved this Agreement and, subject to the conditions set forth herein, the Transaction;

 

WHEREAS , the board of directors of the Purchaser and the Purchaser, in its capacity as the sole member and manager of Merger Sub, have each approved and consented to the Merger, the execution and delivery by the Purchaser and Merger Sub of this Agreement and, subject to the conditions set forth herein, the consummation of the Transactions in accordance with the DLLCA as well as all other applicable Laws; and

 

WHEREAS , as an inducement for the Purchaser to enter into the Transactions, each of Leonard S. Dino, Jr., Albert Thigpen, and David M. Byrne has entered into the Restrictive Covenant Agreement, substantially in the form attached hereto as Exhibit D , to be effective as of, but contingent on the occurrence of, the Closing.

 

6



 

AGREEMENT

 

In consideration of the mutual covenants and promises contained herein and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Parties agree as follows:

 

ARTICLE I
THE SECURITIES PURCHASE AND THE MERGER

 

1.1                                Sale and Purchase of Blockers’ Equity .  On the Closing Date, immediately prior to the Effective Time and immediately following the dissolution of LDI Nautic VIII-A Splitter, L.P. (“ Nautic VIII-A Splitter ”), pursuant to Section 6.11 , each Blocker Seller, severally and not jointly, shall sell and transfer (or cause to be sold and transferred) to the Purchaser, and the Purchaser shall purchase from each Blocker Seller, all of the Blockers’ Equity held by such Blocker Seller, free and clear of all Liens (other than those imposed by or arising out of state or federal securities laws), for a purchase price equal to the sum of (i) a portion of the Transaction Consideration attributable to the applicable Blockers’ Equity, and (ii) a contingent right to receive a portion of the Additional Payment, if any, distributable thereto pursuant to Section 2.5 , in each case in accordance with the Allocation Statement.  The portion of the Transaction Consideration payable by the Purchaser to each Blocker Seller at the Closing in exchange for its Blockers’ Equity shall be (i) allocated as between the Cash Consideration and the Stock Consideration as set forth in the Allocation Statement, and (ii) equal to the portion of the Transaction Consideration that would have been allocable to the Blockers’ Units held by the Blocker owned by such Blocker Seller in accordance with the Allocation Statement).  Any portion of the Additional Payment, if any, payable to a Blocker Seller shall be payable in cash in accordance with terms hereof. The purchase and sale of Blockers’ Equity described in this Section 1.1 shall be referred to in this Agreement as the “ Securities Purchase ”.

 

1.2                                The Merger .  On the terms and subject to the conditions contained herein, at the Effective Time, Merger Sub shall, pursuant to the provisions of the DLLCA, be merged with and into the Company (the “ Merger ”), and the separate entity existence of Merger Sub shall thereupon cease in accordance with the provisions of the DLLCA.  The Company shall be the surviving limited liability company in the Merger and shall continue to exist as the surviving limited liability company under its present name pursuant to the provisions of the DLLCA.  The separate existence of the Company with all its rights, privileges, powers and franchises shall continue unaffected by the Merger.  The Merger shall have the effects specified in the DLLCA.  From and after the Effective Time, the Company shall be referred to herein as the “ Surviving Company ”.

 

1.3                                Certificate of Merger .  On the Closing Date and in connection with the Closing, the Parties shall cause a certificate of merger in the form of Exhibit A attached hereto (the “ Certificate of Merger ”) to be properly executed and filed in accordance with the DLLCA with the Secretary of State of the State of Delaware.  The Merger shall be effective at the time (the “ Effective Time ”) and on the date of the filing of the Certificate of Merger in accordance with the DLLCA.

 

7



 

1.4                                Effect of Merger .  At the Effective Time, the effect of the Merger shall be as provided in the applicable provisions of the DLLCA.  Without limiting the generality of the foregoing, and subject thereto, at the Effective Time by virtue of the Merger and without any action on the part of Merger Sub or the Company, all of the property, rights, privileges, powers and franchises of the Company and Merger Sub shall vest in the Surviving Company, and all debts, liabilities and duties of the Company and Merger Sub shall become the debts, liabilities and duties of the Surviving Company.

 

1.5                                Certificate of Formation .  At the Effective Time by virtue of the Merger and without any action on the part of Merger Sub or the Company, the certificate of formation of Merger Sub in effect immediately prior to the Effective Time will become the certificate of formation of Surviving Company, except that the name of the Surviving Company will be “LDI Holding Company, LLC” until thereafter changed or amended as provided therein or under applicable Law.

 

1.6                                Limited Liability Company Agreement .  Subject to the provisions of Section 6.8 , the limited liability company agreement of the Surviving Company shall be amended and restated at and as of the Effective Time in a form acceptable to Purchaser.  Such amended and restated limited liability company agreement shall be the limited liability company agreement of the Surviving Company until amended in accordance with applicable Law.

 

1.7                                Closing .  Subject to the terms and conditions of this Agreement, the closing of the Transactions (the “ Closing ”) shall take place at 10:00 a.m., Eastern Time, at the offices of Goodwin Procter LLP, 100 Northern Avenue, Boston, MA 02210, no later than two (2) Business Days following the satisfaction or waiver of all conditions precedent specified under Article VII hereof (except for those conditions which by their terms are to be satisfied at the Closing but subject to the satisfaction or waiver of such conditions), or such other date, place and time as the Parties may agree in writing (the “ Closing Date ”); provided , however , that in no event shall the Closing Date be earlier than the date that is thirty (30) days following the date of this Agreement without the prior written consent of the Purchaser and the Company.

 

1.8                                Deliveries at Closing .

 

(a)                                  At (or prior to) the Closing, the Company shall deliver (or cause to be delivered) to the Purchaser:

 

(i)                                      an officer’s certificate, dated as of the Closing Date, duly executed by an authorized officer of the Company (in his or her capacity as such and not in his or her individual capacity), relating to the satisfaction of the Closing conditions set forth in Section 7.2(a)  and Section 7.2(b) ;

 

(ii)                                   the Estimated Closing Statement and the Allocation Statement, each duly executed by an authorized officer of the Company;

 

(iii)                                the following certifications: (A) a certificate from the Company in a form and substance compliant with Treasury Regulations Section 1.1445-11T(d)(2), certifying that fifty percent or more of the value of the gross assets of the Company does not consist of “United States real property interests” (as defined in Section 897(c)(1)(A) of the Code) and that the Person executing such certificate is a general partner of the Company within the meaning of such Section of the Treasury Regulations, and (B) a statement from each Blocker issued to Purchaser, pursuant to Treasury Regulations Sections 1.897-2(h), certifying that none of such Blocker Seller’s Blocker Equity is a U.S. real property interest, along with (1) a form of notice to the Internal Revenue Service, prepared and executed before (but no more than 30 days before) the Closing by a responsible corporate officer of such Blocker and otherwise in accordance with the requirements of Treasury regulation Section 1.897-2(h) and 1.1445-2(c)(3), certifying that none of such Blocker’s Blocker Equity is a “United States real property interest” (as defined in Section 897(c)(1)(A) of the Code), (2) a form of notice to the IRS, prepared and executed before (but no more than 30 days before) the Closing by a responsible corporate officer of such Blocker and otherwise in accordance with the requirements of Treasury Regulations Section 1.897(2)(h)(5) and in form and substance reasonably acceptable to Purchaser, (3) any supplemental statement(s) required by Treasury Regulations Section 1.897-2(h)(5) and (4) written authorization for Purchaser to deliver such notice form(s) to the IRS on behalf of such Blocker upon the Closing;

 

8



 

(iv)                               payoff letters in respect of Indebtedness to be repaid at Closing and authorization to release all Liens related thereto (other than Permitted Liens);

 

(v)                                  evidence reasonably acceptable to the Purchaser of the balances (including invoices from Houlihan Lokey, Inc., Goodwin Procter LLP and BDO USA, LLP and estimates from Phoenix Law Group) for all items composing Selling Expenses and Closing Indebtedness;

 

(vi)                               evidence reasonably acceptable to the Purchaser of the termination of the Equity Incentive Plan, and all Contracts with any (A) Affiliate of the Company or the Subsidiary (including without limitation, all management services agreements), and (B) broker, finder or agent related to, or entered into in connection with, the Transactions;

 

(vii)                            certificates of good standing showing that the Company and the Subsidiary are duly formed, validly existing and in good standing in each jurisdiction in which the Company and the Subsidiary are required to be qualified to conduct business, each dated within 15 Business Days prior to the Closing Date;

 

(viii)                         officers’ certificates, dated as of the Closing Date, duly executed by an authorized officer of each of the Company and the Subsidiary (in his or her capacity as such and not in his or her individual capacity), certifying: (a) that the Governing Documents of the Company and the Subsidiary (which are to be attached to the certificate) are true and correct as of the Closing Date, (b) the names and signatures of the officers authorized to sign this Agreement and the Transaction Documents, and (c) the resolutions of the board of managers and members of the Company and the Subsidiary authorizing the Transactions;

 

(ix)                               those Consents set forth on Schedule 1.8(a)(ix) ; and

 

(x)                                  written resignations, effective as of the Closing Date, of all of the members of the Company Board, any managers of the Subsidiary and any officers of the Company or Subsidiary.

 

(b)                                  At the Closing, each of the Blocker Sellers shall deliver (or cause to be delivered) to the Purchaser:

 

9



 

(i)                                      certificates of good standing showing that the Blockers are duly formed, validly existing and in good standing in the State of Delaware, each dated within 15 Business Days prior to the Closing Date;

 

(ii)                                   officers’ certificates, dated as of the Closing Date, duly executed by an authorized officer of each of the Blockers (in his or her capacity as such and not in his or her individual capacity), certifying: (a) that the Blockers’ Organizational Documents, as applicable (which are to be attached to the certificate) are true and correct as of the Closing Date, and (b) the resolutions of the board of directors and stockholders of the Blockers authorizing the Transactions;

 

(iii)                                Stock certificates, representing the Blockers’ Equity, accompanied with assignments separate from certificate (or other instruments of transfer), duly endorsed in blank and otherwise in the proper form for transfer or affidavits of lost certificates and indemnity agreements;

 

(iv)                               written resignations, effective as of the Closing Date, of all of the members of the board of directors and officers of the Blockers; and

 

(v)                                  an officer’s certificate, dated as of the Closing Date, duly executed by an authorized officer of the applicable Blocker Seller (in his or her capacity as such and not in his or her individual capacity), relating to the satisfaction of the Closing conditions set forth in Section 7.2(c)  and Section 7.2(d)  with respect to such Blocker Seller.

 

(c)                                   At the Closing, the Securityholder Representative shall deliver (or cause to be delivered) to the Purchaser:

 

(i)                                      the Escrow Agreement, duly executed by the Securityholder Representative;

 

(ii)                                   the Paying Agent Agreement, duly executed by the Securityholder Representative. ; and

 

(iii)                                the Subscription Agreements, duly executed by Securityholders representing at least 95% of the Eligible Equity.

 

(d)                                  At the Closing, the Purchaser shall deliver (or cause to be delivered) to the Company:

 

(i)                                      an officer’s certificate, dated as of the Closing Date, duly executed by an authorized officer of the Purchaser (in his or her capacity as such and not in his or her individual capacity), relating to the satisfaction of the Closing conditions set forth in Section 7.3(a)  and Section 7.3(b) ;

 

(ii)                                   the Escrow Agreement, duly executed by a duly authorized officer of the Purchaser and the Escrow Agent; and

 

10



 

(iii)                                the Paying Agent Agreement, duly executed by a duly authorized officer of the Purchaser and the Paying Agent.

 

1.9                                Managers .  As of the Effective Time, the manager(s) of Merger Sub immediately prior to the Effective Time shall be the manager(s) of the Surviving Company and will serve as such until their successors are duly elected or appointed and will qualify in the manner provided in the certificate of formation or limited liability company agreement of the Surviving Company or as otherwise provided by Law, or until their earlier death, resignation or removal.

 

1.10                         Effect on Capital Structure; Transaction Consideration .

 

(a)                                  Merger Sub Limited Liability Company Interests .  As of the Effective Time, the limited liability company interests of Merger Sub issued and outstanding immediately prior to the Effective Time shall, by virtue of the Merger and without any action on the part of Merger Sub, be converted into limited liability company interests in the Surviving Company.

 

(b)                                  Company Limited Liability Company Interests .  As of the Effective Time, by virtue of the Merger and without any action on the part of any holder thereof or any Party, each Unit (other than the Blockers’ Units) shall be canceled and converted into the right to receive (i) a portion of the Transaction Consideration (which, for the avoidance of doubt, will vary depending on the class of such Unit) attributable to such Units in accordance with the Company LLC Agreement, and (ii) a contingent right to receive a portion of the Additional Payment, if any, distributable thereto pursuant to Section 2.5 , in each case in accordance with the Allocation Statement.  The portion of the Transaction Consideration allocable to each such holder shall be allocated as between the Cash Consideration and the Stock Consideration as set forth in the Allocation Statement and any portion of the Additional Payment, if any, payable to such holders shall be payable in cash in accordance with the terms hereof.

 

ARTICLE II
PAYMENTS FOR SECURITIES

 

2.1                                Payments at the Closing .

 

(a)                                  Closing Date Payment .  At the Closing, the Purchaser shall (i) pay (or cause to be paid) to the Paying Agent in consideration of both the Securities Purchase and the Merger in the aggregate, for further distribution to the Sellers in accordance with the Allocation Statement, (i) an aggregate cash amount (the “ Cash Consideration ”) equal to (A) $515,000,000, plus (B) the Closing Cash, plus (C) the Net Working Capital Surplus, if any, minus (D) the Net Working Capital Deficit, if any, minus (E) the Closing Indebtedness, minus (F) the Selling Expenses, minus (G) the Securityholder Expense Amount, minus (H) the Escrow Amount, and (ii) issue to the Sellers, in accordance with the Subscription Agreements, a number of shares of common stock of Purchaser, no par value (the “ Purchaser Common Stock ”) equal to the greatest of (A) $70,000,000 (the “ Stock Consideration Value ”) divided by the closing price of a share of Purchaser Common Stock on the New York Stock Exchange on the Business Day prior to the date hereof, (B) the Stock Consideration Value divided by the lowest of the volume-weighted average closing price of a share of Purchaser Common Stock on the New York Stock Exchange

 

11



 

for (1) the ten (10) trading days immediately prior to the date hereof, (2) the thirty (30) trading days immediately prior to the date hereof, (3) the sixty (60) trading days immediately prior to the date hereof, (4) the ninety (90) trading days immediately prior to the date hereof or (5) the one hundred eighty (180) trading days immediately prior to the date hereof, (C) the Stock Consideration Value divided by the lowest of the volume-weighted average closing price of a share of Purchaser Common Stock on the New York Stock Exchange on the Business Day prior to the Closing Date or (D) the Stock Consideration Value divided by the lowest of the volume-weighted average closing price of a share of Purchaser Common Stock on the New York Stock Exchange for (1) the ten (10) trading days immediately prior to the Closing Date, (2) the thirty (30) trading days immediately prior to the Closing Date, (3) the sixty (60) trading days immediately prior to the Closing Date, (4) the ninety (90) trading days immediately prior to the Closing Date or (5) the one hundred eighty (180) trading days immediately prior to the Closing Date (such number of shares, the “ Stock Consideration ” and, together with the Cash Consideration, the “ Transaction Consideration ”), allocated amongst the Sellers in accordance with the Allocation Statement.  Schedule 2.1(a)  sets forth an example calculation of the determination of Stock Consideration Value as if the Closing Date were the date hereof.

 

(b)                                  Securityholder Expense Amount .  At the Closing, the Purchaser shall deposit (or cause to be deposited) with the Securityholder Representative, a cash amount, by wire transfer of immediately available funds to an account designated by the Securityholder Representative prior to Closing, equal to Two Million Dollars ($2,000,000) (the “ Securityholder Expense Amount ”).  The Securityholder Expense Amount shall be treated as paid to the Securityholders and the Blocker Sellers on the Closing Date for U.S. federal income Tax purposes, but any required withholding shall be made out of other amounts payable to the applicable Securityholder or Blocker Seller on the Closing Date.

 

(c)                                   Escrow Amount .  At the Closing, the Purchaser shall deliver to SunTrust Bank, as escrow agent (the “ Escrow Agent ”), under the escrow agreement dated the Closing Date, by and among the Purchaser, the Securityholder Representative and the Escrow Agent, substantially in the form of Exhibit B attached hereto (the “ Escrow Agreement ”), an amount equal to Seven Million Five Hundred Thousand Dollars ($7,500,000) (the “ Escrow Amount ”).

 

(d)                                  Selling Expenses .  At the Closing, the Purchaser will pay (or cause to be paid) the amount of the Selling Expenses, as set forth on the Estimated Closing Statement, payable to each payee thereof by wire transfer of immediately available funds to such payee’s account as specified in instructions delivered to the Purchaser by the Company prior to the Closing and the Company shall use reasonable best efforts to provide Purchaser, along with the Estimated Closing Statement, with invoices and estimates, as appropriate, with respect to third-party Selling Expenses that are not otherwise required to be delivered in accordance with Section 1.8(a)(v)  hereof.

 

(e)                                   Indebtedness .  At the Closing, the Purchaser shall pay, or cause to be paid, cash in an amount equal to the portion of the Closing Indebtedness owed to such Person, as specified in a payoff letter received from such Person or Persons with respect to items described in clause (i) of the definition of Indebtedness or as specified in instructions delivered to the Purchaser by the Company prior to the Closing for any other item of Indebtedness.

 

12



 

2.2                                Delivery of Funds Procedures .

 

(a)                                  Letter of Transmittal Procedures .  Within 5 Business Days following the date of this Agreement, the Company shall cause each Securityholder to be provided with a Letter of Transmittal, a form of Subscription Agreement and IRS Forms W-9 and W-8BEN.  Upon delivery to the Paying Agent of a Letter of Transmittal duly executed and completed in accordance with its terms by a Unitholder (other than the Blockers) or any Blocker Seller, at the Closing (in the case of Letters of Transmittal delivered prior to the Closing) or within three (3) Business Days of receipt of any other duly executed and completed Letters of Transmittal  (as to each such Letter of Transmittal), such Unitholder or Blocker Seller, as applicable, shall be entitled to be paid the portion of the Cash Consideration under Section 1.1 or 1.10(b) , as applicable, in respect of his, her or its Units or Blockers’ Equity, as the case may be.  No interest or dividends will accrue or subsequently be paid on the consideration payable to any Unitholder or Blocker Seller hereunder.  Upon delivery to Purchaser of an executed Subscription Agreement and a completed IRS Form W-9 or W-8BEN, as applicable, a Seller shall be entitled to be issued, in book form, its share of the Stock Consideration in accordance with the Allocation Statement.  The Company shall use reasonable best efforts to assist Sellers in completing such forms.

 

(b)                                  No Further Ownership Rights .  The consideration paid in respect of the Eligible Equity in accordance with the terms hereof shall be deemed to be in full satisfaction of all rights pertaining to such Eligible Equity.  From and after the Effective Time, the transfer books of each of the Company and the Blockers shall be closed and there shall be no further registration of transfers on the transfer books of the Surviving Company or the Blockers of the Eligible Equity outstanding immediately prior to the Effective Time.

 

(c)                                   Withholding Rights .  The Purchaser and the Company, as applicable, shall be entitled to deduct and withhold from the consideration otherwise payable amounts pursuant to this Agreement any amounts required by applicable Tax Law to be so deducted and withheld; provided, that, except for amounts required to be deducted and withheld with respect to the making of such payment under applicable Tax Law as a result of (i) the compensatory nature of such payments or (ii) the Company’s failure to provide the certificate in accordance with Section 1.8(a)(ii) , the Purchaser or the Company, as applicable, shall give reasonable advance notice to and consult with the Securityholder Representative prior to any such withholding.  To the extent that amounts are so withheld by the Purchaser or the Company and remitted to the applicable Governmental Entity, as applicable, such withheld amounts shall be treated for all purposes of this Agreement as having been paid to the applicable Person in respect of which such deduction and withholding was made by the Purchaser or the Company, as applicable, and such amounts shall be delivered by the Purchaser or the Company, as applicable, to the applicable Governmental Entity.

 

2.3                                Estimated Closing Statement; Post-Closing Purchase Price Adjustment .

 

(a)                                  Estimated Closing Statement .  No later than four (4) Business Days prior to the Closing Date, the Company shall deliver to the Purchaser a statement (the “ Estimated Closing Statement ”), prepared in good faith, setting forth (a) an estimate of (i) the Closing Date Net Working Capital Amount (the “ Estimated Net Working Capital ”), (ii) the Closing Cash (the

 

13



 

Estimated Closing Cash ”), (iii) the Closing Indebtedness (the “ Estimated Closing Indebtedness ”), and (iv) the Selling Expenses (the “ Estimated Selling Expenses ”), and (b) on the basis of the foregoing, a calculation of the Cash Consideration (“ Estimated Cash Consideration ”).  The Estimated Closing Statement and all of the calculations set forth therein shall be prepared in accordance with the Agreed Accounting Principles.  Concurrently with the delivery of the Estimated Closing Statement, the Company shall also deliver to the Purchaser and to the Paying Agent the Allocation Statement setting forth the allocations of the payments to be made at Closing based upon the amounts set forth in the Estimated Closing Statement, with the aggregate of such cash payments to be made at Closing not exceeding the Estimated Cash Consideration.

 

(b)                                  Post-Closing Purchase Price Adjustment .

 

(i)                                      For purposes of determining any final adjustments to the Cash Consideration in accordance with the process specified in this Section 2.3(b) :

 

(A)                                if the Final Closing Cash is greater than or less than the Estimated Closing Cash, there shall be a positive adjustment or negative adjustment to the Estimated Cash Consideration, respectively, in determining the Final Cash Consideration;

 

(B)                                if the Final Closing Indebtedness is greater than or less than the Estimated Closing Indebtedness, there shall be a negative adjustment or positive adjustment to the Estimated Cash Consideration, respectively, in determining the Final Cash Consideration;

 

(C)                                if the Final Selling Expenses are greater than or less than the Estimated Selling Expenses, there shall be a negative adjustment or positive adjustment to the Estimated Cash Consideration, respectively, in determining the Final Cash Consideration;

 

(D)                                if the Final Net Working Capital exceeds the Estimated Net Working Capital, then:

 

(i)                                      if the Estimated Net Working Capital was equal to or greater than the Upper Collar, the excess of the Final Net Working Capital over the Estimated Net Working Capital shall be a positive adjustment to the Estimated Cash Consideration in determining the Final Cash Consideration,

 

(ii)                                   if the Estimated Net Working Capital was less than the Upper Collar but greater than or equal to the Lower Collar and the Final Net Working Capital exceeds the Upper Collar, the excess of the Final Net Working Capital over the Upper Collar shall be a positive adjustment to the Estimated Cash Consideration in determining the Final Cash Consideration,

 

(iii)                                if the Estimated Net Working Capital was less than the Upper Collar but greater than or equal to the Lower Collar and the Final Net Working Capital is equal to or less than the Upper Collar, there shall be no adjustment to the Estimated Cash Consideration in determining the Final Cash Consideration,

 

14



 

(iv)                               if the Estimated Net Working Capital was less than the Lower Collar and the Final Net Working Capital is greater than the Upper Collar, an amount equal to the sum of (1) the excess of the Final Net Working Capital over the Upper Collar plus (2) the excess of the Lower Collar over the Estimated Net Working Capital shall be a positive adjustment to the Estimated Cash Consideration in determining the Final Cash Consideration,

 

(v)                                  if the Estimated Net Working Capital was less than the Lower Collar and the Final Net Working Capital is greater than the Lower Collar but less than or equal to the Upper Collar, an amount equal to the excess of the Lower Collar over the Estimated Net Working Capital shall be a positive adjustment to the Estimated Cash Consideration in determining the Final Cash Consideration, and

 

(vi)                               if the Estimated Net Working Capital was less than the Lower Collar and the Final Net Working Capital is less than or equal to the Lower Collar, an amount equal to the excess of the Final Net Working Capital over the Estimated Net Working Capital shall be a positive adjustment to the Estimated Cash Consideration in determining the Final Cash Consideration;

 

(E)                                 if the Estimated Net Working Capital exceeds the Final Net Working Capital, then:

 

(i)                                      if the Estimated Net Working Capital was equal to or greater than the Upper Collar and the Final Net Working Capital is equal to or greater than the Upper Collar, the excess of the Estimated Net Working Capital over the Final Net Working Capital shall be a negative adjustment to the Estimated Cash Consideration in determining the Final Cash Consideration,

 

(ii)                                   if the Estimated Net Working Capital was equal to or greater than the Upper Collar and the Final Net Working Capital is less than the Upper Collar but equal to or greater than the Lower Collar, the excess of the Estimated Net Working Capital over the Upper Collar shall be a negative adjustment to the Estimated Cash Consideration in determining the Final Cash Consideration,

 

(iii)                                if the Estimated Net Working Capital was greater than the Upper Collar and the Final Net Working Capital is less than the Lower Collar, an amount equal to the sum of (1) the excess of the Estimated Net Working Capital over the Upper Collar plus (2) the excess of the Lower Collar over the Final Net Working Capital shall be a negative adjustment to the Estimated Cash Consideration in determining the Final Cash Consideration,

 

(iv)                               if the Estimated Net Working Capital was less than the Upper Collar but greater than or equal to the Lower Collar and the Final Net Working Capital is equal to or greater than the Lower Collar, there shall be no adjustment to the Estimated Cash Consideration in determining the Final Cash Consideration,

 

(v)                                  if the Estimated Net Working Capital was less than the Upper Collar but greater than or equal to the Lower Collar and the Final Net Working Capital

 

15



 

is less than the Lower Collar, the excess of the Lower Collar over the Final Net Working Capital shall be a negative adjustment to the Estimated Cash Consideration in determining the Final Cash Consideration, and

 

(vi)                               if the Estimated Net Working Capital was less than the Lower Collar, the excess of the Estimated Net Working Capital over the Final Net Working Capital shall be a negative adjustment to the Estimated Cash Consideration in determining the Final Cash Consideration; and

 

(F)                                  if the Final Net Working Capital is equal to the Estimated Net Working Capital, there shall be no adjustment to the Estimated Cash Consideration in determining the Final Cash Consideration.

 

(ii)                                   The Purchaser shall deliver, or cause to be delivered, to the Securityholder Representative, as soon as practicable, but in no event more than ninety (90) days after the Closing Date, a preliminary statement prepared in good faith (the “ Preliminary Statement ”) setting forth (x) the calculation of (A) the Net Working Capital Surplus, if any, (B) the Net Working Capital Deficit, if any, (C) the Closing Cash, (D) the Closing Indebtedness, and (E) the Selling Expenses, along with reasonable supporting detail to evidence the calculations of such amounts and (y) on the basis of the foregoing, a calculation of the Cash Consideration.  The Preliminary Statement and all of the calculations set forth therein shall be prepared in accordance with the Agreed Accounting Principles. On the first (1st) Business Day following the date that Purchaser delivers the Preliminary Statement to the Securityholder Representative, Purchaser and the Securityholder Representative shall execute and deliver to the Escrow Agent a joint written instruction instructing the Escrow Agent to release and distribute the amount (if any) (the “ Escrow Release Amount ”) equal to (1) the Escrow Amount, minus (ii) the full amount (if any) that would be payable to Purchaser pursuant to Section 2.3(b)(v)  if the Preliminary Statement were the Final Statement, to the Paying Agent, for further distribution to the Sellers in respect of all Eligible Equity, in accordance with the Allocation Statement, an updated version of which will be delivered by the Securityholder Representative to Purchaser and the Paying Agent in connection therewith.  If the Escrow Release Amount is not a positive number, then Purchaser and the Securityholder Representative shall not deliver to the Escrow Agent such a joint written instruction and the Escrow Release Amount will be deemed to be zero ($0) for all purposes under this Agreement.

 

(iii)                                The Securityholder Representative shall have forty-five (45) days to review the Preliminary Statement from the date of its receipt thereof (the “ Review Period ”).  During the Review Period, the Securityholder Representative shall have reasonable access (including the right to make photocopies) during normal business hours to the books and records, personnel and advisors of the Company and the Subsidiary to the extent reasonably required in connection with such review.  If the Securityholder Representative objects to any aspect of the Preliminary Statement, the Securityholder Representative must deliver a written notice of such objection, specifying in reasonable detail the items so disputed together with the basis for such dispute (the “ Objection Notice ”) to the Purchaser on or prior to the expiration of the Review Period.  If the Securityholder Representative delivers an Objection Notice to the Purchaser prior to the expiration of the Review Period as provided in this Section 2.3(b) , the Purchaser and the

 

16



 

Securityholder Representative shall, for a period of thirty (30) days thereafter (the “ Resolution Period ”), attempt in good faith to resolve the matters contained therein, and any written resolution, signed by each of the Purchaser and the Securityholder Representative, as to any such matter shall be final, binding, conclusive and non-appealable for all purposes hereunder.  In the event the Securityholder Representative does not deliver an Objection Notice to the Purchaser as provided in this Section 2.3(b)  prior to the expiration of the Review Period, the Securityholder Representative shall be deemed to have agreed to the Preliminary Statement in its entirety, which Preliminary Statement or undisputed portions thereof (as the case may be) shall be final, binding, conclusive and non-appealable for all purposes hereunder.

 

(iv)                               If, at the conclusion of the Resolution Period, the Purchaser and the Securityholder Representative have not reached an agreement with respect to all disputed matters contained in the Objection Notice, then within ten (10) Business Days thereafter, the Purchaser and the Securityholder Representative shall submit for resolution those of such matters remaining in dispute to Grant Thornton LLP, or if such firm is unavailable or unwilling to so serve, to a mutually acceptable nationally recognized independent accounting firm (as the case may be, the “ Neutral Arbitrator ”).  The Neutral Arbitrator shall act as an arbitrator to resolve (based solely on the applicable provisions of this Agreement and written presentations of the Purchaser and the Securityholder Representative and not by independent review) only those matters submitted to it in accordance with the first sentence of this Section 2.3(b)(iv) .  The Purchaser and the Securityholder Representative shall direct the Neutral Arbitrator to render a resolution of all such disputed matters within thirty (30) days after its engagement or such other period agreed upon in writing by the Purchaser and the Securityholder Representative.  The resolution of the Neutral Arbitrator shall be set forth in a written statement delivered to each of the Purchaser and the Securityholder Representative and shall be final, binding, conclusive and non-appealable for all purposes hereunder.  The Preliminary Statement, once modified and/or agreed to in accordance with this Section 2.3(b)(iv) , shall become the “ Final Statement ,” and will determine the Closing Date Net Working Capital Amount (the “ Final Net Working Capital ”), the Closing Cash (the “ Final Closing Cash ”), the Closing Indebtedness (the “ Final Closing Indebtedness ”), and the Selling Expenses (the “ Final Selling Expenses ”), the calculation of which will produce the Cash Consideration as set forth in the Final Statement (referred to herein as the “ Final Cash Consideration .”

 

(v)                                  All fees and expenses relating to the work performed by the Neutral Arbitrator shall be borne by the Purchaser, on the one hand, and the Securityholder Representative, on the other hand, based upon the percentage which the portion of the contested amount not awarded to each Party bears to the amount actually contested by such Party, as determined by the Neutral Arbitrator.  Except as provided in the preceding sentence, all other costs and expenses incurred by the Parties in connection with resolving any dispute hereunder before the Neutral Arbitrator shall be borne by the Party incurring such cost and expense.

 

(vi)                               If the Estimated Cash Consideration exceeds the Final Cash Consideration (the amount of such excess, the “ Downward Adjustment Amount ”), then the Securityholder Representative and the Purchaser shall promptly execute and deliver a joint written instruction to the Escrow Agent to (x) effectuate disbursement of the Downward Adjustment Amount to the Purchaser from the Escrow Account, and (y) effectuate the

 

17



 

disbursement of the remaining amount of the Escrow Amount, if any, to the Paying Agent, for further distribution to the Sellers in respect of all Eligible Equity, in accordance with the Allocation Statement, an updated version of which will be delivered by the Securityholder Representative to Purchaser and the Paying Agent in connection therewith.

 

(vii)                            If the Final Cash Consideration exceeds the Estimated Cash Consideration (the amount of such excess, the “ Upward Adjustment Amount ”), then (x) the Purchaser shall pay, within three (3) Business Days after the date on which the Preliminary Statement becomes the Final Statement, by wire transfer of immediately available funds, to the Paying Agent, for further distribution to Sellers in respect of all Eligible Equity, in accordance with the Allocation Statement, an updated version of which will be delivered by the Securityholder Representative to Purchaser and the Paying Agent in connection therewith, an amount equal to the Upward Adjustment Amount, and (y) the Securityholder Representative and the Purchaser shall promptly execute and deliver a joint written instruction to the Escrow Agent to effectuate the disbursement of the Escrow Amount to the Paying Agent, for further distribution to the Sellers in respect of all Eligible Equity, in accordance with the Allocation Statement, an updated version of which will be delivered by the Securityholder Representative to Purchaser and the Paying Agent in connection therewith.

 

2.4                                Escrow Account; Securityholder Expense Amount Holdback .

 

(a)                                  The Escrow Amount to be deposited with the Escrow Agent pursuant to Section 2.1(c)  shall be held in a designated escrow account (the “ Escrow Account ”) in accordance with the terms of this Agreement and the Escrow Agreement.

 

(b)                                  The Securityholder Expense Amount deposited with the Securityholder Representative pursuant to Section 2.1(b)  shall be held in an account maintained by the Securityholder Representative (the “ Holdback Account ”) for the Securityholder Representative to hold on behalf of the Sellers pursuant to the terms of Section 10.10 .  The Holdback Account need not be invested, and need not earn interest or other income.  To the extent any amount becomes payable out of the Holdback Account to the Sellers, the Securityholder Representative shall cause such amounts to be paid in accordance with this Section 2.4 .

 

(c)                                   The Parties agree that for federal and applicable state and local income Tax purposes:  (i) Purchaser shall be treated as the owner of the Escrow Account and all interest and earnings earned from the investment and reinvestment of the Escrow Amount, or any portion thereof, shall be allocable to Purchaser pursuant to Section 468B(g) of the Code and Proposed Treasury Regulation Section 1.468B-8, (ii) the right of the Sellers to the Escrow Account shall be treated as deferred contingent purchase price eligible for installment sale treatment under Section 453 of the Code and any corresponding provision of state, local or non-U.S.  Law, as appropriate, (iii) if and to the extent any amount of the Escrow Account is actually distributed to the Sellers, interest may be imputed on such amount as required by Section 483 or 1274 of the Code and (iv) in the event any interest and earnings earned thereon paid to the Sellers under this Agreement exceeds the imputed interest, such interest shall be treated as interest or other income and not as purchase price.  Clause (iv) of the preceding sentence is intended to ensure that the right of the Sellers to the Escrow Amount and any interest and earnings earned thereon is not

 

18



 

treated as a contingent payment without a stated maximum selling price under Section 453 of the Code and the Treasury Regulations promulgated thereunder.  All Parties hereto shall file all Tax Returns consistently with the foregoing provisions of this Section 2.4(c) .

 

2.5                                Payment of Additional Payments .  Any Additional Payment required to be paid to the Sellers pursuant to the terms of this Agreement or the Escrow Agreement shall be allocated among the Sellers in accordance with the Allocation Statement and shall be paid to or on behalf of such Persons, by wire transfer of immediately available funds, to the Paying Agent, for further distribution to each Seller in respect of all Eligible Equity, in accordance with the Allocation Statement, an updated version of which will be delivered by the Securityholder Representative to Purchaser and the Paying Agent in connection therewith; provided , that , that no Seller shall be entitled to receive Additional Payments until such Person shall have delivered a duly executed and completed Letter of Transmittal.

 

2.6                                Allocation of Purchase Price .  The Parties agree to allocate the Transaction Consideration and any other relevant items (as determined for U.S. federal income Tax purposes) among the assets of the Company in accordance with the purchase price allocation methodology set forth in Schedule 2.6  for purposes of Section 1060, Section 751, and Section 755, as applicable, of the Code and the applicable Treasury Regulations (the “ Tax Allocation ”).  As promptly as reasonably practicable (but in any event within ninety (90) days) after the determination of the Closing Date Net Working Capital Amount, as finally determined, the Securityholder Representative shall deliver to the Purchaser a schedule of such allocation (the “ Tax Allocation Schedule ”).  Purchaser shall have thirty (30) days after receipt of same to review and comment on the Tax Allocation Schedule.  If, within ten (10) days of the end of such thirty (30) day period, Purchaser notifies Securityholder Representative of Purchaser’s disagreement with the Tax Allocation Schedule, then Purchaser and Securityholder Representative shall, during the ensuing seven (7) days, negotiate in good faith to resolve such disagreement, failing which such disagreement shall be submitted to the Neutral Arbitrator for resolution in accordance with the procedures of Section 2.3(b) , mutatis mutandis ; provided , that any resolution made by the Neutral Arbitrator shall be made in a manner consistent with the purchase price allocation methodology set forth in Schedule 2.6 .  The Purchaser and Unitholders and their Affiliates shall report, act and file Tax Returns including, but not limited to, IRS Form 8594 (with respect to the Purchaser) if required under applicable Tax Law and statements under Treasury Regulations Sections 1.755-1(d) and 1.751-1(a)(3) (with respect to the Unitholders), in all respects and for all purposes consistent with the Tax Allocation Schedule, as the same may be modified by agreement of Purchaser and Securityholder Representative, or by the Neutral Arbitrator, in accordance with the foregoing.  Neither the Purchaser nor the Unitholders shall take any position for Tax purposes (whether in Tax audits or on Tax Returns) that is inconsistent with the Tax Allocation Schedule (as so modified) unless required to do so by applicable Law.

 

2.7                                Allocation Statement .  The Purchaser, Merger Sub and after the Effective Time, the Surviving Company, will be entitled to rely conclusively and without independent verification on the Allocation Statement, and will have no liability to the Sellers for making payments and

 

19



 

issuing the Stock Consideration in accordance with such Allocation Statement and this Agreement or for the Paying Agent making any payments.

 

2.8                                Accredited Investor .  Notwithstanding anything herein to the contrary, only Sellers that are “accredited investors” as defined in Rule 501 of Regulation D shall be entitled to receive Stock Consideration.  All Sellers that are not “accredited investors” shall receive all of their Transaction Consideration hereunder in cash, and with Purchaser’s obligations to make cash payments and issue Stock Consideration hereunder (and under the Subscription Agreements) being correspondingly adjusted.  For the avoidance of doubt, no such cash payment shall alter the amount of cash payable to any other Seller hereunder.

 

ARTICLE III
REPRESENTATIONS AND WARRANTIES OF THE COMPANY

 

The Company represents and warrants to the Purchaser as follows:

 

3.1                                Status; Authority; Conflicts .

 

(a)                                  The Company is a limited liability company, was duly organized and is validly existing under the laws of its jurisdiction of formation, has all requisite limited liability company power and authority to carry on its business as now conducted and to own or lease and operate its properties and assets, and is duly qualified to do business as a foreign entity under the laws of each jurisdiction where such qualification is necessary.  The jurisdictions where the Company is so qualified are set forth on Schedule 3.1(a) .

 

(b)                                  (i) each of the Company and Subsidiary has all requisite limited liability company power and authority to execute and deliver the Transaction Documents to which it is a party, to carry out its obligations under such Transaction Documents and to consummate the Transactions; (ii) the execution and delivery of the Transaction Documents to which the Company and Subsidiary is a party and the consummation of the Transactions have been duly and validly authorized by the Company and Subsidiary, as applicable, and no other proceedings on the part of the Company or Subsidiary are necessary to approve the Transaction Documents to which the Company or Subsidiary, as applicable, is a party or to consummate the Transaction; and (iii) this Agreement has been duly and validly executed and delivered by the Company, and assuming the due authorization, execution, and delivery by the other Parties, constitutes the valid and binding agreement of the Company enforceable against the Company in accordance with the terms and conditions of this Agreement, subject to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation, fraudulent conveyance and other similar Laws and principles of equity affecting creditors’ rights and remedies generally (the “ General Enforceability Exceptions ”).

 

(c)                                   Except as set forth on Schedule 3.1(c) , the execution and delivery of the Transaction Documents to which the Company or the Subsidiary is a party, as applicable, does not, and the consummation of the Transactions, and performance by the Company or the

 

20



 

Subsidiary, as applicable, of its obligations hereunder and thereunder, whether with or without the passage of time, the giving of notice or both, will not result in any breach of any of the provisions of, constitute a default under, result in a violation of, give any third party the right to terminate or to accelerate any obligation under, result in the creation of any Lien upon the Units or any assets of the Company or the Subsidiary, conflict with, give rise to a right of termination, modification, cancellation or acceleration of any obligation or to a loss of a benefit, in each case under:

 

(i)                                      the Governing Documents of the Company or the Subsidiary;

 

(ii)                                   any material Contract, any Law or any Order applicable to the Company or the Subsidiary in any material respect; or

 

(iii)                                without limiting the foregoing, require the Consent of, notice to, or filing with, any Person.

 

3.2                                Capitalization of the Company .

 

(a)                                  Schedule 3.2(a)  accurately sets forth the authorized and outstanding Units and the name of each Unitholder and the number and class or series of equity securities of the Company held thereby, and are owned beneficially and of record by the Unitholders free and clear of all Liens other than Liens under applicable federal and state securities Laws.  All of the Units have been duly authorized and validly issued and have been offered, issued and delivered in compliance with applicable Laws and Governing Documents.

 

(b)                                  As of the date of this Agreement, except as set forth on Schedule 3.2(b) , there are no outstanding subscriptions, options, warrants, commitments, preemptive rights, deferred compensation rights, equity appreciation rights, “phantom” equity rights, calls, puts, rights to subscribe, Contracts, agreements, arrangements or commitments of any kind to which the Company is a party relating to the sale or issuance of, or outstanding securities convertible into or exercisable or exchangeable for, any Units or which restrict the transfer of any such Units.

 

(c)                                   Except as provided on Schedule 3.2(c) , there are no outstanding contractual obligations, commitments or arrangements (contingent or otherwise) to repurchase, redeem or otherwise acquire or with respect to the voting, restrictions on transfer, or any other rights or restrictions of any Units or other equity interests or any other securities of the Company or the Subsidiary.

 

3.3                                Subsidiaries .

 

(a)                                  All of the outstanding equity interests in Leehar Distributors, LLC (the “ Subsidiary ”), a Delaware limited liability company, and wholly-owned subsidiary of the Company, (i) have been validly issued in compliance with applicable Laws and Governing Documents and (ii) are free and clear of any and all Liens other than Liens that secure

 

21



 

Indebtedness that will be paid off at the Closing.  Except as set forth on Schedule 3.3(a) , all of the outstanding equity interests of the Subsidiary are beneficially owned, directly or indirectly, by the Company.  There are no outstanding (x) options, warrants, or other rights to purchase from the Subsidiary any equity interests of the Subsidiary, (y) securities convertible into or exchangeable for equity interests of the Subsidiary, or (z) other commitments of any kind for the issuance of equity interests or options, warrants, or other securities of the Subsidiary.  There are no outstanding contractual obligations, commitments or arrangements (contingent or otherwise) to repurchase, redeem or otherwise acquire or with respect to the voting, restrictions on transfer, or any other rights or restrictions of any equity interests or any other securities of the Subsidiary.

 

(b)                                  Except for the Subsidiary, the Company does not own any capital stock of, or other equity interest in, or any interest convertible into, or exercisable or exchangeable for, any capital stock of, or other equity interest in, any other Person.  The Subsidiary does not own any capital stock of, or other equity interest in, or any interest convertible into, or exercisable or exchangeable for, any capital stock of, or other equity interest in, any other Person.

 

(c)                                   The Subsidiary is a limited liability company, was duly formed and is validly existing under the laws of Delaware and has all requisite organizational power and authority to carry on its business as now conducted and to own or lease and operate its properties and assets, and is duly qualified to do business as a foreign entity under the laws of each jurisdiction where such qualification is necessary.   The jurisdictions where the Subsidiary is so qualified are set forth on Schedule 3.3(a) .

 

3.4                                Financial Statements .

 

(a)                                  The Company has Made Available to the Purchaser audited consolidated financial statements of the Company consisting of a balance sheet as of December 31, 2016 and the related statements of income and retained earnings, shareholders’ equity and cash flows for the period from and including August 17, 2016 to December 31, 2016 (the “ Annual Financial Statements ”) and unaudited consolidated financial statements consisting of a consolidated balance sheet as of September 30, 2017 and the related consolidated statements of income and retained earnings, shareholders’ equity and cash flows for the nine (9)-month period then ended (the “ Interim Financial Statements ” and together with the Annual Financial Statements, including any notes and schedules thereto, the “ Financial Statements ”).  The balance sheet of the Company as of September 30, 2017 is referred to herein as the “ Balance Sheet ” and the date thereof as the “ Balance Sheet Date .” The Financial Statements (including the notes and auditors’ reports thereto, if any) have been prepared (i) in accordance with the books and records of the Company and Subsidiary (which books and records, are in turn, accurate and complete) and (ii) in conformity with GAAP applied on a consistent basis throughout the periods covered thereby, and fairly present in all material respects the consolidated financial condition, results of operations, cash flows and shareholders’ equity of the Company as of the respective dates of, and for the periods referred to in, the Financial Statements, subject to, in the case of the Interim Financial Statements, the absence of footnote disclosure and normal year-end adjustments, none of which are material, individually or in the aggregate.

 

22



 

(b)                                  The Company and the Subsidiary (and any predecessor of any of the foregoing) have established and adhered to and maintain a system of internal accounting controls which is sufficient to provide assurance (1) regarding the reliability of financial reporting, (2) that transactions are executed with management’s general or specific authorization, (3) all transactions are recorded as necessary to permit the preparation of financial statements in conformity with GAAP, consistently applied, and to maintain proper accountability for items, (4)  recorded accountability for items is compared with actual levels at reasonable intervals and appropriate action is taken with respect to any differences and (5) regarding prevention or timely detection of unauthorized acquisition, use or disposition of assets.  Except as set forth on Schedule 3.4(b) , during the past three (3) years, there has not been (i) any significant deficiency or weakness in any system of internal accounting controls used by the Company or the Subsidiary, (ii) to the Knowledge of the Company, any fraud or other wrongdoing that involves any of the management or other Employees of the Company or the Subsidiary who have a role in the preparation of financial statements, financial reporting or the internal accounting controls used by the Company or the Subsidiary or (iii) any written claim or allegation or, to the Knowledge of the Company, any other claim or allegation regarding any of the foregoing.

 

(c)                                   The Allocation Statement is complete and correct in all respects, is prepared in accordance with the Company LLC Agreement, and does not omit any Person who is entitled to be paid any portion of the Estimated Cash Consideration, the Closing Indebtedness and/or the Selling Expenses in accordance with the terms of this Agreement.  The holders of Indebtedness and Selling Expenses are set forth on Schedule 3.4(c) .  There will not be any Closing Indebtedness or Selling Expenses that are not reflected in the calculation of the Final Cash Consideration.

 

3.5                                Title to Assets .

 

(a)                                  The Company and the Subsidiary own or lease, free and clear of Liens (except Permitted Liens), all machinery, equipment, and other tangible assets necessary for, or used in, the conduct of the business of the Company and the Subsidiary as presently conducted and as presently proposed by the Company and the Subsidiary to be conducted.

 

(b)                                  Each such tangible asset is free from material defects (patent and latent), has been maintained in all material respects in accordance with normal industry practice, is in good operating condition and repair (subject to normal wear and tear), and is suitable in all material respects for the purposes for which it presently is used and presently is proposed to be used.

 

(c)                                   There is no material property or obligation of the Company or the Subsidiary, including uncashed checks to vendors, customers or employees (but excluding non-refunded overpayments or unclaimed subscription balances), that is escheatable or payable to any Governmental Entity.

 

3.6                                Real Property .

 

(a)                                  Neither the Company nor its Subsidiary owns any real property.

 

23



 

(b)                                  The real property demised by the lease and sublease agreements described on Schedule 3.6(b)  (the “ Real Property Leases ”) constitutes all of the real property leased or subleased by the Company and the Subsidiary (the “ Leased Real Property ”).  Schedule 3.6(b)  lists, and the Real property Leases shall be deemed to include, all leases, subleases, occupancy agreements, addenda, amendments, modifications, extension or renewal elections and guaranties affecting the Company and the Subsidiary’s interest in and to the Leased Real property, and the Company has Made Available to the Purchaser true and complete copies of the Real Property Leases.  The Real Property Leases are in full force and effect, enforceable in accordance with their terms, subject to proper authorization and execution of such Real Property Leases by the other parties thereto and the General Enforceability Exceptions.  No real property is used in connection with the business of the Company and the Subsidiary as now conducted other than the Leased Real Property.  Except as set forth on Schedule 3.6(b) : (i) neither the Company nor the Subsidiary is in breach or default under any of the Real Property Leases or has received any written notice of any default or event that with notice or lapse of time, or both, would constitute a default by the Company or the Subsidiary under such Real Property Leases or give rise to any defenses, offsets, claims or credits which the other party under each such Real Property Lease may have against the Company or the Subsidiary; (ii) to the Knowledge of the Company, the other party to each Real Property Lease is not in breach or default under such Real Property Lease, no condition exists that would give rise to any defenses, offsets, claims or credits by the Company or the Subsidiary under such Real Property Lease, and no portion of the security deposit under any such Real Property Lease, if applicable, has been applied and not replenished; (iii) the Company and/or the Subsidiary, as applicable, has a good and valid leasehold interest in all Leased Real Property and  has not collaterally assigned, mortgaged, deeded in trust or granted any other Lien in such Real Property Lease or any interest therein other than Permitted Liens; (iv) there are no Liens affecting the Real Property Leases, other than Permitted Liens; (v) the Real Property Leases constitute all written agreements of any kind for the leasing, rental, use or occupancy of the Leased Real Property by the Company or the Subsidiary; (vi) neither the Company nor the Subsidiary (and for periods prior to November 1, 2016, the Subsidiary’s Predecessor) has received any written notice from any Governmental Entity that any of the improvements on the Leased Real Property or the Company or the Subsidiary’s use of the Leased Real Property violates any use or occupancy restrictions, any item of record or any zoning or building code; (vii) the Leased Real Property has access to all utilities necessary for the operation of the Company and the Subsidiary’s business as now conducted, (viii) to the Knowledge of the Company, there is no pending condemnation or eminent domain proceeding with respect to the Leased Real Property; and (ix) all Permits, licenses and approvals necessary for the occupancy and use of the Leased Real Property for the use as now conducted by the Company and the Subsidiary have been obtained.

 

3.7                                Absence of Certain Changes and Events .  From December 31, 2016 until the date of this Agreement, no fact, event or circumstance has occurred or arisen that, individually or in combination with any other fact, event or circumstance, has had or would reasonably be expected to have a Material Adverse Effect.  Except as set forth on Schedule 3.7 , from the Balance Sheet Date until the date of this Agreement, neither the Company nor the Subsidiary has taken any of the following actions:

 

24



 

(a)                                  made changes in any method of accounting or accounting practice of the Company or Subsidiary, except as required by a change in GAAP or applicable Law or as disclosed in the notes to the Financial Statements;

 

(b)                                  made, revoked or changed any Tax election, changed any annual Tax accounting period, adopted or changed any method of Tax accounting, filed any amended Tax Return, entered into any closing agreement with respect to Taxes, waived any claim for refund or credit of Taxes, settled any audit, examination or Legal Proceeding related to Taxes, surrendered any right to claim a Tax refund, or consented to the extension or waiver of the limitations period applicable to any Tax Proceeding;

 

(c)                                   entered into any Contract (or series of related Contracts) outside the ordinary course of business;

 

(d)                                  entered into any Contract (or series of related Contracts) with any Affiliate of the Company or the Subsidiary;

 

(e)                                   accelerated, terminated, modified or cancelled any Contract (or series of related Contracts) involving more than $500,000 (individually or in the aggregate) to which the Company or the Subsidiary is a party or by which it is bound;

 

(f)                                    permitted, allowed or suffered any Lien upon any of its assets, tangible or intangible, or incurred, assumed or guaranteed any Indebtedness other than borrowings under the Credit Facility in the ordinary course of business;

 

(g)                                   sold, leased, licensed, transferred, assigned or otherwise disposed of any of their assets, except in the ordinary course of business and except for any assets having an aggregate value of less than $250,000;

 

(h)                                  issued, sold or delivered any Units or issued or sold any securities convertible into, or options with respect to, or warrants to purchase or rights to subscribe for, any Units;

 

(i)                                      other than as required by applicable Law, (A) materially increased the compensation of any officer, manager, employee, contractor or director of the Company or the Subsidiary, other than as provided for in any Employee Plan, (B) hired or terminated any officer, or manager of the Company or the Subsidiary, or employees or contractors with expected annual compensation or remuneration in excess of $200,000 or (C) entered into, amended or terminated any employment, severance, retention or change in control Contract with any Employee that is not terminable at will;

 

(j)                                     failed to pay any wages or compensation due to any employee or contractor, changed the exempt or nonexempt status of any employee for purposes of the Fair Labor Standards Act and/or any comparable Law, or changed the employment or contractor classification of any employee or contractor;

 

25



 

(k)                                  adopted, amended, modified or terminated any Employee Plan or any Employee Plan or arrangement that would constitute an Employee Plan if it were in existence on the date hereof;

 

(l)                                      implemented any layoff of employees that would reasonably be expected to implicate the WARN Act;

 

(m)                              acquired by merger or consolidation with, or by purchase of a substantial portion of the assets, stock or other equity of, or by any other manner, any business or any Person or any division thereof;

 

(n)                                  adopted any plan of merger, consolidation, reorganization, liquidation or dissolution or filed a petition in bankruptcy under any provisions of federal or state bankruptcy Law or consented to the filing of any bankruptcy petition against it under any similar Law;

 

(o)                                  made any investment (by contribution to capital, property transfers, purchase of securities or otherwise) in, or made any loan or advance (other than travel and similar advances to its employees) in excess of $250,000 to any Person other than in the ordinary course of business;

 

(p)                                  entered into, modified or terminated any labor or collective bargaining agreement of the Company or the Subsidiary;

 

(q)                                  failed to maintain in full force and effect any insurance policy in effect, except for any policy replaced by a new or successor policy of substantially similar coverage;

 

(r)                                     terminated, amended, failed to renew or preserve or failed to maintain in full force and effect any material permit, except for amendments completed in the ordinary course of business, or any registration or application for any Intellectual Property Rights;

 

(s)                                    declared, set aside or paid any dividend or made any distribution (other than tax distributions) with respect to the Units (whether in cash or in kind) or redeemed, purchased or otherwise acquired any of the Units;

 

(t)                                     effected any recapitalization, reclassification, unit split or like change to its classification;

 

(u)                                  paid, discharged, settled or satisfied any material claims or material Liabilities, other than in the ordinary course of business; or

 

(v)                                  entered into any agreement, in writing or otherwise, to take any of the foregoing actions.

 

3.8                                Taxes .  Except as set forth on Schedule 3.8 :

 

(a)                                  All Tax Returns required to be filed by the Company or the Subsidiary have been timely filed with the appropriate Tax Authorities, taking into account any applicable

 

26



 

extensions.  All Taxes owed by the Company or the Subsidiary (whether or not shown to be due on any Tax Return) have been paid.  Each such Tax Return is complete and accurate in all material respects.

 

(b)                                  No deficiencies for Taxes with respect to the Company or the Subsidiary have been claimed, proposed or assessed by any Tax Authority that have not been resolved and, if required, paid.  There are no pending or ongoing audits or examinations of any Tax Returns with respect to the Company or the Subsidiary by the relevant Tax Authorities and no such audit or examination has been threatened in writing, or to the Knowledge of the Company, otherwise by any Taxing Authority. Neither the Company nor the Subsidiary has waived any statute of limitations relating to Taxes with respect to the Company or the Subsidiary, and neither the Company nor the Subsidiary has agreed to any extension of time with respect to a Tax assessment or deficiency related to any such Taxes, which extension is in effect as of the date hereof.

 

(c)                                   There are no Liens for Taxes on any of the assets of the Company or the Subsidiary, other than Permitted Liens.

 

(d)                                  Neither the Company nor the Subsidiary is a party to or bound by any Tax indemnification, Tax allocation or Tax sharing agreement (including any closing agreement, gain recognition agreement or other material agreement relating to Taxes, but excluding, for this purpose, any agreement entered into in the ordinary course of business that is primarily not related to Taxes, such as leases, licenses or credit agreements).

 

(e)                                   Neither the Company nor the Subsidiary has ever been a member of a Relevant Group (other than a Relevant Group that includes only one or more other Target Companies).  Neither the Company nor the Subsidiary has any Liability for the Taxes of any other Person (apart from another Target Company) under Section 1.1502-6 of the Treasury regulations (or any similar provision of Law), as a transferee or successor, by Contract (excluding, for this purpose, any Contract entered into in the ordinary course of business that is primarily not related to Taxes, such as leases, licenses or credit agreements) or otherwise.

 

(f)                                    Neither the Company nor the Subsidiary owns any interest in any Person (other than the Subsidiary) that is, for federal income Tax purposes, (i) classified as a “partnership” within the meaning of Section 7701(a)(2) of the Code, (ii) disregarded as separate from its owner within the meaning of Section 301.7701-3 of the Treasury Regulations or (iii) a “controlled foreign corporation” within the meaning of Section 957 of the Code.

 

(g)                                   Neither the Company nor the Subsidiary (i) is a party to any “listed transaction,” as defined in Code Section 6707A(c)(2) and Treasury Regulations Section 1.6011-4(b)(2), (ii) has failed to disclose on its federal income Tax Returns any position taken therein that could give rise to a substantial understatement of federal income Tax within the meaning of Code Section 6662, (iii) is a party to any plan or arrangement described in Code Section 6111(d) or Code Section 6662(d)(2)(C)(ii)(III) or (iv) has “participated” in a “reportable transaction” within the meaning of Treasury Regulations section 1.6011-4.

 

27



 

(h)                                  All Taxes that the Company or Subsidiary is or was required to have withheld or collected have been duly withheld or collected and, to the extent required, have been paid to the appropriate Taxing Authority or Governmental Entity, including all Taxes required to have been withheld or collected and paid in connection with amounts paid or owing to any employee, former employee, non-resident, partner, independent contractor, creditor, shareholder, Affiliate, customer, vendor or other third party, and all IRS Forms W-2 and 1099 required with respect thereto have been properly completed and timely filed.

 

(i)                                      The unpaid Taxes of the Company and Subsidiary (i) did not, as of the Balance Sheet Date, exceed the reserve for Tax liability (rather than any reserve for deferred Taxes established to reflect timing differences between book and Tax income) set forth on the face of the Balance Sheet and (ii) will not, as of the Closing Date, exceed Taxes of the Company and the Subsidiary included in the Closing Indebtedness as finally determined hereunder.

 

(j)                                     Neither the Company nor the Subsidiary has engaged in a trade or business through a permanent establishment (within the meaning of an applicable Tax treaty or convention between the United States and such non-U.S. country), or otherwise been subject to income taxation on a net basis in any country other than the country of its formation.

 

(k)                                  The provisions of Code Section 197(f)(9) do not currently apply to any intangible assets owned (directly or indirectly) by the Company or Subsidiary.

 

(l)                                      None of the assets of the Company or the Subsidiary (i) is “tax-exempt use property” within the meaning of Code Section 168(h) or (ii) secures any debt, the interest on which is exempt from Tax under Code Section 103.

 

(m)                              Neither the Company nor the Subsidiary is a party to any “safe harbor lease” that is subject to the provisions of Section 168(f)(8) of the Internal Revenue Code as in effect prior to the Tax Reform Act of 1986, and neither the Company nor any holder of Units is a “foreign person” within the meaning of the Code.

 

(n)                                  Neither the Company, the Subsidiary, Purchaser nor any Affiliate of Purchaser will be required to include any item of income in, or exclude any item of deduction from, taxable income for any taxable period (or portion thereof) ending after the Closing Date as a result of any (i) change in method of accounting of the Company or Subsidiary for a taxable period ending on or before the Closing Date, (ii) use of an improper method of accounting for a taxable period ending on or before the Closing Date, (iii) installment sale or open transaction disposition made by the Company or Subsidiary on or before the Closing Date, (iv) prepaid amount received by the Company or Subsidiary prior to the Closing Date,  (v) closing agreement under Code Section 7121 (or other comparable agreement) entered into on or before the Closing Date or (vi) cancellation of debt of Company or Subsidiary to which Code Section 108(i) applied.

 

(o)                                  No written claim has been received by the Company or any Subsidiary from any Taxing Authority in a jurisdiction in which such Target Company does not file Tax Returns that such Target Company is or may be subject to taxation by that jurisdiction.

 

28



 

(p)                                  For federal (and, as applicable, state and local) income Tax purposes, (i) the Company is and has, at all times during its existence, been a partnership within the meaning of Section 7701(a)(2) of the Code, and (ii) the Subsidiary is and has, at all times during its existence, been disregarded as an entity separate from the Company under and within the meaning of Treasury Regulations Section 301.7701-3 et seq.

 

(q)                                  The Company has Made Available to Purchaser correct and complete copies of all United States federal income Tax Returns filed by, and all examination reports and statements of deficiencies assessed against or agreed to by, the Company and the Subsidiary since December 31, 2013.

 

(r)                                     Neither the Nautic Splitter, Nautic GP nor Nautic VIII-A Blocker will recognize any taxable income or gain by reason of the dissolution and liquidation of the Nautic Splitter pursuant to Section 6.11 of this Agreement.

 

3.9                                Employees and Employee Benefits .

 

(a)                                  Schedule 3.9(a)  lists all employee benefit plans (as defined in Section 3(3) of ERISA), all material bonus, stock option, stock purchase, restricted stock, incentive, deferred compensation, retiree medical or life insurance, supplemental retirement, severance and other material benefit plans, programs or arrangements, and all material employment, termination, change in control, retention, severance or other similar material contracts or agreements, whether or not subject to ERISA (but not including the Deferred Compensation Agreement and any benefit plan, program or arrangement administered, sponsored or maintained by any Governmental Entity or by any labor union or other third party in connection with any Collective Bargaining Agreement) (i) which are maintained, contributed to or sponsored by the Company and/or the Subsidiary for the benefit of any Employee or (ii) with respect to which the Company or the Subsidiary has any material obligation to any Employee or otherwise has any Liability (collectively, the “ Employee Plans ”).  Copies of the following documents, with respect to each of the Employee Plans, have been Made Available to the Purchaser by the Company to the extent applicable: (i) the current plan document, and all amendments thereto and related current trust documents, insurance contracts or other funding arrangements, and all amendments thereto; (ii) the Form 5500 annual report and all schedules and statements thereto for the three (3) most recently completed plan years for which such Form 5500 annual report has been submitted to the IRS and DOL, (iii) the most recent IRS determination, opinion or advisory letter; (iv) the most recent summary plan descriptions and all subsequent summaries of material modifications, if any; and (v) any material written communications to or from any Governmental Entity (outside of the ordinary course of business) in the current and preceding three (3) calendar years relating to such Employee Plan. Such copies are true, correct and complete in all material respects.

 

(b)                                  Except as would not reasonably be expected to be material to the Company or Subsidiary, (i) each Employee Plan has been established and administered in accordance with its terms and applicable Law, (ii) as of the date hereof, there is no pending or, to the Knowledge of the Company, threatened actions, claims or lawsuits relating to any Employee Plans, the assets of any of the trusts under such plans, the plan sponsor or the plan administrator of such plans, or against any fiduciary of such plans with respect to the operation of such plans (other than routine benefit claims), and (iii) as of the date hereof, no Employee Plan is, to the Knowledge of the Company, the subject of an examination or audit by a Governmental Entity. Each Employee Plan that is intended to be qualified under Section 401(a) of the Code has timely received a current favorable determination letter from the IRS (or, if a prototype plan or volume

 

29



 

submitter plan, can rely on a current opinion or advisory letter from the IRS to the prototype plan or volume submitter plan sponsor) that the Employee Plan is so qualified, and, to the Knowledge of the Company, no event or circumstance has occurred since the date of such determination (or opinion or advisory) letter from the IRS that would adversely affect the qualified status of any such Employee Plan.

 

(c)                                   No Employee Plan is, and none of the Company or the Subsidiary has any Liability with respect to, an “employee pension benefit plan” as defined in Section 3(2) of ERISA that is subject to Title IV of ERISA or the funding standards of Section 302 of ERISA or Section 412 of the Code, a “multiemployer plan” as defined in Section 3(37) of ERISA or Section 414(f) of the Code, or a “multiple employer plan” within the meaning of Section 210(a) of ERISA or Section 413(c) of the Code.  There is no lien pursuant to Sections 303(k) or 4068 of ERISA or Section 430(k) of the Code in favor of, or otherwise enforceable by the Pension Benefit Guaranty Corporation or any other entity with respect to any of the Company’s or the Subsidiary’s assets. No Employee Plan provides post-termination or retiree health or welfare benefits other than as required by Section 4980B of the Code for which the covered individual pays the full cost of coverage.

 

(d)                                  The Company and the Subsidiary have complied with the applicable provisions of the ACA, including, but not limited to, if applicable to the Company or the Subsidiary, the employer shared responsibility provisions relating to the offer of “minimum essential coverage” to “full-time” employees that is “affordable” and provides “minimum value” (as defined in Section 4980H of the Code and related regulations) and the applicable employer information reporting provisions under Section 6055 and 6056 of the Code and all related regulations.

 

(e)                                   All contributions (including, without limitation, all employer contributions and employee salary reduction contributions) that are due have been made within the time periods prescribed by ERISA and the Code to each Employee Plan that is an “employee pension benefit plan” as defined in Section 3(2) of ERISA and all contributions for any period ending on or before the Closing Date that are not yet due have been made to each such Employee Plan or properly accrued.  All premiums or other payments for all periods ending on or before the Closing Date have been paid with respect to each Employee Plan that is an “employee welfare benefit plan” as defined in Section 3(1) of ERISA.

 

(f)                                    There have been no non-exempt “prohibited transactions” as defined in Section 406 of ERISA and Section 4975 of the Code with respect to any Employee Plan.  No fiduciary as defined in Section 3(21) of ERISA has any Liability for breach of fiduciary duty or any other failure to act or comply in connection with the administration or investment of the assets of any Employee Plan.

 

(g)                                   Neither the Company or the Subsidiary is obligated under the Employee Plans or under any other arrangement that is a nonqualified deferred compensation plan or otherwise to pay any separation, severance, termination or similar benefit as a result of any transactions contemplated by this Agreement or solely as a result of a change in control or ownership within the meaning of Section 280G of the Code.  Neither the execution of this

 

30



 

Agreement or the other documents relating to this Agreement, nor the consummation of the transactions contemplated hereunder or thereunder, will increase the amount of benefits otherwise payable under any Employee Plan or result in the acceleration of the time of payment, funding or vesting of any such benefits.

 

3.10                         Compliance with Laws; Permits .

 

(a)                                  The Company and the Subsidiary are and, together with the Subsidiary’s Predecessor for periods prior to November 1, 2016, for the past five (5) years have been, in compliance, in all material respects, with all applicable Laws to which the Company or the Subsidiary is subject, and no claim has been (i) filed or (ii) to the Knowledge of the Company, threatened against the Company or the Subsidiary or any such Employee alleging a violation of any such applicable Laws or against the Company or the Subsidiary.  During the past three (3) years, neither the Company nor the Subsidiary nor, prior to November 1, 2016, the Subsidiary’s Predecessor, has received any written notification from any Governmental Entity (i) alleging that the Company or the Subsidiary is not in compliance in any material respect with any applicable Laws, (ii) threatening to revoke a Permit, (iii) requiring or threatening to require that the Company or the Subsidiary, or stating that the Company or the Subsidiary is required to enter into any Order or agreement with a Governmental Entity relating to the operations of the Company or the Subsidiary or (iv) advising the Company or the Subsidiary that a Governmental Entity is contemplating issuing or requesting any such Order or agreement.

 

(b)                                  Schedule 3.10(b)  contains a complete and correct list of all Permits which are held by the Company and the Subsidiary in connection with the operation of their respective businesses.  Each of the Company and the Subsidiary possesses all of the Permits necessary for it to lawfully operate as conducted as of the date of this Agreement in all material respects. All of such material Permits held by or issued to the Company or the Subsidiary, as applicable, are in full force and effect and the Company or the Subsidiary, as applicable, is in compliance in all material respects with each such material Permit and no condition exists that with notice or lapse of time or both would constitute a default under such Permits.  No Legal Proceeding is pending or, to the Knowledge of the Company, has been threatened against the Company or the Subsidiary before or by any Governmental Entity, that (i) would reasonably be expected to lead to the revocation, amendment, failure to renew, limitation, suspension, withdrawal, termination, modification or restriction of any such Permit, or (ii) seeks or imposes injunctive relief or any restriction on the conduct of the Company or the Subsidiary; or (iii) would be reasonably likely to prevent, hinder, modify, interfere, alter, challenge, restrict, make illegal or delay consummation of the transactions contemplated in this Agreement.

 

3.11                         Legal Proceedings; Orders .  Except as set forth on Schedule 3.11 , (a) there are no (and during the three (3) years preceding the date hereof, there have not been any) Legal Proceedings or Orders pending or, to the Knowledge of the Company, threatened against or relating to the Company or the Subsidiary, or for periods prior to November 1, 2016, the Subsidiary’s Predecessor, at law or in equity, or before or by any Governmental Entity, and (b) neither of the Company nor the Subsidiary is or, to the Knowledge of the Company, is threatened to be made, subject to any outstanding Order.  Schedule 3.11 sets forth, with respect to each matter disclosed on such schedule, (i) the parties, (ii) the nature of the dispute, (iii) the relief

 

31



 

sought, (iv) the status of the dispute and (v) the status of any claims with the Company’s or the Subsidiary’s insurance claims related to such matters.  No event has occurred, and no claim, dispute or other condition or circumstance exists, that might directly or indirectly give rise to or serve as a basis for the commencement of any material Legal Proceeding.  With respect to any Legal Proceedings identified on Schedule 3.11 , the Company has Made Available to the Purchaser true and correct copies of all material complaints and filings related to such Legal Proceedings that are within the possession or control of the Company or the Subsidiary.  No matter disclosed on Schedule 3.11 , if decided or settled unfavorably to the Company or the Subsidiary, would be reasonably expected to prevent or adversely affect the consummation of the transactions contemplated under this Agreement, result in any transactions contemplated under this Agreement being declared unlawful or rescinded or have a Material Adverse Effect.

 

3.12                         No Undisclosed Liabilities .  Except as set forth on Schedule 3.12 , neither the Company nor the Subsidiary has any material Liability other than those (i) reflected or reserved against on the Balance Sheet, (ii) which have arisen after the date of the Balance Sheet in the ordinary course of business consistent with past practice of the Company and the Subsidiary (none of which is a Liability for breach of Contract, breach of warranty, tort, infringement, violation of Law or Proceeding), or (iii) with respect to any Selling Expenses arising under this Agreement.

 

3.13                         Accounts Receivable and Payable .

 

Except as set forth on Schedule 3.13 , all accounts and notes receivable of the Company and the Subsidiary (a) represent sales actually made in the ordinary course of business or valid claims as to which full performance has been rendered by the Company or the Subsidiary, as applicable, (b) constitute valid claims of the Company or the Subsidiary that, to the Knowledge of the Company, are not subject to claims of set off or other defenses or counterclaims and (c) with respect to any material accounts receivable, subject to a reserve for bad debts as accurately reflected on the face of the Interim Financials, are collectible within 90 days after billing.  Except as set forth on Schedule 3.13 or specifically reserved for on the Interim Financial Statements, all accounts and notes receivable of the Company and the Subsidiary are current, and there is no dispute regarding the collectability of any such receivables.  The reserve set forth in the Interim Financial Statements against the accounts receivable for returns and bad debts has been calculated in accordance with GAAP, consistently applied, and solely with respect to the Interim Financial Statements, subject to normal year-end adjustments and the absence of disclosures normally made in footnotes.  All accounts payable of the Company and the Subsidiary arose in bona fide arm’s length transactions in the ordinary course of business, and no account payable is delinquent more than sixty (60) days in its payment.

 

3.14                         Contracts .

 

(a)                                  Schedule 3.14(a)  contains a complete and accurate list as of the date hereof, and the Company has Made Available to the Purchaser true, correct and complete copies, of (and in the case of any oral Contract, an accurate description thereof) each of the following executory Contracts to which the Company and/or the Subsidiary is a party (collectively, the “ Material Contracts ”):

 

32



 

(i)                                      all Contracts involving aggregate consideration in excess of $1,500,000;

 

(ii)                                   all Contracts involving aggregate consideration in excess of $1,500,000 and requiring performance by any party more than one (1) year from the date hereof, which cannot be cancelled by the Company or the Subsidiary, as applicable, without penalty or without more than 30 days’ notice;

 

(iii)                                all Contracts that purport to limit, curtail or restrict the ability of the Company or any of its Affiliates to compete in any geographic area or line of business or materially restrict the Persons to whom the Company or any of its Affiliates may sell products or deliver services or restricts the price that the Company or any of its Affiliates may charge for its products or services;

 

(iv)                               all partnership, joint development, or joint venture Contracts;

 

(v)                                  all Contracts that relate to the sale or lease of any of the Company’s or Subsidiary’s assets, other than with respect to the sale or lease of Subsidiary’s assets in the ordinary course of business consistent with past practice, in each case for consideration in excess of $250,000;

 

(vi)                               all Contracts that relate to the acquisition of any business, stock or a material amount of assets of any other Person or any real property (whether by merger, purchase or sale of stock or membership interests, sale of assets or otherwise);

 

(vii)                            all Contracts with Sellers or Affiliates of the Company, Subsidiary or Seller;

 

(viii)                         all Contracts relating to Indebtedness;

 

(ix)                               all Company IP Agreements other than commercially available, unmodified, off-the-shelf software licenses (offered through shrink-wrap or click-wrap) with aggregate licenses, maintenance, support and other fees, in each instance, of $150,000 or less;

 

(x)                                  management Contracts, consulting Contracts, employee leasing Contracts or Contracts for the employment or services of any Contractor, Employee or other Person on a full-time, part-time, consulting or other basis involving annual compensation or remuneration in excess of $150,000 (other than offer letters in the ordinary course consistent with past practice), and all severance, change of control and deferred compensation Contracts;

 

(xi)                               any bonus, profit sharing, incentive, equity option, “phantom” equity, equity purchase, equity appreciation or other similar Contract, commitment or arrangement for the benefit of any current or former Employee or Contractor (other than offer letters in the ordinary course consistent with past practice);

 

33



 

(xii)                            any Contract under which the Company or the Subsidiary has advanced or loaned any amount to any of its managers, officers, Affiliates or employees outside the ordinary course of business;

 

(xiii)                         any Contract under which the Company or the Subsidiary has advanced or loaned to any other Person amounts in the aggregate exceeding $250,000;

 

(xiv)                        any Contract under which the Company or the Subsidiary is lessor of or permits any Person to hold or operate any property, real or personal;

 

(xv)                           any settlement or similar agreement with any Governmental Entity or other Person containing obligations yet to be performed or completed by either or both parties;

 

(xvi)                        any Contract that is a power of attorney executed on behalf of Company or Subsidiary;

 

(xvii)                     any Contract that requires Company or Subsidiary to use any supplier or third party for all or a specified percentage of Company or Subsidiary’s requirements or needs or requires Company or Subsidiary to provide to other parties “most favored nation” pricing;

 

(xviii)                  any Contract with a Material Customer or Material Supplier;

 

(xix)                        all collective bargaining agreements or other material Contracts with any labor organization, union or association to which the Company or the Subsidiary is a party.

 

(b)                                  Each Contract identified or required to be identified on Schedule 3.14(a)  (1) to the extent applicable, was validly assigned from Leehar Distributors, Inc. to the Subsidiary and (2) is in full force and effect and is valid, binding and enforceable in accordance with its terms (assuming each such Contract is a valid and binding obligation of each of the parties thereto other than the Company or the Subsidiary, as applicable) and to the Knowledge of the Company, each other party thereto, except to the extent enforceability may be limited by the General Enforceability Exceptions.  For each Contract identified or required to be identified on Schedule 3.14(a) , neither the Company, the Subsidiary, nor, to Knowledge of the Company, any other Person that is party to any such Contract, is in breach or default thereunder, nor to the Knowledge of the Company, has any notice of breach of default been threatened.

 

3.15                         Environmental Matters .

 

(a)                                  Each of the Company and the Subsidiary is and, together with the Subsidiary’s Predecessor for periods prior to November 1, 2016, for the last five (5) years has been, in compliance with all Environmental Laws;

 

(b)                                  Each of the Company and the Subsidiary holds all Environmental Permits required for the current operation of the business, and is, and, together with the Subsidiary’s Predecessor for periods prior to November 1, 2016, for the last five (5) years has been, in

 

34



 

compliance in all material respects with all such Environmental Permits and, to the extent required prior to the Closing Date, timely and complete applications have been or will be made for renewal, extension or reissuance of all such Environmental Permits, and the Company has not received written information which would lead it to believe that any Environmental Permit may not be renewed, extended or reissued in due course and as requested without the imposition of cost or penalty;

 

(c)                                   Neither the Company nor the Subsidiary (and for periods prior to November 1, 2016, the Subsidiary’s Predecessor) has received, as of the date hereof, any written notice, demand, letter or request for information alleging violation of any Environmental Law nor, as of the date hereof, no Environmental Claim is pending nor, to the Knowledge of the Company, threatened against the Company or the Subsidiary;

 

(d)                                  Neither the Company nor Subsidiary (and for periods prior to November 1, 2016, the Subsidiary’s Predecessor) has treated, stored, disposed of, transported, handled or released, or arranged for or permitted the treatment, storage, disposal, transportation, handling, or release of, any substance, including, without limitation, any Hazardous Material, or owned or operated any property or facility (and no such property or facility is contaminated by any Hazardous Material) in a manner that has given rise to or will give rise to an Environmental Claim;

 

(e)                                   Neither the Company nor any Subsidiary (and for periods prior to November 1, 2016, the Subsidiary’s Predecessor) has, either expressly or by operation of law, assumed or undertaken any Liability or corrective or remedial obligation of any other Person relating to Environmental Laws;

 

(f)                                    Neither the execution and delivery of this Agreement or the Transaction Documents nor the consummation of the transactions contemplated hereunder or thereunder will impose any obligations for site investigation or cleanup, or notification to or consent of Governmental Entity or any other Person, pursuant to any so-called “transaction-triggered” or “responsible property transfer” Environmental Laws; and

 

(g)                                   The Company has Made Available to the Purchaser true and correct copies of all environmental reports, audits, assessments and investigations, and all other material environmental documents, relating to the Company, the Subsidiary, the Company’s operation of the business, the Leased Real Property, any other real property owned or used by the Company, any Subsidiary, or any of the Company’s or the Subsidiary’s Predecessors.

 

3.16                         Employment and Labor Matters .

 

(a)                                  Schedule 3.16(a)  sets forth a true, correct and complete list of all current Employees and a true, correct and complete list of all individual independent contractors of the Company and/or the Subsidiary who are engaged through means other than through a staffing agency, professional employment organization or similar operation, including individuals who are engaged directly or through entities in which the individuals have an ownership interest (each, a “ Contractor ”), and sets forth each Employee’s and Contractor’s (as applicable) (i)

 

35



 

employee identification number, (ii) job title, (iii) location of employment or services, (iv) hire or retention date, (v) base salary, hourly wage, or other remuneration rate, (vi) accrued and unused paid time off, (vii) the amount of any incentive or other additional compensation (including bonus and commission amounts) for which such Employee or Contractor is eligible and the amount of such additional compensation actually paid by each Employee or Contractor during the prior 12 months, (viii) work status (i.e., full-time, part-time, temporary, on leave of absence, etc.) and (ix) status as exempt or non-exempt from the overtime requirements of the Fair Labor Standards Act and similar Laws.

 

(b)                                  Schedule 3.16(b)  contains a complete and accurate list, as of the date hereof, of each collective bargaining or other labor union contract or labor arrangement covering any Employee (the “ Collective Bargaining Agreements ”).  The Company has Made Available true and complete copies of all Collective Bargaining Agreements to the Purchaser.  The Company is in compliance with the terms of the Collective Bargaining Agreements.

 

(c)                                   Except as set forth on Schedule 3.16(c) , (i) there are no activities or proceedings involving any labor union to organize or represent any Employees; (ii) there is no labor strike, labor dispute or work stoppage involving any Employee pending or overtly threatened; (iii) the Company and the Subsidiary are, and, together with the Subsidiary’s Predecessor for periods prior to November 1, 2016, have been, in compliance with all applicable Laws in connection with the Employees and the Contractors; (iv) as of the date hereof, there is no pending or threatened actions, claims or lawsuits brought by any Employee or Contractor under any Laws in connection with his or her employment with or services for the Company or the Subsidiary, respectively, and (v) there are no unfair labor practice charges or other applications or proceedings before a labor relations board or any similar authority currently pending or overtly threatened, involving the Company or the Subsidiary.  No Employee or Contractor has notified the Company or the Subsidiary in writing that such Employee or Contractor intends to terminate his or her employment or engagement, as applicable, within the six-month period following the Closing Date.  Except as set forth on Schedule 3.16(c) , as of the date hereof, all compensation, including wages, commissions, bonuses and accrued vacation payable to all Employees, Contractors of the Company or the Subsidiary for services performed on or prior to the date hereof have been paid in full or are scheduled to be paid in full.  Each Employee and Contractor of, and each other individual performing any services for, the Company or the Subsidiary is, and, together with the Subsidiary’s Predecessor for periods prior to November 1, 2016, during the past five (5) years has been properly classified under applicable Law as a common law employee, independent contractor, leased employee or agent, and neither the Company nor the Subsidiary has any Liability for the improper classification of any employees as independent contractors, exempt from the overtime requirements of the Fair Labor Standards Act or any other applicable Law, or leased employees.

 

(d)                                  Within the preceding two (2) years, neither the Company nor the Subsidiary nor for periods prior to November 1, 2016 the Subsidiary’s Predecessor has implemented any plant closings or layoffs requiring notice under the WARN Act or any similar Law.  Schedule 3.16(d)  sets forth a list of Employees (by date and location) who were laid off by the Company or the Subsidiary during the 90-day period preceding the date hereof.

 

36



 

(e)                                   Except as set forth on Schedule 3.16(e) , neither the execution, delivery and performance of any of this Agreement nor the consummation of the transactions contemplated thereby will (i) result in any payment becoming due from the Company or the Subsidiary to any Employee or Contractor, (ii) increase any benefits payable under any Contract between the Company or the Subsidiary and any Employee or Contractor, or (iii) accelerate the time of payment or vesting of any benefits under any such Contract.

 

(f)                                    (i) All levies, assessments and penalties made against, or premiums owed, by the Company or the Subsidiary pursuant to any applicable workers’ compensation Laws have been paid, and (ii) the Company and/or the Subsidiary have not been reassessed under any such legislation during the past three years, and to the Company’s Knowledge there are no circumstances that would permit a penalty reassessment.

 

(g)                                   The Company or the Subsidiary have withheld all amounts required by Law to be withheld from payments made by it with respect to all Employees, including those with respect to income Tax withholdings, pension plan contributions and employment or unemployment insurance premiums and remittances, and has remitted all such amounts as required within the times required by applicable Laws.

 

3.17                         Intellectual Property .

 

(a)                                  Schedule 3.17(a)  lists all issued Patents, registered Marks, pending applications for registrations of any Marks and pending Patent applications, registered Copyrights and pending applications for registration of any Copyrights and domain name registrations, in each case, held or purported to be owned by the Company and/or the Subsidiary (the “ Registered IP ”). Each item of Registered IP is valid, subsisting and enforceable and, and has not been abandoned or cancelled. No Legal Proceeding is pending, or to the Knowledge of the Company has been threatened, challenging the validity, enforceability, registration, ownership or use of any Company Intellectual Property (other than routine correspondence from the US Patent and Trademark Office or other similar office or administrative body). All necessary registration, maintenance and renewal fees in connection with such Registered IP that are or will be due for payment on or before the Closing Date have been or will be timely paid and all necessary documents and certificates in connection with such Registered IP that are or will be due for filing on or before the Closing Date have been or will be timely filed with the relevant authorities for the purposes of maintaining such Registered IP.

 

(b)                                  Neither the operation of the Company or the Subsidiary, nor for periods prior to November 1, 2016 the Subsidiary’s Predecessor, nor any Company Product, has infringed, misappropriated, diluted, or otherwise violated, and does not infringe, misappropriate, dilute, or otherwise violate any Intellectual Property Rights of any third Person.  No Legal Proceeding is pending or, to the Knowledge of the Company, threatened, accusing the Company or the Subsidiary of infringement, misappropriation, dilution, or violation of any Intellectual Property Rights of any Person in connection with the operation of the Company or the Subsidiary or otherwise. To the Knowledge of the Company, no Person is infringing or, diluting, misappropriating or otherwise violating any Company Intellectual Property.  Neither Company nor Subsidiary (and for periods prior to November 1, 2016, the Subsidiary’s Predecessor) has

 

37



 

received written, or to the Knowledge of the Company, otherwise, notice from any Person (including a cease and desist letter or unsolicited offer to license) claiming that such operation or any act, any Company Product, or any Company Intellectual Property infringes or, dilutes, misappropriates or otherwise violates any Intellectual Property Rights of any Person or constitutes unfair competition or trade practices under the applicable Law.

 

(c)                                   The Company or the Subsidiary is the sole and exclusive legal and beneficial owner of, or has a valid and enforceable right to use (either through ownership or pursuant to a valid written license), each item of Company Intellectual Property, free and clear of any Liens other than Permitted Liens. Each Company IP Agreement is valid and binding on the Company or the Subsidiary party to such Company IP Agreement in accordance with its terms and is in full force and effect. Neither the Company nor, to the Knowledge of the Company any other party thereto is, or is alleged to be, in breach of or default under, or has provided or received any notice of breach of, default under, or intention to terminate (including by non-renewal), any Company IP Agreement. Each of the Company and the Subsidiary has entered into binding, valid and enforceable, written agreements with each current and former employee and independent contractor who have made material contributions to the Company Intellectual Property whereby such employee or independent contractor (A) acknowledges the Company’s (or the Subsidiary’s) exclusive ownership of all Intellectual Property Rights invented, created, or developed by such employee or independent contractor within the scope of his or her employment or engagement with the Company or the Subsidiary; and (B) grants to the Company or the Subsidiary a present, irrevocable assignment of any ownership interest such employee or independent contractor may have in or to such Intellectual Property Rights. No employee or independent contractor scheduled any exceptions or exclusions with respect to any proprietary rights in such Contracts. Neither the execution, delivery, or performance of this Agreement, nor the consummation of the transactions contemplated hereunder, will result in the loss or impairment of, modification of scope of rights or licenses, nor payment of any additional amounts with respect to, or require the consent of any other Person in respect of, the Company’s or the Subsidiary’s right to own or use any Company Intellectual Property

 

(d)                                  The Company and the Subsidiary have taken all steps reasonable under the circumstances to protect and preserve the confidential information and Trade Secrets and any other material non-public, proprietary or confidential information of the Company, the Subsidiary or any Person to whom the Company or the Subsidiary, as applicable, has a confidentiality obligation, including, without limitation, adopting policies applicable to employees of the Company and requiring all employees, contractors and third persons having access thereto to execute written non-disclosure agreements or comparable documentation.  No confidential information or Trade Secrets have been disclosed by the Company or the Subsidiary or authorized to be disclosed by the Company or the Subsidiary to any third party Person other than pursuant to a written non-disclosure agreement; and, to the Knowledge of the Company, no third party Person that is a party to any non-disclosure agreement with the Company or the Subsidiary is in breach of default thereof.  No confidential information or Trade Secrets of the Company or the Subsidiary that are material to the Company or the Subsidiary have been improperly disclosed or misappropriated by another Person. 

 

38



 

(e)                                   Schedule 3.17(e)  contains (i) a correct, current, and complete list of all Company Products; and (ii) except for Open Source Software, a list of all other material Software incorporated in or distributed or licensed with such Company Product in any manner for use in connection with such Company Product.  Other than Intellectual Property Rights licensed to the Company under (a) licenses for Open Source Software, or (b) the licenses set forth in Schedule 3.17(e) , the Company Intellectual Property includes all Intellectual Property Rights that are used in or necessary to the conduct of the business of the Company or the Subsidiary as it currently is conducted by the Company or the Subsidiary.

 

(f)                                    The computers, servers, workstations, routers, hubs, switches, circuits, and other information technology equipment of the Company and the Subsidiary (the “ IT Assets ”) operate and perform in all material respects as required by the operation of the Company, and have not materially malfunctioned or failed in the past three (3) years.  The Company and the Subsidiary have (i) used commercially reasonable efforts to protect the integrity and security of the IT Assets (and all information stored or contained therein) against unauthorized use, access, interruption, modification or corruption; (ii) implemented a written information security program, which includes commercially reasonable data backup, data storage, system redundancy, and disaster avoidance and recovery procedures, and business continuity plans, procedures, and facilities, and act in compliance therewith and (iii) test such plans and procedures on a regular basis, and such plans and procedures have been proven effective upon such testing.  The IT Assets are reasonably sufficient for the immediate needs of the business of the Company and the Subsidiary, including as to capacity and ability to process current peak volumes in a timely manner. The IT Assets are in sufficiently good working condition to perform all information technology operations and include sufficient licensed capacity (whether in terms of authorized sites, units, users, seats, or otherwise) for all Software, in each case as necessary for the conduct of the business of the Company and Subsidiary as currently conducted or contemplated by the Company to be conducted in all material respects.  To the Company’s Knowledge there have been no unauthorized intrusions or breaches of the security the IT Assets or the occurrence of circumstances or events that require the Company or the Subsidiary to give notice to a data subject or otherwise conduct an investigation into the Company’s security.

 

(g)                                   Schedule 3.17(g)  sets forth a correct, current, and complete list of each item of Open Source Software that is incorporated into, combined with, linked with, provided to any Person as a services, provided via a network as a service or application, or otherwise made available with any Company Product, and for each such item of Open Source Software, (i) the applicable Company Product and (ii) the name and version number of the applicable license agreement. Neither Company nor Subsidiary has used Open Source Software in any manner that would or could (i) require the disclosure or distribution in source code form of any current Company Product or any portion thereof, (ii) require the licensing of any current Company Product or any portion thereof for the purpose of making derivative works, or (iii) impose any restriction on the consideration to be charged for the distribution of any current Company Product or any portion thereof.

 

(h)                                  Except as set forth on Schedule 3.17(h) , the Company and the Subsidiary have not disclosed, licensed or made available to any Person, or permitted the disclosure or

 

39



 

delivery to any escrow agent or other Person of, any Company Source Code, except for disclosures to the Company’s or the Subsidiary’s employees, contractors or consultants under agreements that prohibit use or disclosure except in the performances of services to the Company or the Subsidiary.  To the Company’s Knowledge, no event has occurred, and no circumstance or condition exists, that (with or without notice or lapse of time, or both) shall, or would reasonably be expected to, result in the disclosure or delivery by the Company or the Subsidiary to any party of any Company Source Code.  To the Knowledge of the Company, there has been no unauthorized theft, reverse engineering, decompiling, disabling, or other unauthorized disclosure of or access to any Company Source Code.

 

(i)                                      The Company and the Subsidiary are in material compliance with all applicable Laws and contractual obligations relating to the privacy or use of information regarding or provided by users of Company Products, or to the collection, storage, transfer and any other processing of any Personally Identifiable Information (“ Company Privacy Laws ”). The Company and the Subsidiary have established commercially reasonable policies and procedures regarding the security of Personally Identifiable Information in its possession, custody or control.  Each of the Company and the Subsidiary is in material compliance with the terms of all Contracts to which such entity is a party to relating to data, privacy, security, or breach notification (including provisions that impose conditions or restrictions on the collection, use, storage, transfer, or disposal of Personally Identifiable Information). With respect to any Company Privacy Law: (i) neither the execution, delivery, or performance of this Agreement nor the consummation of any of the transactions contemplated by this Agreement will result in any violation of any Company Privacy Laws, and (ii) no claims have been asserted, or to the Company’s Knowledge, are threatened against the Company or the Subsidiary alleging any violation of any Company Privacy Law.

 

(j)                                     All Company Products operate in accordance with their documented specifications and as the Company and its Subsidiaries have warranted to their customers. To the Company’s Knowledge, all Company Products (and all parts thereof) are free of “back door,” “time bomb,” “Trojan horse,” “worm,” “drop dead device,” “virus” or other Software routines or hardware components intentionally designed to permit unauthorized access or the unauthorized disablement or erasure of such Company Product (or all parts thereof) or data or other Software of users (“ Contaminants ”).

 

(k)                                  The Company and the Subsidiary have a privacy notice(s) regarding the collection, use, and disclosure of Personally Identifiable Information in connection with the operation of the Company’s business (including via Company and/or Subsidiary websites and mobile applications) and is and, together with the Subsidiary’s Predecessor for periods prior to November 1, 2016, in the past three (3) years has been in compliance with such privacy notice(s). The Company and the Subsidiary each have posted a privacy notice in a clear and conspicuous location on all websites and any mobile applications own or operated by the Company and the Subsidiary.

 

3.18                         Customers and Suppliers Schedule 3.18 contains a complete and accurate list of (i) the fifteen (15) largest customers of the Company and the Subsidiary based on, and together with, a listing of the revenue for such customer for the twelve months ended December 31, 2016

 

40



 

and the eight (8) months ended August 31, 2017 (each a “ Material Customer ”) and (ii) the ten (10) largest suppliers of the Company and the Subsidiary based on, and together with a listing of, the purchases by the Company and the Subsidiary of products and/or services provided by such supplier for each of the twelve months ended December 31, 2016 and the eight (8) months ended August 31, 2017 (each a “ Material Supplier ”).  Except as set forth on Schedule 3.18 , none of such suppliers or customers has notified the Company or the Subsidiary in writing, or to the Knowledge of the Company, has otherwise threatened, indicated or provided notice that (i) the customer or supplier intends to discontinue its relationship with the Company or the Subsidiary, as applicable, or (ii) the customer or supplier intends to materially reduce or change the terms of its purchases from, or provision of, supplies to the Company or the Subsidiary, as applicable.

 

3.19                         Healthcare Regulatory Compliance .

 

(a)                                  Healthcare Regulatory Permits . (i) the Company, the Subsidiary and all their managers, officers, directors and professionally licensed employees or agents (“ Professional Personnel ”) have all material Permits and Professional Licenses required by Healthcare Regulatory Laws (Permits and Professional Licenses, collectively  (“ Healthcare Regulatory Permits ”) to operate the business of the Company as it is presently conducted; (ii) each Healthcare Regulatory Permit is valid, unrestricted, in good standing and subsisting and in full force and effect; (iii) the operation of the business of the Company as it is currently conducted is not in material violation of, nor is the Company in material default or violation under, any Healthcare Regulatory Permit; (iv) to the Knowledge of the Company, no event has occurred or been threatened which, with notice or the lapse of time or both, would constitute a material default or violation of any material terms, condition or provision of any Healthcare Regulatory Permit; and (v) there are no actions pending or, to the Knowledge of the Company, threatened, that seek the revocation, cancellation, suspension or adverse modification of any Healthcare Regulatory Permit. To the Knowledge of the Company, each director, officer, employee, agent, shareholder and independent contractor of the Company and the Subsidiary possesses all material Healthcare Regulatory Permits necessary for the lawful conduct of his or her duties and obligations in the operation of the Company.

 

(b)                                  Compliance with Healthcare Regulatory Laws .

 

(i)                                      The Company and the Subsidiary are, and, together with the Subsidiary’s Predecessor for periods prior to November 1, 2016, for the last three years have been, in compliance in all material respects with all applicable Healthcare Regulatory Laws.

 

(ii)                                   The operation of the business of the Company and the Subsidiary, as it is currently conducted, is not in violation of, nor is the Company in default or violation under, any Healthcare Regulatory Laws in any material respect.

 

(iii)                                To the Knowledge of the Company, no event has occurred or been threatened which, with notice or the lapse of time or both, would constitute a material violation of any terms, condition or provision of any Healthcare Regulatory Laws.

 

41



 

(iv)                               Neither the Company, the Subsidiary, nor, to the Knowledge of the Company, any of their directors, officers, agents, employees, shareholders or independent contractors:

 

(A)                                are or have been convicted of or charged or threatened with prosecution or, to the Knowledge of the Company, is under an investigation or subject to any enforcement action or Order by a Governmental Entity, including CMS, the U.S. Department of Health and Human Services Officer of Inspector General, Office for Civil Rights and the DOJ, or assessed any Civil Monetary Penalty, for any violation of a Healthcare Regulatory Law; or

 

(B)                                are excluded, suspended or debarred from participation, or are otherwise limited, restricted or ineligible to participate, in any Federal Healthcare Program.

 

3.20                         Related Party Transactions .  Except pursuant to any Employee Plans or other arrangements with respect to compensation or employment arrangements with employees, officers or managers, which have been Made Available to Purchaser, there are no transactions or agreements involving the payment for, or provision of goods and services to, or assumption of Liabilities, between the Company and/or the Subsidiary, on the one hand, and any Affiliate of the Company or the Subsidiary, on the other hand, other than those contemplated by this Agreement and the other Transaction Documents.  No Affiliate of the Company or the Subsidiary, and no Securityholder has any interest in or owns any asset, tangible or intangible, of the Company or the Subsidiary.

 

3.21                         Brokers and Finders .  There are no claims for brokerage commissions, finders’ fees or similar compensation in connection with the Transactions based on any arrangement or agreement made by or on behalf of the Company or the Subsidiary other than obligations to Houlihan Lokey, Inc., which obligations are Selling Expenses.

 

3.22                         Insurance .

 

Schedule 3.22 sets forth the following information with respect to each Insurance Policy (including policies providing property, casualty, liability and workers’ compensation coverage) to which the Company or the Subsidiary is a party:

 

(a)                                  the name of the insurer, the name of the policyholder and the name of each covered insured;

 

(b)                                  the policy number and the period of coverage; and

 

(c)                                   the type and amount of coverage.

 

With respect to each such Insurance Policy: (A) the policy is legal, valid, binding, enforceable and in full force and effect, except as enforceability may be limited by the General Enforceability Exceptions; (B) neither the Company not the Subsidiary is in breach or default (including with respect to the payment of premiums or the giving of notices), and no event has occurred which, with notice or the lapse of time, would constitute such a breach or default, or permit termination, modification or acceleration, under the policy; and (C) no party to the policy

 

42



 

had repudiated any provision thereof.  The Insurance Policies are sufficient for compliance with all applicable Laws and Contracts to which the Company or the Subsidiary is a party or by which the Company or the Subsidiary is bound.

 

3.23                         Service Liability Claims .

 

(a)                                  Except as set forth on Schedule 3.23(a) , there are no Service Liability Claims.

 

(b)                                  Except (i) as set forth on Schedule 3.23(b) , (ii) for conditions or warranties implied or imposed by any applicable Law, or (iii) as contained in the Company’s or the Subsidiary’s standard terms and conditions of sale or service, neither the Company nor the Subsidiary has given any warranty or made any representation in respect of products or service supplied, sold or leased by it.

 

(c)                                   Except (i) as set forth on Schedule 3.23(c) , and (ii) except as otherwise occurs in the ordinary course, each service rendered by the Company and the Subsidiary has been in material conformity with all applicable contractual commitments and all express and implied warranties.

 

3.24                         Officers and Managers; Bank Accounts .

 

(a)                                  Schedule 3.24(a)  lists all officers and managers of the Company and the Subsidiary.

 

(b)                                  Set forth on Schedule 3.24(b)  is an accurate and complete list showing: (a) the name of each bank in which the Company or the Subsidiary has an account, credit line or safe deposit box and the names of all Persons authorized to draw thereon or to have access thereto other than investment accounts of the Company and the Subsidiary.

 

3.25                         Books and Records .

 

The minute books of the Company and the Subsidiary contain complete and correct records of all meetings held of, and actions taken by written consent of, the holders of voting securities, the board of managers or Persons exercising similar authority, and committees of the board of managers of the Company and the Subsidiary, and no meeting of any such holders, board of managers, Persons, or committee has been held, and no other action has been taken, for which minutes or other evidence of action have not been prepared and are not contained in such minute books.  The Company and the Subsidiary have at all times maintained complete and correct records of all issuances and transfers of the Units.  At the Closing, all such minute books and records will be in the possession of the Company and the Subsidiary and located at the principal office of the Subsidiary.

 

3.26                         No Other Representations and Warranties .

 

NONE OF THE COMPANY, THE SUBSIDIARY OR THEIR RESPECTIVE REPRESENTATIVES OR DIRECT OR INDIRECT EQUITYHOLDERS HAS MADE, AND

 

43



 

SHALL NOT BE DEEMED TO HAVE MADE, ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED OR OF ANY NATURE WHATSOEVER RELATING TO THE COMPANY, THE SUBSIDIARY OR THE BUSINESS OF THE COMPANY OR ANY OF THE SUBSIDIARY OR OTHERWISE IN CONNECTION WITH THE TRANSACTION, AND DISCLAIM ALL LIABILITY AND RESPONSIBILITY FOR ANY REPRESENTATION OR WARRANTY MADE OR COMMUNICATED (ORALLY OR IN WRITING, INCLUDING ANY OPINION, INFORMATION OR ADVICE WHICH MAY HAVE BEEN PROVIDED BY THEIR REPRESENTATIVES) TO THE OTHER PARTIES, OTHER THAN THOSE REPRESENTATIONS AND WARRANTIES OF THE COMPANY EXPRESSLY SET FORTH IN THIS ARTICLE III.

 

(a)                                  Without limiting the generality of the foregoing, except as expressly set forth in this Article III , none of the Company, the Subsidiary or any other Person (including, without limitation, any Representative or direct or indirect equityholder of the Company or the Subsidiary) has made, and shall not be deemed to have made, any express or implied representation or warranty, either written or oral, at law or in equity or of any nature whatsoever, in the materials relating to the business of the Company and/or the Subsidiary made available to the Purchaser or its Affiliates or Representatives or any other Persons, including due diligence materials, or in any presentation of the business of the Company and/or the Subsidiary by management of the Company and/or the Subsidiary or others in connection with the Transaction, and no statement contained in any of such materials or made in any such presentation or other materials shall be deemed a representation or warranty hereunder or otherwise or deemed to be relied upon by the Purchaser or Merger Sub in executing, delivering and performing this Agreement and the Transactions.  It is understood that any estimates, budgets, projections or other predictions, any data, any financial information or any memoranda or offering materials or presentations, including any offering memorandum or similar materials made available by the Company and/or the Subsidiary and/or their respective Representatives or direct or indirect equityholders, are not and shall not be deemed to be or to include representations or warranties of the Company and/or the Subsidiary, and are not and shall not be deemed to be relied upon by the Purchaser or Merger Sub or any of their Affiliates in executing, delivering and performing this Agreement and the Transaction.

 

ARTICLE IV
REPRESENTATIONS AND WARRANTIES OF BLOCKER SELLERS

 

Each Blocker Seller, severally and not jointly, solely with respect to itself and the Blocker that it owns, represents and warrants to the Purchaser as follows:

 

4.1                                Status; Authority; Conflicts .

 

(a)                                  Each Blocker Seller and each Blocker owned by such Blocker Seller was duly formed, incorporated or organized, as applicable, and is validly existing under the laws of its jurisdiction of formation, incorporation or organization, as applicable, has all requisite partnership, corporate or requisite limited liability company power and authority, as applicable, to carry on its business as now conducted and to own or lease and operate its properties and assets and is duly qualified to do business as a foreign entity under the laws of each jurisdiction

 

44



 

where such qualification is necessary.  The Blockers are only qualified in the jurisdiction of their incorporation and are not required to be qualified under any other jurisdiction.

 

(b)                                  Each Blocker Seller has all requisite partnership power and authority to execute and deliver the Transaction Documents to which it is a party, to carry out its obligations under such Transaction Documents and to consummate the Transaction; (ii) the execution and delivery of the Transaction Documents to which such Blocker Seller is a party and the consummation of the Transactions have been duly and validly authorized by such Blocker Seller and no other proceedings on the part of such Blocker Seller are necessary to approve the Transaction Documents to which such Blocker Seller is a party or to consummate the Transaction; and (iii) this Agreement has been duly and validly executed and delivered by such Blocker Seller, and constitutes the valid and binding agreement of such Blocker Seller enforceable against such Blocker Seller in accordance with the terms and conditions of this Agreement, subject to General Enforceability Exceptions.

 

(c)                                   Except as set forth on Schedule 4.1(c) , the execution and delivery of the Transaction Documents to which each Blocker Seller or Blocker is a party, as applicable, does not, and the consummation of the Transactions, and performance by each Blocker Seller or Blocker, as applicable, of its obligations hereunder and thereunder, whether with or without the passage of time, the giving of notice or both, will not result in any breach of any of the provisions of, constitute a default under, result in a violation of, give any third party the right to terminate or to accelerate any obligation under, result in the creation of any Lien upon the Blockers’ Equity or any assets of the Blocker Sellers or Blockers, conflict with, give rise to a right of termination, modification, cancellation or acceleration of any obligation or to a loss of a benefit, in each case under:

 

(i)                                      the Governing Documents of each Blocker Seller or Blocker;

 

(ii)                                   any Contract, Law or Order applicable to the each Blocker Seller or Blocker in any material respect; or

 

(iii)                                without limiting the foregoing, require the Consent of, notice to, or filing with, any Person (except for such filings as may be required under the HSR Act and the filing of the Certificate of Merger).

 

4.2                                Title .  Such Blocker Seller holds of record and beneficially the Blockers’ Equity set forth on Schedule 4.2 with respect to such Blocker Seller, free and clear of any and all Liens (other than pursuant to the Blockers’ Organizational Documents, and those imposed by or arising out of state or federal securities laws).  Such Blocker Seller has, and as of Closing will have, good and valid title to such Blockers’ Equity.

 

4.3                                Blocker Capitalization .

 

(a)                                  All of the Blockers’ Equity owned by such Blocker Seller has been duly authorized, validly issued, fully paid and non-assessable, are free and clear of any and all Liens (other than those imposed by or arising out of state or federal securities laws), and has been

 

45



 

offered, issued and delivered in compliance with applicable Laws and Organizational Documents.

 

(b)                                  Except as set forth in the Blockers’ Organizational Documents of the Blocker owned by such Blocker Seller, there are no outstanding subscriptions, options, warrants, commitments, preemptive rights, deferred compensation rights, equity appreciation rights, “phantom” equity rights, calls, puts, rights to subscribe, Contracts, agreements, arrangements or commitments of any kind relating to the sale or issuance of, or outstanding securities convertible into or exercisable or exchangeable for, any Blockers’ Equity of the Blocker owned by such Blocker Seller or which restrict the transfer of any such Blockers’ Equity.

 

(c)                                   Except as set forth in the Blockers’ Organizational Documents of the Blocker owned by such Blocker Seller, there are no outstanding contractual obligations, commitments or arrangements (contingent or otherwise) to repurchase, redeem or otherwise acquire or with respect to the voting, restrictions on transfer, or any other rights or restrictions of any Blockers’ Equity or other equity interests or any other securities of such Blocker.

 

(d)                                  The capitalization of such Blocker is set forth on Schedule 4.3(d) , and other than those shares of capital stock set forth on Schedule 4.3(d) , no shares of capital stock of such Blocker are issued and outstanding.

 

4.4                                Brokers or Finders .  There are no claims for brokerage commissions, finders’ fees or similar compensation in connection with the Transactions based on any arrangement or agreement made by or on behalf of the Blocker Sellers or the Blockers owned by such Blocker Sellers, except as described in Section 3.21 .

 

4.5                                Blockers .

 

(a)                                  Such Blocker was formed for the purpose of investing in the Company and holding its portion of the Blockers’ Units;

 

(b)                                  Except as set forth on Schedule 4.5(b) , such Blocker, since the date of its formation or organization, as applicable, (i) has not carried on any business or conducted any operations other than acquiring and holding (directly or indirectly) ownership in the Company and (ii) has not incurred any Indebtedness;

 

(c)                                   Other than in respect of Taxes on the Blocker’s allocable share of taxable income of the Company, immaterial obligations as a direct or indirect member of the Company and immaterial ordinary course expenses (including without limitation those related to filing Tax Returns and maintaining its limited liability company or corporate existence, as applicable), such Blocker has no Liabilities, Contracts, assets or obligations of any nature or direct or indirect interest of any kind in any Person;

 

(d)                                  There are no Legal Proceedings pending or, to the knowledge of such Blocker Seller, threatened, against the Blocker owned by such Blocker Seller;

 

46



 

(e)                                   Since December 31, 2016, such Blocker has not (i) made, revoked or changed any Tax election, (ii) changed any annual Tax accounting period, (iii) adopted or changed any method of Tax accounting, (iv) filed any amended Tax Return, (v) entered into any closing agreement with respect to Taxes, (vi) waived any claim for refund or credit of Taxes, (vii) settled any audit, examination or Legal Proceeding relating to Taxes, (viii) surrendered any right to claim a Tax refund, or (ix) consented to the extension or waiver of the limitations period applicable to any audit, examination or Legal Proceeding relating to Taxes; and

 

(f)                                    Such Blocker is not subject to any Order of any Governmental Entity.

 

(g)                                   Except as set forth on Schedule 4.5(g) ,

 

(i)                                      such Blocker has duly and timely filed (taking into account applicable extensions as to) all Tax Returns that are required to have been filed by it, and all of such Tax Returns are accurate in all material respects;

 

(ii)                                   such Blocker has paid all Taxes required to be paid by it (whether or not shown to be due on any Tax Return);

 

(iii)                                (A) such Blocker is not a party to any action or proceeding by any Tax Authority for assessment or collection of any Taxes from such Blocker and (B) such Blocker has not waived any statute of limitations with respect to any Tax that is currently in effect;

 

(iv)                               there are no Liens for Taxes on any of the assets of such Blocker other than Permitted Liens;

 

(v)                                  such Blocker is not a party to or bound by any Tax indemnification, Tax allocation or Tax sharing agreement (excluding, for this purpose, any agreement entered into in the ordinary course of business that is primarily not related to Taxes, such as leases, licenses or credit agreements);

 

(vi)                               such Blocker (i) is not a party to any “listed transaction,” as defined in Code Section 6707A(c)(2) and Treasury Regulations Section 1.6011-4(b)(2) (ii) has not failed to disclose on its federal income Tax Returns any position taken therein that could give rise to a substantial understatement of federal income Tax within the meaning of Code Section 6662, (iii) is not a party to any plan or arrangement described in Code Section 6111(d) or Code Section 6662(d)(2)(C)(ii)(III) and (iv) has not “participated” in a “reportable transaction” within the meaning of Treasury Regulations section 1.6011-4;

 

(vii)                            such Blocker (A) has never been a member of Relevant Group (other than a Relevant Group no other member of which is not a Target Company) or (B) has no liability for the Taxes of any other Person (other than another Target Company) under Treasury Regulations Section 1.1502-6 (or any corresponding or similar provision of state, local or non-U.S. law), as a transferee or successor, otherwise by operation of Law, or by Contract (excluding any Contract the principal purpose of which is not related to Taxes, such as a lease, license or credit agreement);

 

47



 

(viii)                         such Blocker has never owned an interest in any other corporation or an interest in any partnership or other entity, including an entity the separate existence of which is disregarded for federal income Tax purposes, except for its Units of interest in the Company and, in the case of LDI Nautic VIII-A Blocker, Inc., its interest in Nautic VIII-A Splitter;

 

(ix)                               such Blocker has made no payments, is not obligated to make any payments, and is not a party to any agreement that could obligate it to make any payments, that would not be deductible under Section 280G of the Code (or any similar provision of state, local or foreign Law), and such Blocker has not agreed, and has no actual or potential obligation, to reimburse, pay, gross up or otherwise indemnify any employee or contractor (whether current or former) or any other Person for any Taxes, including Taxes imposed under Sections 409A or 4999 of the Code;

 

(x)                                  all Taxes that such Blocker is or was required to have withheld or collected have been duly withheld or collected and, to the extent required, have been paid to the appropriate Taxing Authority or Governmental Entity, including all Taxes required to have been withheld or collected and paid in connection with amounts paid or owing to any employee, former employee, non-resident, partner, independent contractor, creditor, shareholder, Affiliate, customer, vendor or other third party, and all IRS Forms W-2 and 1099 required with respect thereto have been properly completed and timely filed;

 

(xi)                               the unpaid Taxes of each Blocker did not, as of the most recent balance sheet of such Blocker, exceed the reserve for Tax liability (rather than any reserve for deferred Taxes established to reflect timing differences between book and Tax income) set forth on such balance sheet and (ii) will not, as of the Closing Date, exceed Taxes of such Blocker included in the Closing Indebtedness, as finally determined hereunder;

 

(xii)                            such Blocker has not engaged in any trade or business except through (as a member of) the Company, and such Blocker has earned no income from any trade or business except for the Blocker’s share of the Company’s income from conducting a trade or business, all of which income has been reported by the Company to such Blocker on IRS Schedule K-1 as and to the extent required by Law;

 

(xiii)                         neither such Blocker, Purchaser nor any Affiliate of Purchaser will be required to include any item of income in, or exclude any item of deduction from, taxable income for any taxable period (or portion thereof) ending after the Closing Date as a result of any (i) change in method of accounting of the Blocker for a taxable period ending on or before the Closing Date, (ii) use of an improper method of accounting for a taxable period ending on or before the Closing Date, (iii) installment sale or open transaction disposition made by the Blocker on or before the Closing Date, (iv) prepaid amount received by the Blocker prior to the Closing Date,  (v) closing agreement under Code Section 7121 (or other comparable agreement)

 

48



 

entered into on or before the Closing Date or (vi) cancellation of debt of the Blocker to which Code Section 108(i) applied;

 

(xiv)                        no written (or to the knowledge of such Blocker Seller, other) claim has been received by such Blocker from any Taxing Authority in a jurisdiction in which such Blocker does not file Tax Returns that such Blocker is or may be subject to taxation by that jurisdiction;

 

(xv)                           Such Blocker has Made Available to Purchaser correct and complete copies of all United States federal income Tax Returns filed by, and all examination reports and statements of deficiencies assessed against or agreed to by, such Blocker since December 31, 2013; and

 

(xvi)                        Such Blocker, and each Blocker Seller of any of such Blocker’s Equity, is a United States person within the meaning of Code Section 7701(a)(30).

 

4.6                                No Other Representations and Warranties .

 

(a)                                  The representations and warranties set forth in this Article IV shall constitute the only representations and warranties of each Blocker Seller with respect to the Transaction.

 

NONE OF ANY BLOCKER SELLER OR THE RESPECTIVE REPRESENTATIVES, DIRECT OR INDIRECT EQUITYHOLDERS OR ANY BLOCKER OWNED BY SUCH BLOCKER SELLER HAS MADE, AND SHALL NOT BE DEEMED TO HAVE MADE, ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED OR OF ANY NATURE WHATSOEVER RELATING TO ANY BLOCKER, THE COMPANY, THE SUBSIDIARY OR THE BUSINESS OF ANY BLOCKER, THE COMPANY OR ANY OF THE SUBSIDIARY OR OTHERWISE IN CONNECTION WITH THE TRANSACTION, AND DISCLAIM ALL LIABILITY AND RESPONSIBILITY FOR ANY REPRESENTATION OR WARRANTY MADE OR COMMUNICATED (ORALLY OR IN WRITING, INCLUDING ANY OPINION, INFORMATION OR ADVICE WHICH MAY HAVE BEEN PROVIDED BY THEIR REPRESENTATIVES) TO THE OTHER PARTIES, OTHER THAN THOSE REPRESENTATIONS AND WARRANTIES OF EACH BLOCKER SELLER EXPRESSLY SET FORTH IN THIS ARTICLE IV .

 

(b)                                  Without limiting the generality of the foregoing, except as expressly set forth in this Article IV , no Blocker Seller nor or any other Person (including, without limitation, any Representative or direct or indirect equityholder of such Blocker Seller) has made, and shall not be deemed to have made, any express or implied representation or warranty, either written or oral, at law or in equity or of any nature whatsoever, in the materials relating to the business of any Blocker, the Company and/or the Subsidiary made available to the Purchaser or its Affiliates or Representatives or any other Persons, including due diligence materials, or in any presentation of the business of the Company and/or the Subsidiary by management of the Company and/or the Subsidiary or others in connection with the Transaction, and no statement contained in any of such materials or made in any such presentation or other materials shall be deemed a

 

49



 

representation or warranty hereunder or otherwise or deemed to be relied upon by the Purchaser or Merger Sub in executing, delivering and performing this Agreement and the Transactions.  It is understood that any estimates, budgets, projections or other predictions, any data, any financial information or any memoranda or offering materials or presentations, including any offering memorandum or similar materials made available by any Blocker Seller and/or its Representatives or direct or indirect equityholders, are not and shall not be deemed to be or to include representations or warranties of any Blocker, the Company and/or the Subsidiary, and are not and shall not be deemed to be relied upon by the Purchaser or Merger Sub or any of their Affiliates in executing, delivering and performing this Agreement and the Transaction.

 

ARTICLE V
REPRESENTATIONS AND WARRANTIES OF THE PURCHASER

 

The Purchaser and Merger Sub hereby, jointly and severally, represent and warrant to the Company as follows:

 

5.1                                Organization .  Each of the Purchaser and Merger Sub was duly organized or formed, as the case may be, and is validly existing under the applicable laws of its jurisdiction of organization, has all requisite corporate or requisite limited liability company power and authority, as applicable, to carry on its business as now conducted and to own or lease and operate its properties and assets.

 

5.2                                Authority and Validity .  Each of the Purchaser and Merger Sub has all requisite corporate or requisite limited liability company power and authority, as applicable, to execute and deliver the Transaction Documents to which the Purchaser or Merger Sub is a party, to carry out its obligations under such Transaction Documents and to consummate the Transactions.  The execution and delivery of the Transaction Documents to which the Purchaser or Merger Sub is a party and the consummation of the Transactions has been duly and validly authorized by each of the Purchaser and Merger Sub, and no other proceedings on the part of the Purchaser or Merger Sub are necessary to approve the Transaction Documents to which the Purchaser or Merger Sub is a party or to consummate the Transactions.  This Agreement has been duly and validly executed and delivered by each of the Purchaser and Merger Sub, and assuming the due authorization, execution and delivery by the other Parties, constitutes a valid and binding obligation of each of the Purchaser and Merger Sub, enforceable against each of the Purchaser and Merger Sub in accordance with the terms and conditions of this Agreement, subject to General Enforceability Exceptions.

 

5.3                                No Violation .  The execution and delivery by each of the Purchaser and Merger Sub of the Transaction Documents to which the Purchaser or Merger Sub is a party do not, and the consummation of the Transaction, and performance by each of the Purchaser and Merger Sub of their obligations hereunder and thereunder, will not (i) result in a violation or breach of any provision of the Governing Documents of either the Purchaser or Merger Sub, (ii) result in a material violation or material breach of any provision of any Law or Order applicable to the Purchaser or Merger Sub, or (iii) except with respect to Purchaser’s existing lenders and in connection with the Debt Financing, require the consent of any Person under, conflict with, result in a violation or breach of, constitute a default under or result in the acceleration of any

 

50



 

Contract to which the Purchaser or Merger Sub is a party or by which the Purchaser or Merger Sub is bound or to which any of the Purchaser’s or Merger Sub’s properties or assets is subject, except where the violation, breach, conflict, default, acceleration or failure to give notice would not, individually or in the aggregate, reasonably be expected to delay or impair the Purchaser’s or Merger Sub’s abilities to consummate the Transaction.  No consent, approval, Order, declaration or filing with, or notice to, any Governmental Entity is required by or with respect to the Purchaser or Merger Sub in connection with the execution and delivery of this Agreement and the consummation of the Transaction, except for (x) such filings as may be required under the HSR Act and for filings required under the Exchange Act or under applicable federal and state securities laws, (y) the filing of the Certificate of Merger, and (z) such consents, approvals, Permits, Orders, declarations, filings or notices that the failure to take or make, as the case may be, would not, individually or in the aggregate, reasonably be expected to delay or impair the Purchaser’s or Merger Sub’s abilities to consummate the Transaction.

 

5.4                                Litigation .  There are no Legal Proceedings pending or, to the knowledge of the Purchaser or Merger Sub, threatened, against or affecting the Purchaser or Merger Sub or any of their respective Affiliates that relate to this Agreement or the Transactions, nor is there any Order of any Governmental Entity binding on Purchaser or Merger Sub, that challenges the validity or enforceability of this Agreement or seeks to enjoin or prohibit consummation of, or seek other material equitable relief with respect to, the Transactions or that would, individually or in the aggregate, reasonably be expected to delay or impair the Purchaser’s or Merger Sub’s abilities to consummate the Transactions.

 

5.5                                Brokers or Finders .  All negotiations relating to this Agreement and the Transactions have been carried on without the intervention of any Person acting on behalf of the Purchaser or Merger Sub in such manner as to give rise to any valid claim against any Securityholder, any Blocker Seller, any Blocker or the Company and/or the Subsidiary for any brokerage or finder’s commission, fee, or similar compensation.

 

5.6                                Financing .  The Purchaser has delivered to the Company and attached hereto as Exhibit E true, complete and correct copies of each of the executed Financing Letters.  The Purchaser has fully paid (or caused to be paid) any and all commitment fees or other fees in connection with the Financing Letters that are required to be paid on or prior to the date hereof, and as of the date hereof, the Financing Letters are in full force and effect and are legal, valid and binding obligations of the Purchaser, and to the knowledge of the Purchaser, the other parties thereto enforceable in accordance with their terms, subject to bankruptcy, insolvency, fraudulent transfer and similar laws of general applicability relating to or affecting creditors’ rights and to general equity principles.  As of the date of this Agreement none of the obligations or commitments under the Financing Letters have been withdrawn, rescinded, terminated or replaced in any respect, and, to the knowledge of the Purchaser, no such withdrawal, rescission, termination or replacement of the obligations or commitments thereunder is contemplated as of the date of this Agreement.  There are no conditions precedent or other contingencies relating to the funding of the Debt Financing equal to the Required Amount (as defined below) other than as expressly set forth in the Financing Letters.  As of the date of this Agreement, (i) Purchaser is not in breach of any of the terms or conditions set forth in any of the Financing Letters, (ii) no event has occurred or circumstance exists which, with or without notice, lapse of time or both, would

 

51



 

reasonably be expected to constitute a breach by the Purchaser or failure by the Purchaser to satisfy any condition precedent set forth in the Financing Letters, (iii) no party to any of the Financing Letters has notified the Purchaser of its intention to terminate or reduce its commitment under the Financing Letter and (iv) Purchaser has no reason to believe that any of the conditions to the Debt Financing will fail to timely be satisfied or that the full amount of the Debt Financing will be unavailable on the Closing Date assuming that the conditions set forth in Sections 7.1 and 7.2 are satisfied in accordance with their terms.  As of the date of this Agreement, there are no side letters or other agreements, contracts or arrangements to which the Purchaser is a party relating to the Financing Letters that would reasonably be expected to adversely affect the availability of the Financing in any material respect, other than as set forth in the Financing Letters.  The aggregate net proceeds from the Debt Financing (both before and after giving effect to any “flex” provisions) together with available cash or other sources of immediately available funds will be sufficient to consummate the Transactions, including the payment of all amounts required to be paid under Section 2.1 , the payment of any fees and expenses of or payable by Purchaser and any related repayment or refinancing of any Closing Indebtedness, and any other amounts required to be paid in connection with the consummation of the Transactions, including amounts required to be paid in connection with the Financing Letters and all fees, expenses and other amounts in connection with the Debt Financing (the “ Required Amount ”). The obligations of Purchaser to consummate the Merger at Closing upon satisfaction of the conditions precedent set forth in Section 7.01 are not contingent on Purchaser’s ability to obtain the Financing.

 

5.7                                Solvency .  Immediately following the Effective Time, and after giving effect to the Merger and assuming the accuracy of the representations in ARTICLE III and ARTICLE IV and the financial information for the Company provided to Purchaser and the compliance by Sellers and the Company with this Agreement, the Surviving Company and the Subsidiary on a consolidated basis will be Solvent.  For purposes of this Agreement, “ Solvent ” when used with respect to the Surviving Company, means that, as of immediately following the Effective Time and after giving effect to the Merger, (a) the Present Fair Saleable Value of its assets will, as of such date, exceed its liabilities as of such date, (b) the Surviving Company will not have, as of such date, an unreasonably small amount of assets or capital for the business in which it is engaged or will be engaged, and (c) the Surviving Company will be able to pay its debts as they become absolute and matured, in the ordinary course of business.  The term “Solvency” shall have a correlative meaning.  For purposes of the definition of “Solvent”, “debt” means liability on a right to payment, whether or not such a right is reduced to judgment, liquidated, unliquidated, fixed, contingent, matured, unmatured, disputed, undisputed, legal, equitable, secured or unsecured.  “ Present Fair Saleable Value ” means the amount that may be realized if the aggregate assets of the Surviving Company (including goodwill) are sold as an entirety with reasonable promptness in an arm’s length transaction under present conditions for the sale of comparable business enterprises.

 

5.8                                SEC Filings; Financial Statements .  Purchaser has timely filed all forms, reports and documents required to be filed by it with the United States Securities and Exchange Commission (the “ SEC ”) since January 1, 2016 through the date of this Agreement (collectively, the “ Purchaser SEC Documents ”).  Each of the Purchaser SEC Documents, at the time of its filing complied in all material respects with the applicable requirements of the Securities Act, the

 

52



 

Exchange Act and the Sarbanes-Oxley Act of 2002, as amended, and any rules and regulations promulgated thereunder applicable to the Purchaser SEC Documents.  As of their respective dates (or, if amended prior to the date hereof, as of the date of such amendment), the Purchaser SEC Documents did not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements made therein, in light of the circumstances in which they were made, not misleading.  The financial statements (including any related notes) contained in the Purchaser SEC Documents fairly present, in all material respects, the consolidated financial position of Purchaser and its Subsidiaries as of the respective dates thereof and the consolidated results of operations of Purchaser and its Subsidiaries for the periods covered thereby in accordance with GAAP applied on a consistent basis throughout the periods covered (except as may be indicated in the notes to such financial statements or, in the case of unaudited statements, as permitted by Form 10-Q of the SEC, and except that unaudited financial statements may not contain footnotes and are subject to year-end adjustments).

 

5.9                                Legal Compliance; NYSE Requirements .  Purchaser and Merger Sub are in compliance with all applicable New York Stock Exchange (the “ NYSE ”) requirements applicable to the listing of Purchaser’s securities on the NYSE, except where the failure to comply would not have a material and adverse effect on the Purchaser or Merger Sub.  Purchaser is not required to obtain stockholder approval of this Agreement or the transactions contemplated hereby pursuant to the rules of the NYSE applicable to listed companies.  None of the Purchaser, Merger Sub or any of their respective Subsidiaries is in default or violation of any law, statute, ordinance, regulation, rule, order, judgment or decree of a Governmental Entity that is applicable to the Purchaser, Merger Sub or any of their respective Subsidiaries or by which any property or asset of the Purchaser, Merger Sub or their respective Subsidiaries is bound, except for any such conflicts, defaults or violations that have not, or would not reasonably be expected to have, a material and adverse effect on the Purchaser or Merger Sub.

 

5.10                         Absence of Certain Changes or Events .  Since June 30, 2017 and until the date of this Agreement, except as disclosed in the Purchaser SEC Documents, Purchaser has conducted its business only in the ordinary course of business, consistent with past practice in all material respects, and there has not occurred:  (a) any change, event or condition (whether or not covered by insurance) that, individually or in the aggregate with any other changes, events or conditions, has resulted in, or would reasonably be expected to result in, a material adverse effect of the Purchaser, (b) any declaration, setting aside or payment of any dividend or other distribution (whether in cash, stock or property) with respect to Purchaser Common Stock, (c) any amendment of any provision of the Articles of Incorporation or bylaws of, or of any material term of any outstanding security issued by, Purchaser, (d) any material change in any method of accounting or accounting practice of Purchaser except for any such change required by a change in GAAP, or any split, combination or reclassification of Purchaser Common Stock or any issuance or the authorization of any issuance of any other securities in respect of, in lieu of, or in substitution for shares of Purchaser Common Stock.

 

5.11                         S-3 Eligibility; Registration Statement .  Purchaser is eligible to register secondary offerings of securities, including the resale of the shares of Purchaser Common Stock constituting the Stock Consideration on a registration statement on Form S-3 under the Securities

 

53



 

Act and a well-known seasoned issuer as defined under Rule 405 of the Securities Act.  Subject to Purchaser continuing to meet the requirements for well-known seasoned issuer status at Closing and receipt of the Required Financials and Audits, to Purchaser’s Actual Knowledge, no reason exists which would prevent a registration statement for the Registrable Securities on Form S-3 filed at the Closing (the “ Registration Statement ”) from becoming automatically effective upon filing with the SEC pursuant to this Agreement.  Any such Registration Statement and any amendments or supplements thereto, when and if filed in accordance with this Agreement, will comply as to form in all material respects with the requirements of the Securities Act.  At the time the Registration Statement or any amendment or supplement thereto becomes effective, the Registration Statement, as amended or supplemented, will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein not misleading, in light of the circumstances in which they are made.  The representations and warranties contained in this Section 5.11 will not apply to statements or omissions in the Registration Statement or any amendment or supplement thereto based upon information furnished to Purchaser by the Company specifically for use therein.

 

5.12                         Capitalization and Related Matters .

 

(a)                                  The authorized capital stock of Purchaser (“ Purchaser Capital Stock ”) consists of 590,000,000 shares of Purchaser Common Stock and 10,000,000 shares of preferred stock.  As of the date hereof, 68,873,219 shares of Purchaser Common Stock (net of treasury shares) were issued and outstanding. As of the date hereof, no shares of Purchaser Company Preferred Stock are issued and outstanding As of the date hereof, Purchaser has outstanding employee stock options to purchase an aggregate of 5,847,648 shares of Purchaser Common Stock (of which options to purchase an aggregate of 1,399,396 shares of Purchaser Common Stock were exercisable) (“ Purchaser Options ”).  Other than the Purchaser Options and except pursuant to the Purchaser’s 2014 Omnibus Incentive Plan, there are no outstanding subscriptions, options, warrants, commitments, preemptive rights, deferred compensation rights, agreements, arrangements or commitments of any kind to which the Purchaser is a party relating to the issuance of, or outstanding securities convertible into or exercisable or exchangeable for, any shares of capital stock of any class or other equity interests of the Purchaser.  All shares of Purchaser Capital Stock have been duly authorized, and all issued and outstanding shares of Purchaser Common Stock have been validly issued and are fully paid and non-assessable.

 

(b)                                  The shares of Purchaser Common Stock to be issued in accordance with this Agreement will, upon such issuance, be duly authorized, validly issued, fully paid and non-assessable, free of any Liens (other than Liens created by this Agreement or any obligations of the holder thereof to comply with applicable laws in connection with the sale or transfer thereof), will be issued without violation of the Securities Act or applicable state securities laws.

 

5.13                         No Other Representations .  NONE OF THE PURCHASER, THE MERGER SUB OR THEIR RESPECTIVE REPRESENTATIVES OR DIRECT OR INDIRECT EQUITYHOLDERS HAS MADE, AND SHALL NOT BE DEEMED TO HAVE MADE, ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED OR OF ANY NATURE WHATSOEVER RELATING TO THE PURCHASER, THE MERGER SUB OR THE BUSINESS OF THE PURCHASER OR THE MERGER SUB OR OTHERWISE IN

 

54



 

CONNECTION WITH THE TRANSACTION, AND DISCLAIM ALL LIABILITY AND RESPONSIBILITY FOR ANY REPRESENTATION OR WARRANTY MADE OR COMMUNICATED (ORALLY OR IN WRITING, INCLUDING ANY OPINION, INFORMATION OR ADVICE WHICH MAY HAVE BEEN PROVIDED BY THEIR REPRESENTATIVES) TO THE OTHER PARTIES, OTHER THAN THOSE REPRESENTATIONS AND WARRANTIES OF THE COMPANY EXPRESSLY SET FORTH IN THIS ARTICLE V.

 

5.14                         Due Diligence Investigation; No Other Representations .  Each of the Purchaser and Merger Sub is an informed and sophisticated Person, and has engaged expert advisors experienced in the evaluation and acquisition of companies such as the Blockers, the Company and the Subsidiary as contemplated hereunder.  Each of the Purchaser and Merger Sub has undertaken such investigation and has been provided with and has evaluated such documents and information as it has deemed necessary to enable it to make an informed and intelligent decision with respect to the execution, delivery and performance of this Agreement and the Transactions.  Each of the Purchaser and Merger Sub has been afforded the opportunity to obtain any additional information necessary, including gaining access to the Representatives of the Blockers, the Company and the Subsidiary, to verify the accuracy of any such information or of any representation or warranty made by the Blocker Sellers, the Company and/or the Subsidiary hereunder or otherwise to evaluate the merits of the Transactions.  Each of the Purchaser and Merger Sub has completed to its satisfaction its own due diligence review with respect to the Blockers, the Company and the Subsidiary and is entering into the Transactions based on the foregoing investigation and due diligence.  Without limiting the generality of the foregoing, each of the Purchaser and Merger Sub acknowledges that (a) none of the Blocker Sellers, the Company, the Subsidiary, their respective Representatives or direct or indirect equityholders has made or is making any representation or warranty with respect to (i) any estimates, budgets, projections or predictions delivered to or made available to the Purchaser or Merger Sub or any other Person of future revenues, future results of operations (or any component thereof), future cash flows or future financial condition (or any component thereof) of the Blockers, the Company, the Subsidiary or the future business and operations of the Blockers, the Company and the Subsidiary or (ii) any other information or documents made available to the Purchaser or Merger Sub or their Representatives with respect to the Blockers, the Company and the Subsidiary, or any of their respective businesses, assets, liabilities or operations, except as expressly set forth in Article III and/or Article IV hereof, and (b) neither the Purchaser nor Merger Sub has relied nor will either rely upon any of the information described in sub clauses (i) and (ii) of clause (a) above or any other information, representation or warranty, except those representations or warranties set forth in Article III and/or Article IV hereof (in each case, as qualified by the Disclosure Schedule), in negotiating, executing, delivering and performing the Transaction Documents, as applicable, and the Transaction.  The Purchaser and Merger Sub hereby acknowledge and agree to the disclaimers set forth in Section 3.26 and Section 4.6 and that, except to the extent specifically set forth in Article III and/or Article IV hereof (in each case, as qualified by the Disclosure Schedule), the Purchaser and Merger Sub are acquiring the Blockers, the Company and the Subsidiary on an “as is, where is” basis with all faults.

 

55



 

ARTICLE VI
ADDITIONAL AGREEMENTS

 

6.1          Publicity .  The Parties will, and will cause each of their respective Affiliates and representatives to, maintain the confidentiality of this Agreement and will not, and will cause each of their respective Affiliates not to, issue or cause the publication of any press release or other public announcement or disclosure with respect to this Agreement or the Transactions without the prior written consent of the Securityholder Representative and the Purchaser, which consent shall not be unreasonably withheld; provided , however , that (a) upon the Closing, the Securityholder Representative and the Purchaser shall release a joint (or separate) press release that is mutually agreed upon, and (b) this Section 6.1 shall not prohibit (i) any disclosure by a Party to the extent that such Party reasonably determines, after consultation with outside legal counsel, that such action is required by Law or by the rules of any applicable self-regulatory organization, the SEC or the NYSE, in which event such Party will use its commercially reasonable efforts to consult with the Securityholder Representative and the Purchaser and allow reasonable time to comment on such disclosure, and to reasonably incorporate any such comments to the extent related to the Company or the terms of the transactions contemplated hereby, in advance of such disclosure, (ii) any disclosure to the Securityholders, (iii) any disclosure to any representative of any Securityholder who needs to know such information for the purpose of evaluating the Transaction, and (iv) disclosure by a Securityholder or any of its Affiliates, that is, in each case, an investment fund, as part of such Person’s ordinary course reporting or review procedure or to such Person’s investors or prospective investors or otherwise in connection with such Person’s ordinary course fundraising, marketing, information or reporting activities.

 

6.2          Commercially Reasonable Efforts; Notices and Consents .

 

(a)           Subject to the terms hereof, during the period from the date of this Agreement until the Closing or the earlier termination of this Agreement pursuant to ARTICLE IX (the “ Pre-Closing Period ”), the Parties shall each use commercially reasonable efforts to (a) take, or cause to be taken, all actions, and do, or cause to be done, and to assist and cooperate with the other Parties in doing, all things necessary, proper or advisable to consummate and make effective the Transactions as promptly as practicable; (b) obtain from any Governmental Entity or any other third party described in Schedule 3.1(c)  any consents or Orders required to be obtained or made by the Parties in connection with the authorization, execution and delivery of this Agreement, the other Transaction Documents and the consummation of the Transaction; (c) as promptly as practicable, make all necessary filings, and thereafter make and cooperate with the other Parties with respect to any other required submissions, with respect to this Agreement and the Transactions required under (i) the HSR Act and any related governmental request thereunder (it being agreed that the Parties shall make the necessary filing with the appropriate Governmental Entity in accordance with the HSR Act within five (5) Business Days after the execution of this Agreement and shall seek early termination with respect thereto), and (ii) the applicable antitrust laws of any other jurisdiction; and (d) execute or deliver any additional instruments reasonably necessary to consummate the Transactions in accordance with the terms hereof. Notwithstanding anything herein to the contrary, (x) the failure to obtain any consent or Order (including those set forth on Schedule 3.1(c)  but other than those consents expressly

 

56



 

required to be obtained on Schedule 1.8(a)(ix)  and the HSR Approval) shall not serve as the basis for the Purchaser to terminate this Agreement pursuant to Section  9.1 , and (y) under no circumstances shall the Company or the Subsidiary be required to make payment to any Person or incur any other liability to secure such Person’s consent, except as set forth in the Estimated Closing Statement.

 

(b)           The Parties shall cooperate fully with one another to comply as promptly as practicable with all governmental requirements applicable to the Transactions, subject to applicable Law, including by (i) timely furnishing to each other all information concerning the Purchaser, the Target Companies and/or their respective Affiliates that counsel to the Purchaser and the Company reasonably determine is required to be included in such documents, (ii) promptly providing the Company and Purchaser with copies of all written communications to or from any Governmental Entity relating to any competition filings submitted in connection with the Merger, (iii) keeping each other reasonably informed of any communication received or given in connection with any Legal Proceeding by the Purchaser or the Company, in each case regarding the Merger, (iv) permitting the Company or the Purchaser (as the case may be) to review and incorporate the other Party’s reasonable comments in any communication given by it to any Governmental Entity or in connection with any proceeding related to the HSR Act or applicable antitrust laws of any other jurisdiction, and (v) to the extent there are meetings with respect to any Governmental Entity in connection with requests under the HSR Act or applicable antitrust laws of any other jurisdiction, permitting each Party to attend such meetings if so requested by such Party.  The Purchaser will pull and re-file any notice under the HSR Act only if the other Parties agree.

 

(c)           The Parties will use their respective reasonable best efforts to resolve favorably any review or consideration of the antitrust aspects of the Transactions by any Governmental Entity with jurisdiction over the enforcement of any applicable antitrust laws, including by (i) responding promptly to and complying fully with any request for additional information or documents under the HSR Act and applicable antitrust laws of any other jurisdiction and (ii) vigorously defending, through appeal, any Legal Proceeding brought by any Governmental Entity or other Person seeking to enjoin, prevent or delay the consummation of the Transaction.  Nothing in this Agreement shall require the (1) Company, the Subsidiary or their respective Affiliates to take or agree to take any action with respect to their business or operations unless the effectiveness of such agreement or action is conditioned upon the Closing and (2) the Purchaser or any of its Affiliates to agree to (i) sell, hold, divest, discontinue or limit, before or after the Closing, any assets, businesses or interests of Purchaser or any of its Affiliates; or (ii) any conditions relating to, or changes or restrictions in, the operations of any such assets, businesses or interests which, in either case, would reasonably be expected to result in a Material Adverse Effect or materially and adversely impact the economic or business benefits to Purchaser of the transactions contemplated by this Agreement.

 

(d)           During the Pre-Closing Period, the Company will promptly notify the Purchaser in writing of any fact, change, condition, circumstance or occurrence or nonoccurrence of any event of that will or is reasonably likely to result in any of the conditions set forth in ARTICLE VII of this Agreement to not be satisfied or any other material development affecting

 

57



 

the ability of the Company or the Sellers to consummate the transactions contemplated by this Agreement.

 

6.3          Conduct of Business .  During the Pre-Closing Period, except as requested or consented to by the Purchaser in writing (which consent shall not be unreasonably withheld, conditioned or delayed), as specifically contemplated by this Agreement or the other Transaction Documents, as required by Law or as set forth on Schedule 6.3 , the Target Companies shall conduct, and shall cause the Subsidiary to conduct, the business in the ordinary course consistent with past practice in all material respects.  Except as specifically contemplated by this Agreement or the other Transaction Documents, as required by Law or as set forth on Schedule 6.3, during the Pre-Closing Period, none of the Target Companies shall do any of the following without the prior written consent of the Purchaser, which consent shall not be unreasonably withheld, conditioned or delayed:

 

(a)           issue, sell or deliver any of the Target Companies’ equity securities or issue or sell any securities convertible into, or options with respect to, or warrants to purchase or rights to subscribe for, any such equity securities;

 

(b)           effect any recapitalization, reclassification, unit distribution, unit split or like change in any of the Target Companies’ capitalization;

 

(c)           amend any Target Company’s Organizational Documents;

 

(d)           make any change in any method of accounting or accounting practice of the Company, except as required by a change in GAAP or applicable Law;

 

(e)           incur, assume or guarantee any Indebtedness other than borrowings under the Credit Facility in the ordinary course of business;

 

(f)            sell or dispose of any material assets, except in the ordinary course of business consistent with past practice;

 

(g)           other than in the ordinary course of business consistent with past practice, or as required by applicable Law, (A) materially increase the compensation of any manager, Employee, Contractor, officer or director of the Company or the Subsidiary, other than as provided for in any Employee Plan or in the form of bonuses paid to members of management of the Company in connection with the transactions contemplated by this Agreement which have been approved by the Company Board, which shall be treated as Selling Expenses, (B) hire or terminate any officer or director of the Company or the Subsidiary or (C) enter into, amend or terminate any material employment, retention or change in control Contract with any Employee or Contractor that is not terminable at will;

 

(h)           except as required by applicable Law or in the ordinary course of business, adopt, amend or modify any Employee Plan;

 

58



 

(i)            acquire by merger or consolidation with, or by purchase of a substantial portion of the assets, stock or other equity of, or by any other manner, any business or any Person or any division thereof, except for the transaction described in Section 6.11 ;

 

(j)            adopt any plan of merger, consolidation, reorganization, liquidation or dissolution or file a petition in bankruptcy under any provisions of federal or state bankruptcy Law or consented to the filing of any bankruptcy petition against it under any similar Law;

 

(k)           make any investment (by contribution to capital, property transfers, purchase of securities or otherwise) in, or make any loan or advance (other than travel and similar advances to its employees in the ordinary course of business) in excess of $250,000 to any Person other than in the ordinary course of business, except for the transaction described in Section 6.11 ;

 

(l)            other than in the ordinary course of business, enter into, terminate or amend any Material Contract, or make any proposal to enter into, terminate, or amend any Material Contract;

 

(m)          enter into, modify or terminate any labor or collective bargaining agreement of the Company or the Subsidiary;

 

(n)           implement any Employee layoffs implicating the WARN Act;

 

(o)           pay, discharge, settle or satisfy any material claims or Liabilities, other than in the ordinary course of business;

 

(p)           sell, assign, transfer, license, abandon, permit to lapse, or otherwise dispose of any of the Target Companies’ assets, including the Target Companies’ Intellectual Property, other than in the ordinary course of business;

 

(q)           make, revoke or change any Tax election, change any annual Tax accounting period, adopt or change any method of Tax accounting, file any amended Tax Return, enter into any closing agreement with respect to Taxes, waive any claim for refund or credit of Taxes, settle any audit, examination or Legal Proceeding relating to Taxes, surrender any right to claim a Tax refund, or consent to the extension or waiver of the limitations period applicable to any audit, examination or Legal Proceeding relating to Taxes;

 

(r)            make or pay any non-Cash distribution, dividend or similar transfer; or

 

(s)            enter into any agreement, in writing or otherwise, to take any of the foregoing actions.

 

Notwithstanding the foregoing and anything else in this Agreement to the contrary, none of the Target Companies shall be prohibited from (i) transferring any Cash held by it whether by distribution, dividend or otherwise, to any Securityholder prior to the Closing, (ii) settling Indebtedness prior to the Closing or (iii) taking any action expressly contemplated by this Agreement.

 

59



 

6.4          Non-Solicit; Confidentiality; Release .

 

(a)           Each of Blocker Seller and Nautic Partners VIII, L.P., a Delaware limited partnership (collectively with the Blocker Sellers, the “ Restricted Parties ” and each, a “ Restricted Party ”) hereby agrees that such Restricted Party will not, and will cause each of such Restricted Party’s Affiliates not to, either alone or in conjunction with any other Person, directly or indirectly, at any time during the three-year period immediately following the Closing Date (i) engage, employ, solicit or contact with a view to the engagement or employment of Len Dino, Albert Thigpen, Janice Forsyth, David Byrne, Tom Hughes and Evan Raml (each a “ Restricted Employee ”); provided , that the foregoing restrictions shall cease as to any Restricted Employee on the date that is two (2) years following the date such Restricted Employee’s employment with the Purchaser, the Company or the Subsidiary, as applicable, is terminated by the Purchaser, the Company or the Subsidiary, as applicable, without cause or (ii) make, publish or communicate to any Person or in any public forum any defamatory or disparaging remarks, comments or statements concerning the Company or the Subsidiary from time to time of any of their respective businesses.

 

(b)           Each Restricted Party will, and will cause such Seller’s Representatives and Affiliates (other than Company) to, keep confidential and not disclose without the prior written consent of the Purchaser or otherwise use any Company Information, except as necessary to consummate the Transactions, and deliver promptly to the Purchaser or destroy, at the request and option of the Purchaser, all tangible embodiments (and all copies) of Company Information which are in such Restricted Party’s possession or under such Restricted Party’s control. If any Restricted Party, based on the written advice of counsel, is legally compelled to disclose any Company Information to any governmental tribunal, such Restricted Party may disclose to the governmental tribunal only the minimum amount of such Company Information as such Restricted Party is legally compelled to disclose; provided, however, that, prior to making any such disclosure, such Restricted Party will provide Purchaser with: (a) prompt written notice of such compulsion so that Purchaser may seek a protective order or other remedy; and (b) reasonable assistance in opposing such disclosure or seeking a protective order or other limitations on disclosure; provided further that such Restricted Party may disclose Company Information to its current and prospective limited partners which are subject to confidentiality agreements in a manner consistent with such Restricted Party’s past practices.

 

(c)           In addition, during the three (3) year period following the Closing, each Restricted Party will not, and will cause its controlled or commonly controlled Affiliates (other than their respective portfolio companies) not to and will not direct any of its or its Affiliates’ portfolio companies to, solicit, cause, induce or encourage, or attempt to solicit, cause, induce or encourage, any of the customers of the Company set forth on Schedule 6.4(b)  to use the Business Services of any Person other than the Company or Purchaser.  For the purposes of this Agreement, “ Business Services ” means the provision of comprehensive pharmacy benefit management services, which shall not include other pharmacy services, including without limitation, the services provided as of the date hereof by ExactCare Pharmacy (whether such services are provided by ExactCare Pharmacy or any other Person).

 

60



 

(d)           In the event of any breach or violation by any Restricted Party of any of the covenants in this Section 6.4 , the time period of such covenant with respect to such Restricted Party will be tolled and will not run until such breach or violation is resolved.

 

(e)           Each Restricted Party acknowledges and agrees that (i) the Restricted Party is familiar with Company’s trade secrets and other Company Information, (iii) the Purchaser, the Company and Subsidiary have a protectable interest in the Company’s and the Subsidiary’s goodwill, in the Company Information and in preventing unfair competition from current and former stockholders, employees and agents, (iii) the restrictions contained in this Section 6.4 are reasonable and necessary to protect the legitimate business interests of the Company and Subsidiary from time to time, including their respective trade secrets, confidential information, reputation, goodwill and substantial relationships with specific prospective or existing customers, and constitute a material inducement to the Purchaser to enter into this Agreement and the other Transaction Documents and to consummate the transactions contemplated hereby and thereby and (iv) in the event of a breach by such Restricted Party of any of the provisions of this Section 6.4 , monetary damages may be inadequate and the Purchaser may have no adequate remedy at law.  Accordingly, in the event of any such breach, the Purchaser and its successors or assigns may, in addition to any other rights and remedies existing in their favor, enforce their rights and such Restricted Party’s obligations hereunder by any Legal Proceeding for specific performance, injunctive and/or other relief, without any requirement of posting a bond or proving actual damages or posting any bond or other security.

 

(f)            The Purchaser acknowledges that the information provided to it in connection with this Agreement and the Transactions is subject to the terms of the letter agreement by and between Nautic Partners, LLC on behalf of the Subsidiary and the Purchaser dated August 22, 2017 (the “ Non-Disclosure and Confidentiality Agreement ”), the terms of which are incorporated herein by reference.  Effective upon, and only upon, the Closing, the Non-Disclosure and Confidentiality Agreement shall terminate.  In the event that this Agreement terminates pursuant to Section  9.1 , however, the Non-Disclosure and Confidentiality Agreement shall continue in full force and effect in accordance with its terms.

 

(g)           Each Restricted Party on behalf of itself and any Affiliate (collectively, the “ Releasing Parties ”), hereby irrevocably, unconditionally, and completely releases the Target Companies, Purchaser, and each of their respective officers, directors, partners, members, managers, shareholders, Affiliates, subsidiaries, Purchaser Related Parties, agents and successors (collectively, the “ Released Parties ”) from any and all Legal Proceedings, controversies, cross-claims, counter-claims, debts, compensatory damages, liquidated damages, punitive or exemplary damages, other damages, claims for costs and attorneys’ fees, or Liabilities of any nature whatsoever in law and in equity, both past and present (arising from events or circumstances occurring from the beginning of the world through and including the Closing) and whether known or unknown, suspected, or claimed against any of the Released Parties which such Releasing Party has or may have (other than those against Purchaser arising under this Agreement), whether arising under any federal, state or local civil or human rights law, or under any other local, state, or federal law, regulation or ordinance, or under any public policy, contract or tort, or under common law; or any claim for breach of contract, infliction of emotional distress, defamation, or any claim for costs, fees, or other expenses, including attorneys’ fees

 

61



 

incurred in these matters (all of the foregoing collectively referred to herein as such Releasing Party’s “ Released Claims ”).  Each Releasing Party represents that he, she or it has made no assignment or transfer of any Released Claim.  Each Releasing Party acknowledges and intends that his, her or its execution and delivery of this release shall be effective as a bar to each and every one of the Released Claims, and expressly consents and agrees that this release shall be given full force and effect according to each and all of its express terms and provisions, including those relating to unknown and unsuspected Released Claims (notwithstanding any state statute that expressly limits the effectiveness of a general release of unknown, unsuspected and unanticipated Released Claims), if any, as well as those relating to any other Released Claims hereinabove mentioned or implied.  Notwithstanding the foregoing, no release of claims under this Agreement shall release any current or former officer, director, stockholder, employee or Affiliate of any Seller, the Company or any Subsidiary of the Company of any future obligation set forth in this Agreement and, with respect to all rights of expressly provided for in Section 6.8 , such rights shall be unaltered, unimpaired and otherwise unaffected by this Section 6.4(g) , and shall remain in full force and effect and are not released or limited, as applicable, hereby.  Notwithstanding the foregoing, nothing in this Section 6.4(g)  shall limit in any manner any rights to indemnification or to advancement or reimbursement of expenses to which any Seller or any Seller’s past or present Affiliates or any other heirs, family members, beneficiaries, executors, administrators, trustees, successors (by merger or otherwise), assigns and all other Persons that have or could potentially derive rights through such party is entitled pursuant to this Agreement.

 

6.5          Exclusivity .  During the Pre-Closing Period, the Restricted Parties and the Company shall, and shall cause the Subsidiary and each of their respective equity holders, directors, officers, managers, employees, agents, advisors or other representatives (collectively, the “ Representatives ”) to, (i) cease and terminate any and all existing contracts, activities, discussions or negotiations with any Person other than the Purchaser with respect to an Acquisition Proposal, (ii) not solicit, initiate or encourage proposals, offers or inquiries from any third party with respect to an Acquisition Proposal, nor provide information or documentation to any third party with respect to evaluating an Acquisition Proposal or assist any attempt by any other Person to do any of the foregoing, (iii) sell, assign, transfer or dispose of any Units and (iv) promptly notify Purchaser if any Acquisition Proposal or any inquiry or contact with any Person with respect thereto is made and the details of such contact.  As used in this Agreement, “ Acquisition Proposal ” means any discussions, negotiations, agreements or other arrangements regarding, or which could lead to, any acquisitions of, dispositions of, and/or investments in, whether by way of equity sale, merger, consolidation or other business combination with any other Person, any equity interests or all or any material portion of assets of the Company and/or the Subsidiary.  Notwithstanding the foregoing, nothing in this Section 6.5 shall in any way prohibit the transaction described in Section 6.11 .

 

6.6          Liquidity of Purchaser Common Stock .

 

(a)           Each Seller agrees that with respect to all Purchaser Common Stock issued to such Seller pursuant to this Agreement (collectively, the “ Restricted Shares ”), such Seller will not, during the period commencing on the Closing Date and ending ninety (90) days after the Closing

 

62



 

Date with respect to one-half of the Restricted Shares and 180 days after the Closing Date with respect to the remaining one-half of the Restricted Shares (such period, the “ Restriction Period ”), offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any Restricted Shares beneficially owned (as such term is used in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”)), by such Seller, or any other securities so owned convertible into or exercisable or exchangeable for the Restricted Shares to the extent any such transactions described above is to be settled by delivery of Restricted Shares (each, a “ Transfer ”).  Notwithstanding the foregoing, the restrictions on Transfer shall not apply to (i) transactions relating to Purchaser Common Stock acquired in open market transactions after the Closing Date, (ii) the following Transfers: (A) as a bona fide gift or gifts, or by will or intestate succession upon the death of any Seller, (B) to any trust for the direct or indirect benefit of (I) any Seller or (II) the immediate family member of any Seller (as that term is defined in Item 404 of Regulation S-K); (C) to any controlled Affiliate; or (D) Transfers required by any rule, regulation, order, writ or decree of any governmental or regulatory authority or agency; provided that in the case of any Transfer pursuant to clauses (A), (B) or (C), each transferee shall sign and deliver a lock up letter substantially in the form of this provision (a copy of which shall be delivered to Purchaser) as a condition precedent to such Transfer or, (iii) at any time during the Restriction Period, any hedging transactions, including without limitation any short sale (whether or not against the box) or any purchase, sale or grant of any right (including without limitation any put or call option), pledge or similar encumbrance or hypothecation with respect to any of the Restricted Shares or with respect to any security that includes, relates to, or derives any significant part of its value from any such shares, provided that in the case of any such pledge, each pledgee shall sign and deliver a lock up letter substantially in the form of this provision (a copy of which shall be delivered to Purchaser) as a condition precedent to any actual transfer or disposition of such pledged Restricted Shares (and not as a condition precedent to the pledge itself) if and to the extent such transfer or disposition were to occur prior to the expiration of the applicable Restriction Period.  The Purchaser shall assist and cooperate with the Sellers (including, by executing any and all documents, agreements and instruments, and taking any further action that the Sellers may reasonably request) as such Seller may reasonably request in order to effect the transactions contemplated in clause (iii) of the preceding sentence.

 

(b)           Each Seller also agrees and consents to the entry of stop transfer instructions with Purchaser’s transfer agent and registrar during the Restriction Period against the Transfer of the Restricted Shares except in compliance with the foregoing restrictions.

 

6.7          Employee Related Matters .

 

(a)           Employment and Benefit Matters .  For the period commencing on the Closing Date and ending on the one (1) year anniversary of the Closing Date, the Purchaser agrees to maintain, or cause to be maintained, the base compensation and benefit levels, including base salary, annual incentive opportunities, retirement and health and welfare benefit plan programs at levels which are, in the aggregate, substantially similar to those in effect for the Employees immediately prior to the Closing.  The Purchaser, the Surviving Company and their respective subsidiaries shall treat, and cause the applicable benefit plans to treat, the service of the Employees with the Company or any subsidiary of the Company (or their predecessor entities) attributable to any period before the Closing Date as service rendered to the Purchaser, the Surviving Company or any of their respective subsidiaries, as applicable, for purposes of eligibility and vesting under the

 

63



 

Purchaser’s, the Surviving Company’s or such subsidiary’s, as applicable, severance policy, sick leave, vacation program, health or welfare benefit plan(s), and such Person’s tax-deferred retirement plans, except where credit would result in duplication of benefits and except where any such benefit plan is not offered to any such Employee.  Without limiting the foregoing, to the extent that any Employee participates in any group health or other welfare benefit plan of the Purchaser, Surviving Company or any of their respective subsidiaries in the one-year period following the Closing Date, (a) the Purchaser, the Surviving Company or such subsidiary shall cause any pre-existing conditions or limitations, eligibility waiting periods or required physical examinations under any health or similar welfare plan of the Purchaser, the Surviving Company or such subsidiary to be waived with respect to the Employees and their eligible dependents, to the extent waived under the corresponding plan in which the Employee participated immediately prior to the Closing Date, and (b) any deductibles, co-pays and maximum out-of-pocket payments by any such Employee under any of the Company’s or its Subsidiary’s health plans in the plan year in which the Closing Date occurs shall be credited towards deductibles, co-pays and maximum out-of-pocket payments under the health plans of the Purchaser, the Surviving Company or any of their respective subsidiaries.  The Purchaser shall, and shall cause the Surviving Company to, recognize vacation days and paid time off previously accrued and reserved for by the Company immediately prior to the Closing Date. Nothing in this Section or any other provision of the Agreement shall be interpreted to obligate the Purchaser or any other entity to continue the employment of any Employee after the Closing or preclude the ability of Purchaser of any other entity to terminate the employment of any Employee at any time and for any reason.

 

(b)           401(k) Plan Matters . If elected by Purchaser in its sole election and by providing written notice to the Company of such election at least three business days prior to the Closing Date, the Company shall cause the Subsidiary to take appropriate and binding corporate action (including any necessary plan amendment), in a form and substance satisfactory to Purchaser, to terminate the Leehar Distributors, LLC 401(k) Retirement Savings Plan effective on a date that precedes the Closing Date, and if such election is exercised, Purchaser may, in its sole discretion, permit an Employee with an account balance in such plan (including an outstanding participant loan balance that is not otherwise in default) to roll over within 90 days of the Closing Date all or a portion of such account balance into the 401(k) type defined contribution retirement plan that may be offered by Purchaser to the Employee after the Closing Date.

 

(c)           Limitations . Purchaser and each Seller acknowledge and agree that all provisions contained in this Section 6.7 are included for the sole benefit of Purchaser, the Company and the Subsidiary and nothing contained herein shall (i) be construed as an amendment to any employee benefit plan or program, (ii) create any third-party beneficiary or other rights in any other Person, including any employee or former employee of any of Purchaser, the Company, the Subsidiary, or any dependent or beneficiary thereof, or (iii) otherwise obligate Purchaser, the Company or the Subsidiary, or any of their respective Affiliates to maintain any particular employee benefit plan or retain the employment of any particular Employee following the Closing Date.

 

(d)           Purchaser shall pay to the Employees the bonus amounts in respect of the calendar year ending December 31, 2017 that are accrued in Current Liabilities as of the Closing within thirty (30) days of the Closing Date.

64



 

6.8          Director and Officer Indemnification and Insurance .

 

(a)           The Purchaser agrees that all rights to indemnification, advancement of expenses and exculpation by the Blockers, the Company and the Subsidiary now existing in favor of each Person who is now, or has been at any time prior to the date hereof or who becomes prior to the Closing Date, an officer, director, trustee, manager, member, employee, partner, consultant, representative, agent, advisor, or unitholder or his, her or its Affiliate, as applicable, of the Blockers, the Company and the Subsidiary (each, together with such Person’s successors, heirs, executors or administrators, a “ D&O Indemnified Person ”), as provided in the Governing Documents of such Blocker, the Company or such Subsidiary, in each case as in effect on the date of such activities or otherwise in effect on the date of this Agreement, will not be amended, repealed or modified in any manner that would adversely affect the rights of the D&O Indemnified Persons for at least six (6) years after the Closing Date; provided , that in the event any claim or claims are asserted or made within such survival period, all such rights to indemnification in respect of any claim or claims shall continue until final disposition of such claim or claims.

 

(b)           The Company shall, or cause the Subsidiary to obtain (the cost of which will shall be paid on a 50/50 basis by the Purchaser, on the one hand, and the Sellers, on the other hand) as of the Closing Date, “tail” directors’ and officers’ liability insurance policies with a claims period of six (6) years from the Closing Date from insurance carriers with at the same or better claims-paying ability ratings as the Company’s current insurance carriers with respect to directors’ and officers’ liability insurance policies, with at least the same coverage and amounts, and containing terms and conditions that are not less advantageous to the D&O Indemnified Person, in each case with respect to claims arising out of or relating to events which occurred on or prior to the Closing Date (including in connection with the Transaction).  After the Closing, none of the Purchaser, the Company, the Subsidiary or any of their respective Affiliates will take any action to negate, cancel or otherwise modify or terminate such “tail” insurance policies.

 

(c)           The obligations of the Purchaser under this Section 6.8 shall not be terminated or modified in such a manner as to adversely affect any D&O Indemnified Person to whom this Section 6.8 applies without the consent of such affected D&O Indemnified Person (it being expressly agreed that the D&O Indemnified Person to whom this Section 6.8 applies shall be third party beneficiaries of this Section 6.8 , each of whom may enforce the provisions of this Section 6.8 ).

 

(d)           In the event the Purchaser, the Blockers, the Company, the Subsidiary or any of their respective successors or assigns (i) consolidates with or merges into any other Person and shall not be the continuing or surviving corporation or entity in such consolidation or merger or (ii) transfers all or substantially all of its properties and assets to any Person, then, and in either such case, proper provision shall be made so that the successors and assigns of the Purchaser, such Blocker, the Company or such Subsidiary, as the case may be, shall assume all of the obligations set forth in this Section 6.8 .

 

65



 

6.9                                Access to Information .

 

(a)                                  Subject to Section 6.9(b) , except pursuant to applicable Law, during the Pre-Closing Period, the Company will, at the Purchaser’s expense:  (i) provide the Purchaser and its Representatives (including any Person who is considering providing financing to the Purchaser to finance all or any portion of the Transaction Consideration who is subject to a written confidentiality agreement with customary restrictions on use and disclosure of information with respect to the Company, the Subsidiary and their respective representatives) with reasonable access, upon reasonable prior notice and during normal business hours at mutually convenient times, to the officers, employees, agents and accountants of the Company, the Subsidiary and their respective assets and properties and books and records, and (ii) furnish the Purchaser and such other Persons with all such information and data (including copies of Contracts, Benefit Plans and other books and records) concerning the business and operations of the Company and the Subsidiary as the Purchaser or any of such other Persons may reasonably request in connection with such investigation, except, in each case, for (1) purposes of environmental inspection, (2) privileged attorney-client communications or attorney work product, (3) information or materials required to be kept confidential by applicable Law, (4) any information that is reasonably pertinent to any litigation in which the Company or the Subsidiary and the Purchaser are adverse parties and (5) information or materials that related to negotiation, execution and delivery of this Agreement.  The information provided pursuant to this Section 6.9 shall be used solely for the purpose of the Transaction.

 

(b)                                  Any such access and/or investigation by the Purchaser and its Representatives shall not unreasonably interfere with any of the businesses or operations of the Company or the Subsidiary.  Neither the Purchaser nor any of its Representatives shall have any contact whatsoever, prior to the Closing Date, with respect to the Company, the Subsidiary or the Transaction with any agent, broker, partner, lender, lessor, vendor, distributor, customer, supplier, employee or consultant of the Company or the Subsidiary, except in consultation with the Company and then only with the express prior written approval of the Company.  All requests by the Purchaser and its Representatives for access or information shall be submitted or directed exclusively to an individual or individuals to be designated by the Company.

 

6.10                         Preservation of Records .  In order to facilitate the resolution of any claims made against or incurred by the Company and/or the Subsidiary prior to the Closing, or for any other reasonable purpose (as reasonably determined by Purchaser), for a period of seven (7) years after the Closing, the Purchaser shall or shall cause its subsidiaries (including the Company) to:

 

(a)                                  retain the books, records and other documents (including personnel files) of the Company and the Subsidiary relating to periods prior to the Closing; and

 

(b)                                  upon reasonable notice and the Securityholder Representative’s expense, afford the Securityholder Representative and its Representatives reasonable access (including the right to make photocopies), upon reasonable prior notice and during normal business hours at mutually convenient hours, to such books and records.; provided, that Purchaser and its subsidiaries will not be required to disclose or provide any information the disclosure of which, in the reasonable judgment of Purchaser, is restricted by Contract or Law, is subject to attorney-client or other privilege, or could result in the disclosures of any trade secrets of third parties or violate any obligation with respect to confidentiality.

 

66



 

6.11                         Dissolution of Nautic VIII-A Splitter .  Nautic Capital VIII, L.P., a Delaware limited partnership (“ Nautic GP ”), and LDI Nautic VIII-A Blocker Inc. (“ Nautic VIII-A Blocker ”), a Delaware corporation, shall cause Nautic VIII-A Splitter to be liquidated and dissolved effective immediately prior to the Closing (the “ Splitter Dissolution ”), as a result of which, among other things, Nautic VIII-A Blocker and Nautic VIII GP shall own directly the Units previously held by Nautic VIII-A Splitter.

 

6.12                         Financing Cooperation .

 

(a)                                  Purchaser shall use its reasonable best efforts to (1) comply in all material respects with each Financing Letter, (2) enforce in all material respects its rights under the Financing Letters and (3) not permit, without the prior written consent of the Company, any material amendment or modification to be made to, or any termination, rescission or withdrawal of, or any material waiver of any provision or remedy under, the Financing Letters or the fee letter referred to in the Financing Letters, that (individually or in the aggregate with any other amendments, modifications or waivers) would reasonably be expected to (x) reduce the aggregate amount of the Financing under the Financing Letters (including by changing the amount of fees to be paid or original issue discount thereof) to an amount less than the Required Amount or (y) impose any new or additional condition, or otherwise amend, modify or expand any condition, to the receipt of any portion of the Debt Financing in a manner that would reasonably be expected to (I) materially delay or prevent the Closing, (II) make the funding of any portion of the Financing (or satisfaction of any condition to obtaining any portion of the Financing) less likely to occur or (III) adversely impact the ability of Purchaser to enforce its rights against any other party to the Financing Letters, the ability of Purchaser to consummate the transactions contemplated hereby or the likelihood of the consummation of the transactions contemplated hereby.

 

(b)                                  Prior to the Closing, at Purchaser’s sole expense, the Company agrees to use, and agrees to cause the Subsidiary to use, reasonable best efforts to provide to the Purchaser such cooperation in connection with arranging, obtaining and syndicating the Debt Financing as is reasonably requested by the Purchaser; provided that such cooperation does not interfere with the ongoing operations of the Company.  Such assistance shall include, but not be limited to, the following (in each case, to the extent applicable with respect to the Debt Financing): (i) participation in, and assistance with, the preparation of the Marketing Materials (and any supplement thereto) and the Marketing Efforts (insofar as they relate to the Company) related to the Debt Financing; (ii) preparation and timely delivery to the Purchaser and the Financing Sources of the Financing Information, which Financing Information shall not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements contained therein not materially misleading in light of the circumstances in which they were made, (iii) provide all information related to the Target Companies required by regulatory authorities under applicable “know your customer” and anti-money laundering rules and regulations and other applicable Law at least five Business Days prior to the Effective Date; (iv) executing and delivering as of, but not effective before, the Effective Time, customary definitive financing documentation as may be reasonably requested by the Purchaser, including pledge and security documents, guarantees, customary officer’s certificates (including, without limitation, delivery of a solvency certificate in customary form), instruments, copies of any

 

67



 

existing surveys, UCC financing statements, filings, security agreements, control agreements, title insurance and other matters ancillary to, or required in connection with, the Debt Financing and taking all other corporate actions reasonably requested by the Purchaser that are necessary to permit the consummation of the Debt Financing, including with respect to corporate actions of the Surviving Company to be effected immediately following the Effective Time, (v) cooperating with Purchaser’s legal counsel in connection with any legal opinions that such legal counsel may be required to deliver in connection with the Debt Financing and  (vi) timely delivering from the Company’s existing lenders customary payoff letters, lien terminations or other instruments of termination or discharge in respect of Indebtedness of the Company contemplated by this Agreement to be repaid at Closing; it being understood and agreed that all materials and information obtained by Purchaser pursuant hereto may be shared with the Financing Sources.  Notwithstanding the foregoing or any other provision of this Agreement to the contrary: (A) such requested cooperation shall not unreasonably interfere with the business or the ongoing operations of the Company or any of its Affiliates; (B) nothing in this Section 6.12 shall require cooperation to the extent that it would (1) cause any condition to the Closing set forth in this Agreement to not be satisfied or otherwise cause any breach of this Agreement or (2) reasonably be expected to conflict with or violate the Company’s or any of its Affiliates’ respective organizational documents or any requirement of law, or result in the contravention of, or result in a violation or breach of, or default under, any Material Contract; (C) prior to the Closing, neither the Company nor any of its Affiliates shall be required to pay any commitment or other fee or incur, or take any action that would reasonably be expected to result in the incurrence of, any other liability or obligation or provide any indemnity in connection with the Debt Financing that is not subject to the occurrence of the Effective Time; (D) none of the Company or its Affiliates, nor any of their directors, officers, managers, members, partners or similar Persons, shall be required to execute or enter into, perform or authorize any agreement (other than, subject to the limitations specified above, customary authorization letters) with respect to the Debt Financing that is not contingent upon the Closing or that would be effective prior to the Effective Time; (E) nothing shall obligate the Company to provide, or cause to be provided, any legal opinion by its counsel, or to provide any information or take any action to the extent it would result in a violation of applicable Law and (F) the Company and its Subsidiaries shall not be required to take any corporate actions prior to the Closing to permit the consummation of the Debt Financing.

 

(c)                                   The Company hereby consents to the customary use of its corporate logos in the Marketing Material in connection with the Debt Financing; provided , that such corporate logos are used solely in a manner that is not intended to, nor reasonably likely to, harm or disparage the Company.

 

(d)                                  Each of the Purchaser and Merger Sub shall, within ten (10) days following written request by the Company, reimburse the Company and its Affiliates for all reasonable costs and expenses incurred by the Company and its Affiliates in connection with the cooperation required by this Section 6.12 .

 

6.13                         Registration Statement .  As promptly as practicable following the date of this Agreement, Purchaser shall prepare to file with the SEC the Registration Statement, pursuant to Rule 415 under the Securities Act, covering the resale of the shares of Purchaser Common Stock

 

68



 

constituting the Stock Consideration (the “ Registrable Securities ”) on a delayed or continuous basis.  In the event that as of the Closing, Purchaser is a well-known seasoned issuer as defined under Rule 405 of the Securities Act and otherwise meets all applicable requirements for eligibility to file an automatic shelf registration statement on Form S-3 (ASR), including but not limited to receipt of the Required Financials and Audits, Purchaser shall file such Registration Statement as promptly as practicable following the Closing.  In the event such conditions are not met, then as promptly as practicable following the Closing and following Purchaser’s receipt of the Required Financials and Audits as required by applicable Law, Purchaser shall file the Registration Statement on Form S-3 with the SEC, such Registration Statement to be reasonably acceptable to the Securityholder Representative.  Purchaser shall use its reasonable best efforts to have the Registration Statement declared effective under the Securities Act as soon as practicable following the filing thereof.  Purchaser shall provide a copy of the Registration Statement or any prospectus included therein to the Securityholder Representative and its designated counsel before filing with the SEC, which documents will be subject to the review and reasonable comment by such Securityholders for a period of at least five (5) Business Days, and Purchaser will not file any such Registration Statement or prospectus to which the Securityholder Representative reasonably object in writing within five (5) Business Days after the receipt thereof.  The comment or objection of the Securityholder Representative shall be deemed reasonable if such Registration Statement or prospectus, as proposed to be filed, contains a material misstatement or omission.  Purchaser and the Company shall ensure that the Registration Statement does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which they were made, not misleading (provided that each Seller shall be solely responsible for the accuracy or completeness of information relating to such Seller and furnished by such Seller (through the Securityholder Representative or its counsel) in writing for inclusion in the Registration Statement and Purchaser and the Merger Sub shall not be responsible for the accuracy or completeness of any information relating to such Sellers and furnished by such Sellers (through the Securityholder Representative) in writing for inclusion in the Registration Statement).  Purchaser agrees and the applicable Sellers shall agree (solely as to itself and not with respect to any other Seller), promptly to correct any information provided by it for use in the Registration Statement if and to the extent that such information shall have become false or misleading in any material respect, and Purchaser further agrees, and the applicable Sellers shall agree, to take all steps necessary to amend or supplement the Registration Statement and to cause the Registration Statement as so amended or supplemented to be filed with the SEC, in each case as and to the extent required by applicable Law.

 

6.14                         Audited Financial Statements .  The Company shall reasonably cooperate with and use reasonable best efforts with respect to, the prompt delivery of all financial statements and information and books and records of the Company necessary for Purchaser to meet, on a timely basis, its SEC filing obligations with respect to the historical and pro forma financial statements and information required by the Securities Act or the Exchange Act or in any registration statement, bank information memorandum, private placement memorandum or offering memorandum reasonably requested by Purchaser.  Without limiting the foregoing, the Company shall reasonably cooperate with and use reasonable best efforts with respect to (i) Purchaser’s preparation of the financial statements of the Company (and its predecessor, as applicable) as of and for the years ended December 31, 2016, 2015 and 2014, the nine months ended September

 

69



 

30, 2017 and any other annual or quarterly financial statements necessary for Purchaser to meet its SEC reporting requirements (together the “ Required Financials ”) and (ii) Purchaser obtaining an unqualified audit opinion in accordance with GAAP with respect to such year-end financial statements and any required auditor consents (together, the “ Audits ”).  The Company shall promptly respond to any requests for information by the auditor in connection with the foregoing.  Notwithstanding the foregoing, Purchaser shall reimburse the Company immediately prior to the Closing for any reasonable out-of-pocket expenses incurred by the Company, Blockers or the Sellers in connection with complying with the terms of this Section 6.14 .  Notwithstanding anything herein to the contrary, Purchaser agrees, subject to the Company’s compliance with this Section 6.14 , that the Required Financials shall be prepared and the Audits shall have been obtained and publicly disclosed in compliance with applicable Law.

 

6.15                         Other Seller Agreements .  In connection with the distribution of the Letter of Transmittal pursuant hereto, the Company shall provide to each Seller other than the Restricted Parties and the individuals who have entered into a Restrictive Covenant Agreement as of the date hereof (the “ Other Sellers ”), a non-solicitation, confidentiality and release agreement in the form attached as Exhibit F hereto (the “ Other Seller Agreement ”).  The Company shall use its commercially reasonable efforts to obtain executed copies of Other Seller Agreements from each Other Seller in connection with or prior to the Closing.

 

ARTICLE VII
CONDITIONS TO CLOSING

 

7.1                                Conditions to Obligations of Each Party .  The respective obligation of each Party to effect the Transactions is subject to the satisfaction at or prior to the Closing of the following conditions:

 

(a)                                  Orders .  No Governmental Entity of competent jurisdiction shall have enacted, issued, promulgated, enforced or entered any Order (whether temporary, preliminary or permanent) or Law that is in effect and restrains, enjoins or otherwise prohibits or challenges the validity or legality of the Transactions; provided , however , that the Parties shall use their commercially reasonable efforts to have any such Order vacated or lifted.

 

(b)                                  HSR Approval . The applicable waiting periods, if any, under the HSR Act shall have expired or been terminated (the “ HSR Approval ”).

 

7.2                                Conditions to Obligations of the Purchaser .  The obligation of the Purchaser and Merger Sub to effect the Transactions is subject to the satisfaction, or waiver by the Purchaser, at or prior to Closing, of the following conditions:

 

(a)                                  Representations and Warranties of the Company . The representations and warranties of the Company set forth in ARTICLE III (other than Sections 3.1(a) , 3.1(b) , 3.1(c)(i) , 3.2 , 3.3 , 3.20 and 3.21 ) of this Agreement shall be true and correct in all respects, as of the date of this Agreement and at and as of the Closing Date as though made on and as of the Closing Date (except to the extent such representations and warranties speak as of an earlier date, in which case such representations and warranties shall be so true and correct as of such earlier

 

70



 

date), except where the failure of such representations and warranties to be true and correct would not reasonably be expected to have a Material Adverse Effect (it being understood that, for purposes of determining the accuracy of such representations and warranties, all “Material Adverse Effect” and other materiality qualifications contained in such representations and warranties shall be disregarded).  The representations and warranties of the Company set forth in Sections 3.1(a) , 3.1(b) , 3.1(c)(i) , 3.2 , 3.3 , 3.20 and 3.21 shall be true and correct in all respects, except for the failure of such representations and warranties set forth in Sections 3.2 and 3.20 to be true and correct as would not reasonably be expected to have more than a de minimis impact on the Company, as of the date of this Agreement and at and as of the Closing Date as though made on and as of the Closing Date (except to the extent such representations and warranties speak as of an earlier date, in which case such representations and warranties shall be so true and correct as of such earlier date).

 

(b)                                  Covenants and Agreements of the Company .  The Company shall have performed all covenants and agreements required to be performed by it under this Agreement in all material respects at or prior to the Closing Date.

 

(c)                                   Representations and Warranties of the Blocker Sellers. The representations and warranties of each Blocker Seller set forth in ARTICLE IV of this Agreement (other than the representations made in Sections 4.1(a) , 4.1(b) , 4.1(c)(i) , 4.2 , 4.3 , 4.4 and 4.5 ) shall be true and correct in all respects, as of the date of this Agreement and at and as of the Closing Date as though made on and as of the Closing Date (except to the extent such representations and warranties speak as of an earlier date, in which case such representations and warranties shall be so true and correct as of such earlier date), except where the failure of such representations and warranties to be true and correct would not reasonably be expected to have a Material Adverse Effect (it being understood that, for purposes of determining the accuracy of such representations and warranties, all “Material Adverse Effect” and other materiality qualifications contained in such representations and warranties shall be disregarded).  The representations and warranties of each Blocker Seller set forth in Sections 4.1(a) , 4.1(b) , 4.1(c)(i) , 4.2 , 4.3 , 4.4 and 4.5 shall be true and correct in all respects, except for the failure of such representations and warranties set forth in Section 4.3 to be true and correct as would not reasonably be expected to have more than a de minimis impact on the Company, as of the date of this Agreement and at and as of the Closing Date as though made on and as of the Closing Date (except to the extent such representations and warranties speak as of an earlier date, in which case such representations and warranties shall be so true and correct as of such earlier date).

 

(d)                                  Performance of Covenants and Agreements of the Blocker Sellers .  Each Blocker Seller shall have performed all covenants and agreements required to be performed by it under this Agreement in all material respects at or prior to the Closing Date.

 

(e)                                   Material Adverse Effect .  Since the date of this Agreement, there has not occurred a Material Adverse Effect.

 

(f)                                    Closing Deliverables .  The Company shall have delivered or caused to be delivered to the Purchaser the deliverables set forth in Section 1.8(a) , each Blocker Seller shall have delivered or cause to be delivered to Purchaser the deliverables set forth in Section 1.8(b) ,

 

71



 

and the Securityholder Representative shall have delivered or caused to be delivered to the Purchaser the deliverables set forth in Section 1.8(c) .

 

7.3                                Conditions to Obligations of the Company .  The obligation of the Company to effect the Transactions is subject to the satisfaction, or waiver by the Company, at or prior to Closing, of the following conditions:

 

(a)                                  Representations and Warranties .  The representations and warranties of the Purchaser and Merger Sub set forth in this Agreement shall be true and correct in all respects, at and as of the Closing Date as though made on and as of the Closing Date (except to the extent such representations and warranties speak as of an earlier date, in which case such representations and warranties shall be so true and correct as of such earlier date), except where the failure of such representations and warranties to be true and correct would not reasonably be expected to have a material and adverse effect on the Purchaser’s or Merger Sub’s ability to consummate the Transactions.

 

(b)                                  Covenants and Agreement of the Purchaser .  Each of the Purchaser and Merger Sub shall have performed all covenants and agreements required to be performed by it under this Agreement in all material respects at or prior to the Closing Date.

 

(c)                                   Closing Deliverables and Actions .  The Purchaser shall have delivered or caused to be delivered to the Company the deliverables set forth in Section 1.8(d) .

 

ARTICLE VIII
CERTAIN TAX MATTERS

 

8.1                                Tax Matters .

 

(a)                                  Notwithstanding anything herein to the contrary, the Purchaser, on the one hand, and the Sellers, on the other hand, shall each pay, when due, fifty percent (50%) any transfer, documentary, sales, use, stamp, registration and other similar Taxes, and all conveyance fees, recording charges and other fees and charges (including any penalties and interest but excluding any Taxes based on or measure by income or gain) incurred in connection with the consummation of the Transactions (collectively, “ Transfer Taxes ”).  The Purchaser shall, at its own expense, file all necessary Tax Returns and other documentation with respect to such Transfer Taxes, and if required by applicable Law or to the extent reasonably requested, the Sellers shall cooperate in the preparation and filing and join in the execution of any such Tax Returns and other documentation.

 

(b)                                  The Purchaser shall take such action as may be necessary to cause the taxable period of each Blocker to end as of the close of business of the Closing Date for federal income Tax purposes and shall not take or permit any Target Company to take any action outside the ordinary course of business on the Closing Date but after the Closing that is not contemplated by this Agreement and increases the Taxes of any Blocker for any taxable period (or portion thereof) ending on or before the Closing Date.

 

72



 

(c)                                   Provided that the Units other than Blocker Units represent at least 50% of the interests in capital and profits of the Company, on account of which, by reason of the transfer of such Units to Purchaser in the Merger, the Company will, on the Closing Date, terminate as a partnership for federal (and, as applicable, state and local) income Tax purposes under and within the meaning of Section 708(b)(1)(B) and, in consequence, the taxable year of the Company will end on the Closing Date, the Securityholder Representative shall have the right, exercisable by written notice to Purchaser within ten (10) days of the Closing, to elect to cause to be prepared (at Sellers’ expense) any income Tax Returns of the Company and the Subsidiary for taxable periods ending on or before the Closing Date for which the items of income, deductions, credits, gains or losses are passed through to Sellers under applicable Law (including, for the avoidance of doubt, IRS Form 1065).  All such income Tax Returns (“ Pre-Closing Flow-Through Returns ”) shall be prepared in a manner consistent with past practice of the Company and, in any event, applicable Law, and consistent with the Tax Allocation Schedule (as finally modified).  The Securityholder Representative shall provide Purchaser with a copy of each Pre-Closing Flow-Through Return at least forty-five (45) days prior to the due date for filing such Pre-Closing Flow-Through Return (taking into account all applicable extensions).  Purchaser shall have twenty-one (21) days to review and comment on such Pre-Closing Flow-Through Return, and the Securityholder Representative shall consider any such comments in good faith. If any such Pre-Closing Flow-Through Return either (i) requires the signature of any officer or agent appointed by Purchaser or (ii) reports income or loss allocable to any Blocker in an amount which will cause such Blocker to owe Tax in excess of the amount taken into account in the Closing Indebtedness, and, by the end of such twenty-one (21) day period, Purchaser notifies the Securityholder Representative in writing of Purchaser’s disagreement with such Pre-Closing Flow-Through Return, then Purchaser and Seller shall, during the ensuing ten (10) days, negotiate in good faith to resolve such disagreement, failing which such disagreement shall be submitted to the Neutral Arbitrator for prompt resolution (with the fees of the Neutral Arbitrator to be divided between Purchaser on the one hand, and Securityholder Representative on the other hand, consistent with the fee allocation set forth in Section 2.3(b)(v) ), and the Pre-Closing Flow-Through Return shall be modified as necessary to comport with the Neutral Arbitrator’s decision.  Securityholder Representative or (in the case any such Pre-Closing Flow-Through Return requiring the signature of any officer or agent appointed by Purchaser) Purchaser shall file or cause to be filed when due (taking into account all applicable extensions) each Pre-Closing Flow-Through Return as prepared pursuant to this Section 8.1(c) , provided that if any disagreement over any Pre-Closing Flow-Through Return that is subject to the preceding sentence is not resolved (and such Pre-Closing Flow-Through Return practicably modified as necessary to conform to the resolution of such disagreement) before the due date (taking into account applicable extensions) of such Pre-Closing Flow-Through Return, then Securityholder Representative or (in the case any such Pre-Closing Flow-Through Return requiring the signature of any officer or agent appointed by Purchaser) Purchaser shall timely file such Pre-Closing Flow-Through Return, with any disputed items addressed in the manner which the party filing such Pre-Closing Flow-Through Return deems correct, subject to prompt filing of an amended Pre-Closing Flow-Through Return following (and as necessary to comport with) the resolution of such disagreement (so that such disagreement does not delay the timely filing of the original Pre-Closing Flow-Through Return).

 

73



 

(d)                                  Purchaser shall prepare all Tax Returns of the Target Companies that required to be filed after the Closing Date for Taxable periods that begin on or before the Closing Date, other than any Pre-Closing Flow-Through Returns that Securityholder Representative elects to file under Section 8.1(c)  (all such Tax Returns (other than any Pre-Closing Flow-Through Returns that Securityholder Representative elects to file), “ Purchaser-Prepared Tax Returns ”).  All Purchaser-Prepared Tax Returns shall be prepared and filed in a manner consistent with past practice of the Target Companies, except as required by applicable Law or the other provisions of this Agreement.  Prior to filing any Purchaser-Prepared Tax Return that (i) is not prepared consistent with past practice of the Target Companies (due to a requirement of applicable Law or another provision of this Agreement) and (ii) reports any Tax for which Sellers are liable under this Agreement, Purchaser will permit Securityholder Representative to review and comment on such Purchaser-Prepared Tax Return, and shall not file such Purchaser-Prepared Tax Return more than one day prior to its due date without the consent of the Securityholder Representative, which shall not be unreasonably withheld, conditioned or delayed.  If, in accordance with the foregoing, Purchaser files such Purchaser-Prepared Tax Return without the consent of the Securityholder Representative, and the Securityholder Representative has notified (or, within ten (10) days of such filing, notifies) Purchaser in writing of Securityholder Representative’s disagreement with such Purchaser-Prepared Tax Return, then such disagreement shall be submitted to the Neutral Arbitrator, and such Purchaser-Prepared Tax Return shall amended if and as necessary to conform to the decision of the Neutral Arbitrator (whose fees shall be divided between Purchaser on the one hand, and Seller on the other hand, consistent with the fee allocation set forth in Section 2.3(b)(v) ).

 

(e)                                   The Securityholder Representative and the Purchaser shall cooperate fully, as and to the extent reasonably requested by the other Party, in connection with the filing of any Tax Returns for the Target Companies, the filing and prosecution of any Tax claims, and any audit, litigation or other proceeding with respect to Taxes of the Target Companies.  Such cooperation shall include making employees available on a mutually convenient basis to provide assistance in the preparation of Tax Returns and additional information and explanation of any material provided hereunder.

 

ARTICLE IX
TERMINATION

 

9.1                                Termination Events .  This Agreement may be terminated at any time prior to the Closing:

 

(a)                                  by either Purchaser or the Company if the Closing has not occurred on or before December 31, 2017 (the “ Outside Date ”) on the Business Day following delivery of written notice thereof to the other parties hereto; provided , that neither Purchaser nor the Company shall be entitled to terminate this Agreement pursuant to this Section 9.1(a)  if such Person’s willful breach of this Agreement has prevented the consummation of the Transactions as of such date; provided , further that either the Purchaser or the Company may at its election provide that the Outside Date shall be extended until January 14, 2018 by sending written notice to the other party on or after the Outside Date, and such extension shall supersede any notice sent by the other party to terminate this Agreement on the same date;

 

74



 

(b)                                  by mutual written consent of the Company and the Purchaser;

 

(c)                                   by either the Purchaser or the Company if a Governmental Entity shall have (i) issued a non-appealable final judgment, order, writ, injunction, decree, stipulation, ruling, decision, verdict, determination, agreement or award (“ Order ”), or (ii) enacted, enforced or deemed applicable to the Transactions a Law in final form, in each case having the effect of permanently restraining, enjoining, prohibiting or making illegal the consummation of the Transactions ( provided , however , that the Party seeking to terminate pursuant to this Section 9.1(c)  shall have used commercially reasonable efforts to have any such Order or other action vacated or lifted and shall not be in breach in any material respect of any of its obligations hereunder);

 

(d)                                  by the Purchaser: (i) upon a breach of any representation, warranty, covenant or agreement of the Company set forth in this Agreement such that the conditions set forth in Section 7.2(a) , Section 7.2(b) , Section 7.2(c)  or Section 7.2(d)  would not be satisfied (a “ Seller Terminating Breach ”); provided , however , that if such Seller Terminating Breach is curable prior to the expiration of thirty (30) days from the date of written notice to the Company of its occurrence through the exercise of the Company’s commercially reasonable efforts, and for so long as the Company continues to exercise such commercially reasonable efforts, the Purchaser may not terminate this Agreement under this Section 9.1(d)  until the expiration of such thirty (30) day period without such Seller Terminating Breach having been cured (but in no event shall the preceding proviso be deemed to extend the Outside Date (as such may be extended pursuant to Section 9.1(a) ) set forth in Section 9.1(a) ); or (ii) if satisfaction of any of the conditions set forth in Section 7.2 is or becomes impossible (other than through the failure of the Purchaser to comply with its obligations under this Agreement); provided , further , that the Purchaser shall not be entitled to terminate this Agreement pursuant to this clause Section 9.1(d)  at any time during which the Purchaser would be unable to satisfy the conditions in Section 7.3(a)  or Section 7.3(b)  hereof; or

 

(e)                                   by the Company:  (i) upon a breach of any representation, warranty, covenant or agreement of the Purchaser or Merger Sub set forth in this Agreement such that the conditions set forth in Section 7.3(a)  or Section 7.3(b)  would not be satisfied (a “ Purchaser Terminating Breach ”); provided , however , that if such Purchaser Terminating Breach is curable prior to the expiration of thirty (30) days from the date of written notice to the Purchaser of its occurrence through the exercise of the Purchaser’s commercially reasonable efforts, and for so long as the Purchaser continues to exercise such commercially reasonable efforts, the Company may not terminate this Agreement under this Section 9.1(e)  until the expiration of such thirty (30) day period without such Purchaser Terminating Breach having been cured (but in no event shall the preceding proviso be deemed to extend the Outside Date (as such may be extended pursuant to Section 9.1(a) ) set forth in Section 9.1(a) ); or (ii) if satisfaction of any of the conditions set forth in Section 7.3 is or becomes impossible (other than through the failure of the Company to comply with its obligations under this Agreement); provided , further , that the Company shall not be entitled to terminate this Agreement pursuant to this Section 9.1(e)  at any time during which the Company would be unable to satisfy the conditions in Section 7.2(a) , Section 7.2(b) , Section 7.2(c)  and Section 7.2(d)  hereof.

 

75



 

(f)            by the Company, if prior to the Outside Date (i) the conditions set forth in Sections 7.1 and 7.2 have been satisfied as of such date (other than those conditions that by their nature are to be satisfied at the Closing that would be satisfied at a Closing as of such date) or have been waived in writing by the Purchaser, (ii) the Company is ready, willing and able to consummate the transactions contemplated by this Agreement at the Closing and has irrevocably certified thereto in writing to the Purchaser, and (iii) the Purchaser fails to complete the Closing within three (3) Business Days following the date the Closing should have occurred pursuant to Section 1.7 due to the failure by the Debt Financing Source to fund for any reason the Debt Financing.

 

9.2          Effect of Termination .

 

(a)           The Parties’ termination rights under Section 9.1 are in addition to any other rights they may have under this Agreement or otherwise, and the exercise of a right of termination hereunder will not be an election of remedies, except as provided in Section 9.2(b) .  Subject to Section 9.2(b) , if this Agreement is terminated pursuant to Section 9.1 , all further obligations of the Parties under this Agreement will terminate; provided , however , that if this Agreement is terminated by the Purchaser, on the one hand, or the Company, on the other hand, because of the willful and material breach of this Agreement by the other, the terminating Party’s right to pursue all legal remedies will survive such termination unimpaired, except to the extent that the Reverse Termination Fee is payable in connection with such termination; provided further , that the provisions of Section 6.1 , this Section 9.2 and in ARTICLE X shall survive any termination of this Agreement.

 

(b)           Notwithstanding anything herein to the contrary, if this Agreement is terminated pursuant to Section 9.1(e)  or (f)  or is terminated pursuant to Section 9.1(a)  at a time when the Company is entitled to terminate this Agreement pursuant to any of Section 9.1(e)  or (f) , then the Purchaser shall pay Fifty Million Dollars ($50,000,000) in cash (the “ Reverse Termination Fee ”) to the Company no later than two (2) Business Days after such termination, by wire transfer to an account designated by the Company.  The Parties hereto acknowledge and agree (i) that the provisions contained in this Section 9.2(b)  are an integral part of the transactions contemplated by this Agreement and are included herein in order to induce the Company and the Blocker Sellers to enter into this Agreement and to reimburse the Company and the Blocker Sellers for incurring the costs and expenses related to entering into this Agreement and consummating the transactions contemplated by this Agreement and (ii) that any amounts payable pursuant to this Section 9.2(b)  do not constitute a penalty.  If the Purchaser fails to pay the Reverse Termination Fee and the Company commences an action to obtain the Reverse Termination Fee that results in a judgment against the Purchaser for the Reverse Termination Fee or any portion thereof, then the Purchaser shall pay the Company’s reasonable costs and expenses (including reasonable attorney’s fees, expenses and disbursements) incurred in connection with such action, together with interest on the Reverse Termination Fee at the “prime rate” as published in The Wall Street Journal , Eastern Edition, in effect on the date such payment was required to be made through the date of payment (calculated daily on the basis of a year of 365 days and the actual number of days elapsed, without compounding); provided however, that if such action does not result in a judgment against Purchaser for payment of the Reverse Termination Fee, the Company shall pay to Purchaser reasonable costs and expenses

 

76



 

(including reasonable attorney’s fees, expenses and disbursements) incurred in connection with such action.  Notwithstanding anything to the contrary in this Agreement, the parties agree that (1) the Reverse Termination Fee shall be the sole and exclusive remedy of the Company, the Securityholder Representative and the Blocker Sellers and each of their respective Affiliates in the event that this Agreement is terminated pursuant to any of Sections 9.1(e)  or (f)  or is terminated pursuant to Section 9.1(a)  at a time when the Company is entitled to terminate this Agreement pursuant to any of Sections 9.1(e)  or (f) .  Upon payment of the Reverse Termination Fee, none of Purchaser, its financing sources, or any of their respective Affiliates or of any of the foregoing shall have any further liability or obligation relating to or arising out of this Agreement or the transactions contemplated herein or the Financing Letters whether by or through a claim by or on behalf of a Party hereto or any other Person (including a claim to enforce the Financing Letters) or otherwise.  For the avoidance of doubt, in no event shall Purchaser be required to pay the Reverse Termination Fee on more than one occasion.

 

ARTICLE X
MISCELLANEOUS

 

DEFINITIONS

 

10.1        Defined Terms .  For purposes hereof, the following terms, when used herein with initial capital letters, shall have the respective meanings set forth herein:

 

1               ACA ” means, collectively, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 or any successor law, and regulations and rules issued pursuant to that Act or any successor law.

 

2               Additional Payments ” means, if and when payable pursuant to the terms of this Agreement, the amounts payable to the Sellers (i) from the Escrow Account pursuant to the terms of this Agreement and the Escrow Agreement, (ii) from the Holdback Account pursuant to the terms of this Agreement, and/or (iii) pursuant to Section 8.1 .

 

3               Affiliate ” of a Person means any other Person that controls, is controlled by, or is under common control with, the first mentioned Person.  For purposes of this definition, “control,” when used with respect to any specified Person, means the power, directly or indirectly, to direct or cause the direction of the management and policies of such Person whether through ownership of voting securities or by contract or otherwise, and the terms “controlling” and “controlled by” have meanings correlative to the foregoing.

 

4               Agreed Accounting Principles ” means the Company’s methodologies, practices, estimation techniques, assumptions and principles used in the preparation of the Balance Sheet as set forth on Schedule 10.1(a) .

 

5               Agreement ” has the meaning set forth in the Preamble.

 

77



 

6               Allocation Statement ” means a spreadsheet setting forth the manner in which the Transaction Consideration, as well as any Additional Payment to be made pursuant to this Agreement, is to be allocated among the Sellers, including the allocation of the Transaction Consideration for each Seller as between Cash Consideration and Stock Consideration, as delivered from time to time to Purchaser and to the Paying Agent by the Company and/or the Securityholder Representative in accordance with this Agreement. The Allocation Statement shall be prepared in accordance with the Company LLC Agreement, including without limitation, Sections 3.2 and 8.12 thereof and the definition of “Proceeds” therein.

 

7               Balance Sheet ” has the meaning set forth in Section 3.4 .

 

8               Blocker ” means any of LDI Nautic VII Blocker, Inc., a Delaware corporation, LDI Nautic VIII-A Blocker, Inc. a Delaware corporation, and Oak HC/FT LDI Blocker Corp., a Delaware corporation (collectively, the “ Blockers ”).

 

9               Blocker Sellers ” has the meaning set forth in the Preamble.

 

10            Blockers’ Equity ” means the equity interests of the Blockers, collectively.

 

11            Blockers’ Organizational Documents ” means the certificate of formation, certificate of incorporation, limited liability company agreement, bylaws and similar organizational documents of the Blockers, in each case as amended and/or restated from time to time, by and among the parties thereto.

 

12            Blockers’ Units ” means the Units of the Company owned directly by the Blockers including the Units of the Company directly owned by Nautic VIII-A Blocker following the Splitter Dissolution.

 

13            Business Day ” shall mean any day other than a Saturday, Sunday or day on which banks are permitted to close in St. Louis, Missouri or New York City, New York.

 

14            Cash ” means all cash, cash equivalents of the Target Companies on a consolidated basis, plus received cash and checks whether or not cleared but net of checks written but not yet cleared, in each case determined as of the Effective Time in accordance with the Agreed Accounting Principles.

 

15            CERCLA ” shall mean the United States Comprehensive Environmental Response, Compensation and Liability Act, 42 U.S.C. § 9601 et seq. , as amended.

 

16            Certificate of Merger ” has the meaning set forth in Section 1.2 .

 

17            Closing ” has the meaning set forth in Section 1.7 .

 

18            Closing Cash ” means Cash calculated as of the Effective Time and in accordance with the Agreed Accounting Principles.

 

78



 

19            Closing Date ” has the meaning set forth in Section 1.7 .

 

20            Closing Date Net Working Capital Amount ” means the amount by which (i) Current Assets exceeds (ii) Current Liabilities, in each case, determined as of the Effective Time and in accordance with the Agreed Accounting Principles.

 

21            Closing Indebtedness ” means the Indebtedness of the Target Companies as of the Effective Time and calculated in accordance with the Agreed Accounting Principles.

 

22            Code ” shall mean the Internal Revenue Code of 1986, as amended.

 

23            Collective Bargaining Agreements ” has the meaning set forth in Section 3.14(a) .

 

24            Company ” has the meaning set forth in the Preamble.

 

25            Company Board ” has the meaning set forth in the Recitals to this Agreement.

 

26            Company Information ” means any information that has value to a Target Company and is not generally known to the public or its competitors, including client lists and information, design details, technical information and specifications, marketing techniques, plans and procedures, instruction manuals, know-how, trade secrets, information concerning market conditions, marketing and business information generally, scientific information, financial information, price policies and other material of whatever description regarding the products, services, affairs, businesses or method of carrying on business of such Target Company.

 

27            Company IP Agreements ” means all licenses, sublicenses, consent to use agreements, settlements, coexistence agreements, covenants not to sue, waivers, releases, permissions, and other Contracts, whether written or oral, relating to Intellectual Property Rights to which the Company or the Subsidiary is a party, beneficiary, or otherwise bound.

 

28            Company Intellectual Property ” means all Intellectual Property Rights owned or licensed by the Company or a Subsidiary, including all rights of the Company and the Subsidiary to sue or otherwise recover for any past, present or future infringement, misappropriation, dilution, or other violation thereof.

 

29            Company LLC Agreement ” means that certain Amended and Restated Limited Liability Company Agreement of the Company, dated as of November 1, 2016, as amended, by and among the Company and the members of the Company thereto.

 

30            Company Privacy Law ” has the meaning set forth in Section 3.15(h) .

 

31            Company Products ” means all products and services currently commercially marketed, distributed, hosted, maintained, supported, sold or licensed out by the Company or the Subsidiary to its customers.

 

79



 

32            Company Sites ” means any Internet websites owned, maintained or operated by the Company or the Subsidiary.

 

33            Company Source Code ” means any human readable Software source code that is owned or licensed by the Company or the Subsidiary and that is (A) incorporated in any Current Company Product or (B) owned by the Company or the Subsidiary and material to the business of the Company or the Subsidiary as it is currently conducted.

 

34            Consent ” shall mean any approval, consent, ratification, waiver, authorization from any Person or other action of, or any filing with or notice to any Person.

 

35            Contaminants ” has the meaning set forth in Section 3.17(a) .

 

36            Contract ” shall mean any oral or written agreement, contract, note, loan, purchase order, letter of credit, indenture, security or pledge agreement, covenant not to compete, license, lease, commitment, promise, undertaking or other business or commercial arrangement (in each case, including any extension, renewal, amendment or other modification).

 

37            Credit Facility ” means that certain Loan and Security Agreement, dated as of November 1, 2016, by and among the Company, Leehar Distributors, LLC, Ally Bank, Madison Capital Funding LLC, Capital One, National Association, and the other financial institutions listed on the signature pages thereto, as amended.

 

38            Current Assets ” means the aggregate amount of all current assets of the Target Companies listed as categories of current assets on Schedule 10.1(a) , on a consolidated basis and in accordance with the Agreed Accounting Principles; provided , however , that Current Assets shall not include any Cash or any Tax assets (including deferred Tax assets to take into account differences in timing between book and tax income).

 

39            Current Liabilities ” means the aggregate amount of all current liabilities of the Target Companies listed as categories of current liabilities on Schedule 10.1(a) , on a consolidated basis and in accordance with the Agreed Accounting Principles; provided , however , that Current Liabilities shall not include any Indebtedness, Selling Expenses or other liabilities either paid on or prior to the Closing Date by or on behalf of the Company or any Tax liabilities (including any relating to deferred Taxes to take into account differences in timing between book and tax income).

 

40            D&O Indemnified Person ” has the meaning set forth in Section 6.8(a) .

 

41            Deal Communications ” has the meaning set forth in Section 10.18 .

 

42            Debt Financing ” means the third-party debt financing to be obtained by Purchaser at or prior to the Effective Time in connection with the transactions contemplated by this Agreement on the terms and conditions set forth in the Financing Letters.

 

43            Disclosure Schedules ” shall mean the disclosure schedules dated as of the date of this Agreement which sets forth the exceptions to the representations and warranties

 

80



 

contained herein and certain other information called for by this Agreement.  Unless otherwise specified, each reference in this Agreement to any numbered schedule is a reference to that numbered schedule which is included in the Disclosure Schedules.  Exceptions and information with respect to particular representations and warranties are set forth in the numbered schedule that corresponds to the schedule reference in the applicable representation and warranty to which such exception relates; provided , that , information contained in the Disclosure Schedules under any particular schedule is deemed disclosed with respect to other schedules where the applicability of such information to such other schedules is reasonably apparent on its face, regardless of whether a cross-reference to the applicable schedule is actually made.  Any matter disclosed in the Disclosure Schedules shall not be deemed an admission or representation as to the materiality of the item so disclosed.  Nothing in the Disclosure Schedules constitutes an admission of any Liability or obligation of the Company to any third party or shall confer or give to any third party any remedy, claim, Liability, reimbursement, cause of action or other right.

 

44            DLLCA ” has the meaning set forth in the Recitals to this Agreement.

 

45            DOJ ” means the Department of Justice of the United States.

 

46            Downward Adjustment Amount ” has the meaning set forth in Section 2.3(b)(v) .

 

47            Effective Time ” has the meaning set forth in Section 1.2 .

 

48            Eligible Equity ” means collectively, the Blockers’ Equity and the Units (other than the Blockers’ Units) that are outstanding immediately prior to the Effective Time, giving effect to the Company LLC Agreement, including without limitation, Section 3.2 thereof and the definition of “Proceeds” therein.

 

49            Employee ” shall mean any person who is a current part-time or full-time employee of the Company or the Subsidiary.

 

50            Employee Plans ” has the meaning set forth in Section 3.8(a) .

 

51            Environmental Claim ” means any investigation, hearing, claim, action, suit or litigation by any Person for liability or potential liability (including liability or potential liability for enforcement, investigatory costs, cleanup costs, natural resource damage, governmental response costs, property damage, personal injury, fines or penalties) based on (i) the discharge, emission, Release of any Hazardous Materials or (ii) the violation of any applicable Environmental Laws.

 

52            Environmental Law ” shall mean all applicable foreign, federal, state or local laws, rules or regulations promulgated thereunder and orders, consent orders, judgments, or rulings issued, promulgated or entered pursuant thereto, regarding pollution or protection of the natural resources and the environment, including, but not limited to, (i) laws regarding the emissions, discharges, releases of Hazardous Materials into the indoor or outdoor environment and (ii) laws relating to the identification, generation, manufacture, processing, distribution, use, treatment, storage, disposal, recovery, transport or other handling of Hazardous Materials.

 

81



 

Environmental Laws shall include, but not be limited to, CERCLA, the Federal Water Pollution Control Act (33 U.S.C. § 1251 et seq. ), the Resource Conservation and Recovery Act, 42 U.S.C. § 6901 et seq. , as amended, the Safe Drinking Water Act (21 U.S.C. § 349, 42 U.S.C. §§ 201, 300f), the Toxic Substances Control Act (15 U.S.C. § 2601 et seq. ), the Clean Air Act (42 U.S.C. § 7401 et seq. ) or any other similar foreign, federal, state or local law of similar effect, each as amended.

 

53            Environmental Permits ” shall mean all licenses, permits, authorizations, or consents from any Governmental Entity required for the operation of the Company or the Leased Property under Environmental Laws.

 

54            Equity Incentive Plan ” means the Company’s Equity Incentive Plan.

 

55            ERISA ” shall mean the Employee Retirement Income Security Act of 1974 or any successor law, and regulations and rules issued pursuant to that Act or any successor law.

 

56            Escrow Account ” has the meaning set forth in Section 2.4(a) .

 

57            Escrow Amount ” has the meaning set forth in Section 2.1(c) .

 

58            Escrow Agent ” has the meaning set forth in Section 2.1(c) .

 

59            Escrow Agreement ” has the meaning set forth in Section 2.1(c) .

 

60            Escrow Release Amount ” has the meaning set forth in Section 2.3(b) .

 

61            Estimated Cash Consideration ” has the meaning set forth in Section 2.2(a) .

 

62            Estimated Closing Cash ” has the meaning set forth in Section 2.3(a) .

 

63            Estimated Closing Debt Indebtedness ” has the meaning set forth in Section 2.3(a) .

 

64            Estimated Closing Statement ” has the meaning set forth in Section 2.3(a) .

 

65            “Estimated Net Working Capital ” has the meaning set forth in Section 2.3(a) .

 

66            Estimated Selling Expenses ” has the meaning set forth in Section 2.3(a) .

 

67            Federal Healthcare Program ” means the Medicare, 42 C.F.R. § 1395 et seq. and Medicaid Programs, 42 C.F.R. § 1396 et seq., the CHAMPUS Program, the TRICARE Program, 10 U.S.C. Section 1071 et seq. and any other federal, state or local reimbursement program involving payment of governmental funds (including “Federal health care programs” as defined in 42 U.S.C. § 1320a 7b(f)).

 

82



 

68            Final Statement ” has the meaning set forth in Section 2.3(b)(iv) .

 

69            Final Cash Consideration ” has the meaning set forth in Section 2.3(b)(iv) .

 

70            Final Closing Cash ” has the meaning set forth in Section 2.3(b)(iv) .

 

71            Final Closing Indebtedness ” has the meaning set forth in Section 2.3(b)(iv) .

 

72            Final Net Working Capital ” has the meaning set forth in Section 2.3(b)(iv) .

 

73            Final Selling Expenses ” has the meaning set forth in Section 2.3(b)(iv) .

 

74            Financial Statements ” has the meaning set forth in Section 3.4 .

 

75            Financing Information ” means the financial information of the Company required by Section 5 of Exhibit B to the Financing Letters.

 

76            Financing Letters ” means the executed commitment letter, dated as of November 15, 2017, among JPMorgan Chase Bank, N.A. and Capital One, National Association, pursuant to which, upon the terms and subject to the conditions set forth therein, the lenders party thereto have committed to provide debt financing in an aggregate amount set forth therein for the purpose of funding a portion of the payments required to be made by the Purchaser pursuant to Section 2.1 .

 

77            Financing Sources ” means any entities that have committed to provide or otherwise entered into agreements to provide the Debt Financing, including the banks party to the Financing Letters and any joinder agreements related thereto (including the definitive agreements executed in connection with the Financing Letters) and any administrative agents, collateral agents, and any former, current or future direct or indirect equityholders, controlling persons, members, directors, officers, employees, agents, Affiliates, attorneys, representatives of the foregoing and their successors and assigns.

 

78           “ Fraud means a claim for common law fraud with a specific intent to deceive based on a representation contained in this Agreement; provided that, at the time such representation was made, (a) such representation was materially inaccurate, (b) the Party making such representation had actual Knowledge of the material inaccuracy of such representation, (c) the Party making such representation had the specific intent to deceive the other Party, and (d) the other Party acted in reliance on such inaccurate representation and suffered financial injury as a result of such material inaccuracy.

 

79            GAAP ” shall mean United States generally accepted accounting principles and practices applied on a consistent basis.

 

80            General Enforceability Exceptions ” has the meaning set forth in Section 3.1(b) .

 

81            Goodwin ” has the meaning set forth in Section 10.18 .

 

82            Governing Documents ” means with respect to any particular entity, (i) if a corporation, the articles or certificate of incorporation and the bylaws (or similar organizational documents for any entity organized or existing in any non-U.S. jurisdiction), (ii) if a limited partnership, the limited partnership agreement and the articles or certificate of limited partnership (or similar organizational documents for any entity organized or existing in any non-

 

83



 

U.S. jurisdiction), (iii) if a limited liability company, the articles of organization or certificate of formation and the limited liability company agreement or operating agreement (or similar organizational documents for any entity organized or existing in any non-U.S. jurisdiction), (iv) if any other type of entity (including any non-U.S. entity), the formation or organizational documents and the governing documents, and (v) any amendment or supplement to any of the foregoing.

 

83            Governmental Entity ” shall mean any foreign, federal, state, provincial, local or other jurisdiction, governmental authority, including any governmental agency, branch, department, official or entity, any court or other tribunal including quasi-governmental authority of any nature.

 

84            Hazardous Materials ” shall mean any substance that is listed, defined, designated or classified as, or otherwise determined to be, hazardous, radioactive, infectious, reactive, corrosive, ignitable, flammable or toxic or a pollutant, contaminant, chemical, industrial material, sewage, waste or other substance subject to regulation, control or remediation under any Environmental Law.

 

85            Healthcare Regulatory Laws ” means all state and federal laws and regulations relating to the provision or administration of, or pricing or payment for the distribution, dispensing and possession of drugs and the provision of other healthcare products or services, including, without limitation: (i) all state and federal healthcare fraud and abuse laws and regulations, including, without limitation: (A) the Anti-Kickback Statute, 42 U.S.C. § 1320a-7b, 42 C.F.R. § 1001.952, (B) the Civil Monetary Penalties Law, 42 U.S.C. § 1320a-7a, (C) the federal physician self-referral prohibition, 42 U.S.C. § 1395nn, 42 C.F.R. § 411.351 et seq., and (D) the False Claims Act, 31 U.S.C. § 3729 et seq. (E) the federal false coding statute, 42 U.S.C. § 1320a-7a; (ii) the Food and Drug and Cosmetic Act, 21 U.S.C. § 301 et seq.; (iii) the Controlled Substances Act, 21 U.S.C. § 801 et seq., 21 C.F.R. § 1300 et seq.; (iv)  federal or state laws relating to billing or claims for reimbursement submitted to any third party payor; (iv) the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act, the regulations promulgated pursuant thereto and comparable state privacy and security laws and regulations; (v) federal or state laws or regulations relating to the provision of pharmacy benefit management and administration; (vi) Federal Healthcare Program; and (vii) state pharmacy laws or regulations including the operation of pharmacies, the repackaging of drug products, the distribution of prescription drugs or controlled substances, the dispensing of prescription drugs or controlled substances and the labeling, packaging, advertising or adulteration of prescription drugs or controlled substances.

 

86            Healthcare Regulatory Permits ” has the meaning set forth in Section 3.17(a) .

 

87            Holdback Account ” has the meaning set forth in Section 2.4(b) .

 

88            HSR Act ” shall mean the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, and the rules and regulations promulgated thereunder.

 

84



 

89            HSR Approval ” has the meaning set forth in Section 7.1(b) .

 

90            Indebtedness ” means, without duplication, the sum of (i) all Liabilities of the Target Companies for borrowed money, (ii) all Liabilities of the Company or the Subsidiary as lessee or lessees under leases that have been or are required to be recorded as capital leases in accordance with GAAP, (iii) all Liabilities of the Company or the Subsidiary under notes, bonds, debentures or other similar instruments or debt securities, (iv) all Liabilities arising out of any interest rate, currency or other hedge agreements or other hedging, derivative or swap arrangements, (v) all Liabilities under any performance bond, banker’s acceptance or similar credit transactions or any commitment by which either of the Target Companies assures a creditor against a loss (including contingent reimbursement obligations) and all outstanding letters of credit (solely to the extent drawn and outstanding), (vi) all Liabilities for any deferred purchase price related to past acquisitions, whether contingent or otherwise (including any “earn-out” or similar payments or obligations at the maximum amount payable in respect thereof), (vii) all Liabilities arising from cash/book overdrafts, (viii) deferred rent and deferred compensation Liabilities, (ix) any unpaid Pre-Closing Taxes of any Target Company; (x) unpaid Liabilities of the Company or the Subsidiary in respect of any Employee Plan underfunding, (xi) all Liabilities with respect to conditional sale or other title retention agreements, (xii) all Liabilities to current or former equityholders in respect of dividends or other distributions declared prior to Closing and (xiii) any discount amounts provided by the Company or the Subsidiary to the vendor set forth on Schedule 10.3 that do not amortize in the twelve (12) month period following the closing and (xiv) all Liabilities of the type described in clauses (i) through (xiii) above of any Person the payment of which is guaranteed by the Target Companies, in each case together with any accrued but unpaid interest, prepayment premiums and breakage costs related thereto.

 

91            Insurance Policies ” shall mean any insurance policy or contract of insurance of the Company.

 

92            Intellectual Property Rights ” shall mean all of the worldwide rights arising from or in respect of the following, whether protected, created or arising under the Laws of the United States or any foreign jurisdiction: (a) patents, provisional patents and utility models and applications therefor, any reissues, reexaminations, divisionals, continuations, continuations-in-part and extensions thereof, and equivalent or similar rights anywhere in the world in inventions and discoveries, including invention disclosures, invention certificates, and the like (collectively, “ Patents ”); (b) trademarks, service marks, trade names (whether registered or unregistered), service names, industrial designs, brand names, brand marks, trade dress rights, Internet domain names, social media accounts and user names, identifying symbols, logos, emblems, signs or insignia and including all goodwill associated with the foregoing (collectively, “ Marks ”); (c) copyrights, whether registered or unregistered (including copyrights in computer software programs), mask work rights, database rights, works of authorship and other rights corresponding thereto (collectively, “ Copyrights ”); (d) trade secrets, and any other intellectual property rights in confidential and proprietary information, or non-public processes, designs, specifications, technology, know-how, techniques, formulas, inventions, concepts, discoveries, ideas and technical data and information, in each case excluding any rights in respect of any of the foregoing that comprise or are protected by Copyrights or Patents (collectively, “ Trade Secrets ”); (e) any computer programs, operating systems, applications, firmware, and other code, including all source code, object code, application programming interfaces, data files, databases, protocols, specifications, and other documentation thereto (collectively, “ Software ”) and (f)  all

 

85



 

applications, registrations, renewals, extensions and permits related to any of the foregoing clauses (a) through (e).

 

93                                   IRS ” shall mean the United States Internal Revenue Service or any successor agency.

 

94                                   IT Assets ” has the meaning set forth in Section 3.17(f) .

 

95                                   Knowledge of the Company ” and phrases of similar import, shall mean the actual knowledge of Leonard S. Dino, Jr., David M. Byrne, Janice Forsyth or Albert Thigpen, after reasonable inquiry.

 

96                                   Law ” shall mean any federal, state, provincial, local, municipal, foreign, international, multinational or other law, ordinance, statute or treaty.

 

97                                   Legal Proceeding ” shall mean any demand, action, arbitration, audit, examination, claim, complaint, hearing, investigation, litigation or suit (whether civil, criminal or administrative) commenced, brought, conducted or heard by or before, or otherwise involving, any Governmental Entity or arbitrator.

 

98                                   Letter of Transmittal ” means the Letter of Transmittal substantially in the form attached hereto as Exhibit C , which provides for (i) an acknowledgement of the Securityholder of the cancellation of all Units held by such Securityholder, as applicable, in exchange for the right to receive the consideration payable therefor under this Agreement, and (ii) the confirmation of the appointment of the Securityholder Representative.

 

99                                   Liability ” shall mean any direct or indirect liability, indebtedness, obligation, commitment, expense, claim, deficiency, guaranty or endorsement of or by any Person of any type, whether known, unknown, accrued, absolute, contingent, matured, unmatured, liquidated or unliquidated, and whether due or to become due, known or unknown.

 

100                            Lien ” shall mean any charge, claim, community or other marital property interest, lien, pledge, transfer or use restriction, security interest, deed of trust, mortgage, right-of-way, easement, encroachment or servitude, in each case, whether voluntary, involuntary, statutory or otherwise.

 

101                            Lower Collar ” means the amount equal to the Target Net Working Capital Amount minus $2,000,000.

 

102                            Made Available ” means with respect to any document or information, that the same has been made available or is otherwise accessible to Purchaser at least 3 calendar days prior to the date of this Agreement by means of the virtual data room established by the Company titled “Project Leeward” and accessible at http://www.intralinks.com.

 

103                            Marketing Efforts ” means (i) the participation by the Company’s and the Subsidiary’s senior management team, with appropriate seniority and expertise, in (A) the preparation of the Marketing Material and a reasonable number of due diligence sessions related

 

86



 

thereto  (B) a reasonable number of meetings (or calls in lieu of meetings), presentations and roadshows with prospective sources of the Debt Financing, including potential lenders (but not more than one primary bank meeting), in each case during reasonable business hours,  and (ii) the delivery of customary authorization letters in connection with the Marketing Material (including with respect to the presence or absence of material non-public information and accuracy in all material respects when furnished (when taken together with all supplements or updates thereto) of the financial information regarding the Company (other than projections) contained therein).

 

104                            Marketing Material ” means customary syndication documents and materials, including bank books, confidential information memoranda or other information packages, lender presentations, rating agency materials and presentations, and similar documents and materials (including the provision of “backup” support), in connection with the Debt Financing; provided, that the Company shall not be required to prepare any pro-forma or forward-looking financials.

 

105                            Material Adverse Effect ” shall mean any change, effect, event or occurrence that, individually or in the aggregate, (a) does, or would be reasonably expected to, prevent or materially impair, delay or affect the ability of the Company or the Blocker Sellers to consummate the Transactions or (b) has had or would reasonably be expected to have a material adverse effect on the business, assets, liabilities, condition (financial or otherwise) or results of operations of the Company and the Subsidiary taken as a whole; provided , however , that in the case of this clause (b), none of the following shall be deemed in themselves to constitute a Material Adverse Effect and excluding any change, effect, event or occurrence arising from the following: (i) the announcement or pendency or consummation of the Transactions, including any related losses or threatened losses of employees, customers, suppliers, distributors or others having relationships with the Company; (ii) any change, effect, event or occurrence in any industry in which the Company participates, the U.S. economy or any other economy where the Company conducts business (in each case, as a whole) or the capital, banking or financing markets in general or the markets in which the Company operates or any geographical area in which the Company conducts its business; (iii) any “act of God” including weather, natural disasters and earthquakes, hostilities, acts of war, sabotage or terrorism or military actions or any escalation or material worsening of any such hostilities, acts of war, sabotage or terrorism or military actions; (iv) any change in global, national or regional political conditions; (v) changes after the date hereof in GAAP or any change in any applicable Laws, rules or regulations issued by any Governmental Entity; (vi) any failure, in and of itself, by the Company to meet any internal projections or forecasts for any period ending on or after the date of this Agreement (but not the change, effect, event or occurrence underlying, causing or contributing to such failure to the extent such change, effect, event or occurrence would otherwise constitute or contribute to a Material Adverse Effect under this definition); (vi) any existing event or occurrence or circumstance of which the Purchaser has actual knowledge on the date hereof as a result of such existing event or occurrence or circumstance having been expressly disclosed in reasonable detail in the Disclosure Schedules; or (vii) any action taken by a party hereto as expressly required by this Agreement; except, in the case of the foregoing clauses (ii) through (v), any change, effect, event or occurrence that has a material disproportionate effect on the Company or the Subsidiary or the business, assets, liabilities, condition (financial or otherwise) or results of operations of the

 

87



 

Company or the Subsidiary as compared to other participants in the industry in which the Company or the Subsidiary operate.

 

106                            Material Customer ” has the meaning set forth in Section 3.18 .

 

107                            Material Supplier ” has the meaning set forth in Section 3.18 .

 

108                            Merger ” has the meaning set forth in Section 1.1 .

 

109                            Merger Sub ” has the meaning set forth in the Preamble.

 

110                            Nautic VIII-A Blocker ” has the meaning set forth in Section 6.11 .

 

111                            Nautic VIII-A Splitter ” has the meaning set forth in Section 1.1 .

 

112                            Net Working Capital Deficit ” means the amount by which the Closing Date Net Working Capital Amount is less than the Lower Collar.

 

113                            Net Working Capital Surplus ” means the amount by which the Closing Date Net Working Capital Amount is greater than the Upper Collar.

 

114                            Neutral Arbitrator ” has the meaning set forth in Section 2.3(b)(iv) .

 

115                            Non-Disclosure and Confidentiality Agreement ” has the meaning set forth in Section 6.4 .

 

116                            Open Source Software ” means Software that is subject to a license or other agreement commonly referred to as an open source, free Software, copyleft or community source code license (including but not limited to any code or library licensed under the GNU General Public License, GNU Lesser General Public License, BSD License, Apache Software License, or any other public source code license arrangement), including without limitation any license defined as an open source license by the Open Source Initiative as set forth on  www.opensource.org.

 

117                            Order ” has the meaning set forth in Section 9.1(c) .

 

118                            Organizational Documents ” shall mean (a) the articles or certificate of incorporation, all certificates of determination and designation, and the bylaws of a corporation; (b) the partnership agreement and any statement of partnership of a general partnership; (c) the limited partnership agreement and the certificate or articles or declaration of limited partnership of a limited partnership; (d) the operating agreement, limited liability company agreement and the certificate or articles of organization or formation of a limited liability company; (e) the declaration of trust or similar document of any trust; (f) any charter or similar document adopted or filed in connection with the creation, formation or organization of a Person; and (g) any amendment to any of the foregoing.

 

119                            Parties ” shall mean the parties to this Agreement.

 

88



 

120                            Paying Agent ” means Acquiom Financial LLC.

 

121                            Paying Agent Agreement ” means that certain Paying Agent Agreement substantially in the form attached hereto as Exhibit H.

 

122                            Permits ” shall mean all material licenses, permits, provider or supplier numbers, franchises, approvals, authorizations, registrations, certificates, easements, variances, exemptions, Consents or orders of, or filings with, any Governmental Entity, or any other Person, necessary for the present conduct of, or primarily related to the operation of, the Company or Subsidiary under any Laws including any Environmental Permits.

 

123                            Permitted Liens ” shall mean (i) any restriction on transfer arising under applicable securities Law; (ii) liens for current Taxes or other governmental charges not delinquent or the amount or validity of which is being contested in good faith by appropriate proceedings by the Company; (iii) mechanics’, carriers’, workers’, repairers’, landlords’  and similar statutory liens arising or incurred in the ordinary course of business for amounts which are not delinquent or the amount or validity of which is being contested in good faith by appropriate proceedings by the Company; (iv) zoning, entitlement, building and other land use regulations imposed by Governmental Entities; (v) encumbrances, covenants, conditions, restrictions, easements, rights of way, servitudes and other similar matters of record affecting title which do not and would not be reasonable expected to materially impair the occupancy or use of the Leased Real Property; (vi) Liens arising under worker’s compensation, unemployment insurance, social security, retirement and similar legislation; (vii) purchase money liens and liens securing rental payments under capital lease arrangements to the extent limited to the underlying equipment or property purchased or leased, as applicable; and (viii) those Liens set forth on Schedule 10.1(b) .

 

124                            Personally Identifiable Information ” means any information relating to an identified or identifiable natural person, including any information that alone or in combination with other information held by Company or Subsidiary can be used to specifically identify an identifiable natural person, including third party content uploaded by users through the Company Sites, such as tips, reviews, photos, videos, forum postings, home page information, deals, travelogues, comments, and ratings, and email; an identifiable natural person is one who can be identified, directly or indirectly, in particular by reference to an identifier such as a name, an identification number, location data, an online identifier or to one or more factors specific to the physical, physiological, genetic, mental, economic, cultural or social identity of that natural person.

 

125                            Person ” shall mean any individual, corporation (including any non-profit corporation), general or limited partnership, limited liability company, joint venture, estate, trust, association, organization, labor union or other entity or Governmental Entity.

 

126                            Pre-Closing Period ” has the meaning set forth in Section 6.2(a) .

 

127                            Pre-Closing Taxes ” means Taxes for any taxable period beginning on or before the Closing Date, provided that Pre-Closing Taxes for any Straddle Period shall be determined (i) in the case of any real property, personal property or other ad valorem Taxes, as the amount of such Tax for the entire Straddle Period multiplied by a fraction the numerator of which is the number of days in the Straddle Period that occur on or before the Closing Date and

 

89



 

the denominator of which is the total number of days in such Straddle Period, and (ii) in the case of any other Tax (including, for the avoidance of doubt, any Tax based on or measured by income, receipts or payroll), based on an interim closing of the books as of the end of the Closing Date (and for such purpose, the taxable period of any partnership or other pass through entity in which any of the Target Companies holds an interest shall be deemed to terminate as of the end of the Closing Date).

 

128                            Preliminary Statement ” has the meaning set forth in Section 2.3(b)(i) .

 

129                            Privileged Deal Communications ” has the meaning set forth in Section 10.18 .

 

130                            Professional Licenses ” means any and all appropriate licensure, registration or certification required by a Governmental Entity in order for a Person to perform professional services.

 

131                            Purchaser ” has the meaning set forth in the Preamble.

 

132                            Purchaser Related Party ” means (i) the Financing Sources and (ii) the former, current and future Affiliates, representatives, stockholders, members, partners, controlling persons, general or limited partners, managers, directors, officers, employees, agents, or successors and permitted assigns of Purchaser.

 

133                            Real Property Leases ” has the meaning set forth in Section 3.5(b) .

 

134                            Release ” shall mean any spilling, leaking, pumping, pouring, injecting, emitting, discharging, depositing, escaping, leaching, dumping or other releasing into the environment, whether intentional or unintentional and otherwise defined in any Environmental Law.

 

135                            Relevant Group ” means any affiliated, combined, consolidated, unitary or other group for Tax purposes including an affiliated group of corporations within the meaning of Section 1504 of the Code.

 

136                            Representative ” shall mean any officer, director, principal, legal counsel, agent, employee or other representative.

 

137                            Residual Communication ” has the meaning set forth in Section 10.18 .

 

138                            Resolution Period ” has the meaning set forth in Section 2.3(b)(ii) .

 

139                            Review Period ” has the meaning set forth in Section 2.3(b)(ii) .

 

140                            Securityholder Expense Amount ” has the meaning set forth in Section 2.1(b) .

 

90



 

141                            Securityholder Representative ” has the meaning set forth in the Preamble.

 

142                            Securityholders ” means, collectively, the Unitholders (other than the Blockers).

 

143                            Sellers ” means, collectively, the Unitholders (other than the Blockers) and the Blocker Sellers.

 

144                            Seller Terminating Breach ” has the meaning set forth in Section 9.1(d) .

 

145                            Selling Expenses ” means (i) the unpaid obligations of the Company and/or the Subsidiary for all legal, consulting, accounting and other expenses incurred in connection with the Transactions (including any success-based fees) determined as of the Effective Time including to Houlihan Lokey, Inc. and Goodwin, (ii) the amount of any transaction-related bonuses, stay bonuses, sale of the company bonuses, change of control payments or other similar compensatory payments, in each case, payable by the Company and/or the Subsidiary as a result of the Transactions, and (iii) payroll, employment or other Taxes, if any, required to be paid by Purchaser (on behalf of the Company) or the Company with respect to the amounts described in clauses (i) and (ii) above; provided , however , that the Purchaser shall pay for (a) all fees associated with the filing of the notification under the HSR Act and any comparable non-U.S. Laws, as provided in Section 1.1 , (b) fifty percent (50%) of any fees charged by the Escrow Agent and (c) all fees charged by the Paying Agent.

 

146                            Service Liability Claims ” means all Liabilities of the Company or the Subsidiary resulting from or under (i) any warranty made or allegedly made by the Company or the Subsidiary prior to the Closing Date with respect to any product it distributes or uses or any services it renders (“ Business Products ”), (ii) any alleged defect in, non-performance or deficiency of any nature in any Business Product sold or provided (as applicable) prior to the Closing Date, or (iii) any injury to person or property caused or alleged to be caused to any degree by any Business Product sold or provided (as applicable) prior to the Closing Date.

 

147                            Straddle Period ” means any taxable period beginning on or before and ending after the Closing Date.

 

148                            Subscription Agreements ” means those certain Subscription Agreements, in the form attached hereto as Exhibit G , executed by those Sellers receiving Stock Consideration hereunder.

 

149                            Subsidiary ” has the meaning set forth in Section 3.3(a) .

 

150                            Subsidiary’s Predecessor ” means Leehar Distributors, Inc., a Missouri corporation and any other predecessor to Subsidiary or any Person to which the Subsidiary is a successor in interest, in each case, whether as a result of any merger, amalgamation or acquisition of assets or otherwise.

 

151                            Surviving Company ” has the meaning set forth in Section 1.1 .

 

91



 

152                            Target Companies ” means the Blockers, the Company and the Subsidiary.

 

153                            Target Net Working Capital Amount ” means negative Seven Million Two Hundred Thousand Dollars (-$7,200,000).

 

154                            Tax ” or “ Taxes ” shall mean (i) any U.S. federal, state, provincial, local or foreign income, gross receipts, license, payroll, employment-related, excise, escheat goods and services, harmonized sales, severance, stamp, occupation, premium, windfall profits, environmental, customs duties, capital stock, franchise, profits, withholding, social security, unemployment, disability, real property, personal property, sales, use, transfer, land value, registration, value added, alternative or add-on minimum, estimated, withholding or other tax, levy, charge or fee imposed by a Tax Authority or Governmental Entity, including any interest, penalty, or addition thereto, whether disputed or not, (ii) any Liability for or in respect of the payment of any amount of a type described in clause (i) of this definition arising as a result of being or having been a member of a Relevant Group and (iii) any Liability for or in respect of the payment of any amount of a type described in clause (i) or (ii) of this definition as a transferee or successor, by Contract or otherwise.

 

155                            Tax Authority ” and “ Taxing Authority ” mean any U.S. or non-U.S. federal, national, state, provincial, county, or municipal or other local government, any subdivision, agency, commission, or authority thereof, any other Governmental Entity or any quasi-governmental body exercising or purporting to exercise any taxing authority (including authority to assess, collect or otherwise administer any Law relating to any Tax) or any other authority exercising or purporting to exercise Tax regulatory authority.

 

156                            Tax Allocation Schedule ” has the meaning set forth in Section 2.6 .

 

157                            Tax Return ” means any return, declaration, report, claim for refund, or information return or statement related to Taxes, including any schedule or attachment thereto, and including any amendment thereof.

 

158                            Termination Date ” has the meaning set forth in Section 9.1(a) .

 

159                            Transaction Consideration ” has the meaning set forth in Section 2.1 .

 

160                            Transaction Documents ” means this Agreement and all other agreements, instruments and certificates contemplated hereby or thereby to which any Party is a party.

 

161                            Transactions ” means the transactions contemplated by this Agreement, including, without limitation, the sale and purchase of the Blockers’ Equity and the Merger.

 

162                            Transfer Taxes ” has the meaning set forth in Section 8.1(a) .

 

163                            Treasury Regulations ” shall mean the Treasury Regulations promulgated under the Code.

 

92



 

164                            Units ” means the Class A Units, Class B-1 Units, Class B-2 Units and Class B-3 Units of the Company, collectively (each, as defined in the Company LLC Agreement), and any “Unit” means any one of the foregoing.

 

165                            Unitholder ” means a holder of Units that are issued and outstanding as of immediately prior to the Effective Time, in his, her or its capacity as such.

 

166                            Upper Collar ” means the amount equal to the Target Net Working Capital Amount plus $2,000,000.

 

167                            Upward Adjustment Amount ” has the meaning set forth in Section 2.3(b)(vi) .

 

10.2                         Nonsurvival of Representations, Warranties and Agreements .  None of the representations, warranties, covenants and agreements in this Agreement or any other Transaction Document shall survive the Effective Time. Notwithstanding the foregoing, this Section 10.2 shall not limit any covenant or agreement of the Parties which by its terms contemplates performance in whole or in part after the Effective Time or relates to delivery of the Transaction Consideration in full. The parties hereto agree that they will not, and will cause their Affiliates not to, pursue any claims with respect to this Agreement or any of the Ancillary Agreements with respect to fraud or any related common law concepts, except with respect to Fraud.

 

10.3                         Notices .  All notices, requests, demands, claims and other communications which are required or may be given under this Agreement shall be in writing and shall be deemed to have been duly given when received if personally delivered; when transmitted if transmitted by telecopy, electronic or digital transmission method (including electronic mail); the day after it is sent, if sent for next day delivery to a domestic address by recognized overnight delivery service (e.g., Federal Express); and five (5) Business Days after the date mailed by certified or registered mail, postage prepaid, if sent by certified or registered mail, return receipt requested.  In each case notice shall be sent to:

 

(a)                                  (i) if to the Purchaser or, following Closing, the Company:

 

Diplomat Pharmacy, Inc.

4100 South Saginaw

Flint, Michigan 48507

Attn.: Phil Hagerman and Christina Flint

 

with a copy (which shall not constitute notice) to:

 

Honigman Miller Schwartz and Cohn LLP

2290 First National Building

660 Woodward Avenue

Detroit, Michigan  48226

Attn.:    Michael D. DuBay and Philip Desai

Email: mdubay@honigman.com; pdesai@honigman.com

 

(b)                                  (ii) if to the Company (prior to the Closing):

 

93



 

Leehar Distributors, LLC

701 Emerson Road, Suite 301

Creve Coeur, Missouri 63141

Attn.:

Leonard S. Dino

Tel.:

314-652-4121

Email:

ldino@ldirx.com

 

 

with a copy (which shall not constitute notice) to:

 

Goodwin Procter LLP

100 Northern Avenue

Boston, Massachusetts 02210

Attn:

John R. LeClaire and Adam P. Small

Tel:

(617) 570-1144

Email:

JLeClaire@goodwinlaw.com; ASmall@goodwinlaw.com

 

 

 

(c)

(iii)

if to any Blocker Seller:

 

 

 

Nautic Partners

50 Kennedy Plaza, 12 th Floor

Providence, RI 02903

Attn.:

Christopher Corey

Tel.:

401-278-3624

Email:

ccorey@nautic.com

 

 

with a copy (which shall not constitute notice) to:

 

Goodwin Procter LLP

100 Northern Avenue

Boston, Massachusetts 02210

Attn:

John R. LeClaire and Adam P. Small

Tel:

(617) 570-1144

Email:

JLeClaire@goodwinlaw.com; ASmall@goodwinlaw.com

 

 

 

(d)

(iv)

if to the Securityholder Representative:

 

 

 

Nautic Partners

50 Kennedy Plaza, 12 th Floor

Providence, RI 02903

Attn.:

Christopher Corey

Tel.:

401-278-3624

Email:

ccorey@nautic.com

 

 

 

with a copy (which shall not constitute notice) to:

 

94



 

Goodwin Procter LLP

100 Northern Avenue

Boston, Massachusetts 02210

Attn:

John R. LeClaire and Adam P. Small

Tel:

(617) 570-1144

Email:

JLeClaire@goodwinlaw.com; ASmall@goodwinlaw.com

 

10.4                         Titles; References .  The titles, captions or headings of the Articles and Sections herein are inserted for convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement.  All references to dollars in this Agreement and the other Transaction Documents shall be deemed to refer to such amounts in United States Dollars and all references to days or months shall be deemed references to calendar days or months.  Unless the context otherwise requires, any reference to a “Section,” “Exhibit,” or “Schedule” shall be deemed to refer to a section of this Agreement, exhibit to this Agreement or a schedule to this Agreement, as applicable.  Any reference to any federal, state, provincial, county, local or foreign statute or Law shall be deemed also to refer to all rules and regulations promulgated thereunder, unless the context requires otherwise.  For all purposes of and under this Agreement, (i) the word “including” shall be deemed to be immediately followed by the words “without limitation”; (ii) words (including defined terms) in the singular shall be deemed to include the plural and vice versa; (iii) words of one gender shall be deemed to include the other gender as the context requires; (iv) “or” is not exclusive; and (v) the terms “hereof,” “herein,” “hereto,” “herewith” and any other words of similar import shall, unless otherwise stated, be construed to refer to this Agreement as a whole (including the exhibits hereto and the Disclosure Schedules) and not to any particular term or provision of this Agreement, unless otherwise specified.

 

10.5                         Supplement to Disclosure Schedules .  The Company will not have the right to supplement or amend the Disclosure Schedules hereto with respect to any matter hereafter arising; provided , however , that in the event of an event, development or occurrence constitutes or relates to something that has had a Material Adverse Effect, the Company will promptly notify the Purchaser in writing.  Upon receipt of such notice, the Purchaser shall have the right to terminate this Agreement for failure to satisfy the closing condition set forth in Section 7.2(e) ; provided , that if the Purchaser has the right to, but does not elect to terminate this Agreement within five (5) Business Days of its receipt of such notice, then the Purchaser shall be deemed to have irrevocably waived any right to terminate this Agreement with respect to such matter under the closing condition set forth in Section 7.2(e) .

 

10.6                         Entire Agreement; Mutual Drafting .  This Agreement, including the Schedules, Exhibits hereto, the Disclosure Schedules and the other agreements, documents and written understandings referred to herein or otherwise entered into or delivered by the Parties on the date of this Agreement (including the other Transaction Documents), together with the Non-Disclosure and Confidentiality Agreement, constitute the entire agreement among the Parties and supersede all other prior covenants, agreements, undertakings, obligations, promises, arrangements, communications, representations and warranties, whether oral or written, by any Party or by any director, officer, employee, agent, Affiliate or Representative of any Party.  The

 

95



 

Parties have participated jointly in the negotiation and drafting of this Agreement.  In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the Parties and no presumption or burden of proof shall arise favoring or disfavoring any Party by virtue of the authorship of any of the provisions of this Agreement.

 

10.7        Assignment .  Neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned by any of the Parties (whether by operation of law or otherwise) without the prior written consent of the other Parties; provided , that (i) no consent shall be required in connection with an assignment pursuant to Section 6.8(d)  or Section 10.10(g) , (ii) each Blocker Seller may assign its rights and obligations under this Agreement to any of its Affiliates without prior written consent and (b) the Purchaser may assign its rights and obligations under this Agreement (x) to any of its Affiliates, (y) for collateral security purposes or to any third party acquirer of the assets of Purchaser or the Company, in each case, without prior written consent ( provided , however , that any such assignment shall not relieve the Blocker Sellers or the Purchaser of any liability or obligation in connection with this Agreement).  Subject to the preceding sentence, this Agreement will be binding upon, inure to the benefit of and be enforceable by the Parties and their respective, heirs, successors and permitted assigns. Any attempted assignment in violation of this Section 10.7 will be void.

 

10.8        Amendment or Modification .  This Agreement may not be amended except in an instrument in writing signed, (i) prior to the Effective Time and to the extent permitted by applicable Law, on behalf of the Purchaser, Merger Sub, Company and the Securityholder Representative and (ii) after the Effective Time, to the extent permitted by applicable Law, on behalf of the Purchaser, Surviving Company and the Securityholder Representative.  No amendment, supplement, modification or waiver of this Agreement shall be binding unless executed in writing by the Party to be bound thereby.   No course of dealing between or among any Persons having any interest in this Agreement will be deemed effective to modify, amend or discharge any part of this Agreement or any rights or obligations or any Party under or by reason of this Agreement.  Notwithstanding anything to the contrary contained herein, this Section 10.8 and Sections 10.12 , 10.13 , 10.14 , 10.15 , 10.16 and 10.17 may not be modified, waived or terminated in a manner adverse in any respect to the Financing Sources without prior written consent of the relevant Financing Source.

 

10.9        Waiver .  Except where a specific period for action or inaction is provided herein, neither the failure nor any delay on the part of any Party in exercising any right, power or privilege under this Agreement or the documents referred to in this Agreement shall operate as a waiver thereof, nor shall any waiver on the part of any Party of any such right, power or privilege, nor any single or partial exercise of any such right, power or privilege, preclude any other or further exercise thereof or the exercise of any other such right, power or privilege.  The failure of a Party to exercise any right conferred herein within the time required shall cause such right to terminate with respect to the transaction or circumstances giving rise to such right, but not to any such right arising as a result of any other transactions or circumstances.

 

96



 

10.10      Securityholder Representative .

 

(a)           Nautic Capital VIII, L.P. is hereby appointed as the Securityholder Representative and as the true and lawful agent and attorney in fact of the Sellers with full power of substitution to act jointly in the name, place and stead of the Sellers in connection with the Transactions in accordance with the terms of this Agreement.  Without limiting the generality of the foregoing, the Securityholder Representative shall have full organizational power and authority (but not the obligation) to take all actions under the Transaction Documents that are to be taken by the Securityholder Representative.  The Securityholder Representative may take any and all actions that it believes are necessary or appropriate under the Transaction Documents, including executing the Transaction Documents as Securityholder Representative, giving and receiving any notice or instruction permitted or required under the Transaction Documents by the Securityholder Representative, interpreting all of the terms and provisions of the Transaction Documents, authorizing payments to be made with respect hereto or thereto, obtaining reimbursement as provided for herein for all out-of-pocket fees and expenses and other obligations of or incurred by the Securityholder Representative in connection with the Transaction Documents, defending, compromising or settling all claims or disputes under this Agreement, conducting negotiations with the Purchaser and its Representatives regarding such claims or disputes, taking any all other actions specified in or contemplated by the Transaction Documents, and engaging counsel, accountants or other representatives in connection with the foregoing matters.  The Securityholder Representative shall have the full power and authority to interpret all the terms and provisions of the Transaction Documents and to consent to any amendment, supplement or waiver hereof or thereof in its capacity as Securityholder Representative.  All acts of the Securityholder Representative hereunder in its capacity as such shall be deemed to be acts on behalf of the Sellers and not of the Securityholder Representative individually.

 

(b)           The Securityholder Representative shall have the authority (but not the obligation) to:

 

(i)            Receive all notices or documents given or to be given to Securityholder Representative pursuant hereto or to the other Transaction Documents or in connection herewith or therewith and to receive and accept services of legal process in connection with any suit or proceeding arising under this Agreement or the other Transaction Documents;

 

(ii)           Engage counsel, and such accountants and other advisors and incur such other expenses in connection with this Agreement or the other Transaction Documents and the transactions contemplated hereby or thereby as the Securityholder Representative may in its sole discretion deem appropriate; and

 

(iii)          After the date hereof, take such action as the Securityholder Representative may in its sole discretion deem appropriate in respect of:  (A) waiving any inaccuracies in the representations or warranties of the Purchaser and/or Merger Sub, or any breach of a covenant or agreement by the Purchaser and/or Merger Sub, in each case contained in this Agreement or in any document delivered by the Purchaser or Merger Sub pursuant hereto; (B) taking such other action as the Securityholder Representative is authorized to take under any Transaction Document; (C) making all other elections or decisions that the Securityholder

 

97



 

Representative is authorized to make under any Transaction Document; (D) receiving all proceeds and moneys payable to Sellers, documents or certificates and making all determinations, in its capacity as Securityholder Representative, required under any Transaction Document; and (E) all such actions as may be necessary to carry out any of the Transactions, including the defense and/or settlement of any claims or disputes under this Agreement and any waiver of any obligation of the Purchaser, Merger Sub and/or the Surviving Company.  The Securityholder Representative shall not by reason of this Agreement have a fiduciary relationship in respect of any Seller, except in respect of amounts received on behalf of a Seller.

 

(c)           Notwithstanding any provision herein to the contrary, the Securityholder Representative shall have no duties to the Sellers or have any liability to the Sellers with respect to any action taken or not taken, decision made or instruction given by the Securityholder Representative in connection with the Transaction Documents, other than resulting from the Securityholder Representative’s bad faith or willful misconduct.

 

(d)           The Securityholder Representative shall be indemnified by Sellers for and shall be held harmless against any loss, liability or expense incurred by the Securityholder Representative or any of its Affiliates and any of their respective direct or indirect equityholders, consultants, attorneys, accountants, brokers or other Representatives, in each case relating to the Securityholder Representative’s conduct as Securityholder Representative, other than losses, liabilities or expenses resulting from the Securityholder Representative’s bad faith or willful misconduct in connection with its performance under the Transaction Documents.  This indemnification shall survive the termination of this Agreement.  The costs of such indemnification (including the costs and expenses of enforcing this right of indemnification) shall be first deducted from the Holdback Account and shall thereafter be individual obligations of the Sellers in accordance with the Allocation Statement, which obligations may be satisfied as contemplated by Section 10.10(f) .  The Securityholder Representative may, in all questions arising under any Transaction Document, rely on the advice of counsel and for anything done, omitted or suffered in good faith by the Securityholder Representative in accordance with such advice, the Securityholder Representative shall not be liable to the Sellers, the Escrow Agent or any other Person.  In no event shall the Securityholder Representative be liable to the Sellers hereunder or in connection herewith for (i) any indirect, punitive, special or consequential damages or (ii) any amounts other than those that are satisfied out of the Holdback Account.

 

(e)           In the performance of its duties hereunder, the Securityholder Representative shall be entitled to (i) rely upon any document or instrument reasonably believed to be genuine, accurate as to content and signed by any Seller or any Party hereunder and (ii) assume that any Person purporting to give any notice in accordance with the provisions hereof has been duly authorized to do so.

 

(f)            The Securityholder Representative is authorized, in its sole discretion, to comply with final, nonappealable Orders issued or enacted by any Governmental Entity with respect to the Escrow Account and the Holdback Account.  If any portion of the Escrow Amount and/or the Securityholder Expense Amount is at any time attached, garnished or levied upon under any court order, or in case the payment, assignment, transfer, conveyance or delivery of any such property shall be stayed or enjoined by any court order, or in case any order, judgment

 

98



 

or decree shall be made or entered by any court affecting such property or any part thereof, then and in any such event, the Securityholder Representative is authorized, in its sole discretion, but in good faith, to rely upon and comply with any such order, writ, judgment or decree which it is advised by legal counsel selected by it is binding upon it without the need for appeal or other action; and if the Securityholder Representative complies with any such order, writ, judgment or decree, it shall not be liable to any Seller or to any other Person by reason of such compliance even though such order, writ, judgment or decree may be subsequently reversed, modified, annulled set aside or vacated.

 

(g)           The Securityholder Expense Amount shall be withheld from amounts otherwise payable to the Sellers pursuant to this Agreement at the Closing and contributed by the Purchaser on behalf of the Sellers to the Holdback Account as provided in Section 2.1(b) , for the Securityholder Representative to hold on behalf of the Sellers as a fund for any out of pocket fees and expenses (including legal, accounting and other advisors’ fees and expenses, if applicable) incurred by the Securityholder Representative in its capacity as the Securityholder Representative and as a fund, at the sole discretion of the Securityholder Representative, to pay any amounts owing to the Purchaser under this Agreement.  All amounts deposited to the Holdback Account shall be treated for all purposes of this Agreement as having been paid to the Sellers based on the Allocation Statement, and the Purchaser shall have no obligation to any Seller with respect to the Securityholder Expense Amount or the Holdback Account.  Notwithstanding anything to the contrary contained in this Section 10.10 , with respect to any out of pocket fees and expenses (including legal, accounting and other advisors’ fees and expenses, if applicable) incurred by the Securityholder Representative in its capacity as the Securityholder Representative, the Securityholder Representative shall be entitled, in its sole discretion, to have each Seller pay such Seller’s respective portion (determined in accordance with the Allocation Statement) of any out of pocket fees and expenses (including legal, accounting and other advisors’ fees and expenses, if applicable) incurred by the Securityholder Representative in its capacity as the Securityholder Representative, whether such fees and expenses are paid from any amounts remaining in the Holdback Account or otherwise.  In no event will the Securityholder Representative be required to advance its own funds or be liable on behalf of the Sellers or otherwise.  The Securityholder Representative shall distribute (or cause to be distributed) any amounts in the Holdback Account to the Sellers, in accordance with the Allocation Statement at such time or times as the Securityholder Representative shall determine in its sole discretion.

 

(h)           If the Securityholder Representative or its successors or assigns, as the case may be, advise the Sellers that he, she or it is unavailable to perform his, her or its duties hereunder, within three (3) Business Days of notice of such advice, an alternative Securityholder Representative will be appointed by a majority in interest of the Units and will become effective upon not less than ten (10) Business Days’ of prior written notice to Purchaser.  Any references in this Agreement to Securityholder Representative shall be deemed to include any duly appointed successor Securityholder Representative.

 

(i)            Purchaser, Merger Sub and Surviving Company will have the right to rely upon all actions taken or omitted to be taken by Securityholder Representative pursuant to this Agreement and/or any Transaction Document, all of which actions or omissions will be legally binding upon Sellers.  The grant of authority provided for herein (i) is coupled with an interest

 

99



 

and will be irrevocable and survive the death, incompetency, bankruptcy or liquidation of any Seller, and (ii) will survive the consummation of the Merger.

 

10.11      Severability .  If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any rule of law or public policy, such term or provision will be ineffective only to the minimum extent of such invalidity, without invalidating the remainder of such term or provision or all other terms or other provisions of this Agreement.

 

10.12      Governing Law .  This Agreement (and any claim or controversy arising out of or relating to this Agreement) shall be governed by the laws of the State of Delaware without regard to conflict of law principles that would result in the application of any Law other than the laws of the State of Delaware.  Notwithstanding anything herein to the contrary, each Party acknowledges and irrevocably agrees that any proceeding, whether in contract or tort, at law or in equity or otherwise, involving any Financing Source arising out of, or relating to, the transactions contemplated hereby shall be governed by, and construed in accordance with, the laws of the State of New York.

 

10.13      Waiver of Trial by Jury .  EACH PARTY TO THIS AGREEMENT ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE IT HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT AND ANY OF THE AGREEMENTS DELIVERED IN CONNECTION HEREWITH OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY.  EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (A) IT UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF SUCH WAIVERS, (B) IT MAKES SUCH WAIVERS VOLUNTARILY, AND (D) IT HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 10.13 .

 

10.14      Consent to Jurisdiction .  Each Party hereby irrevocably and unconditionally submits, for itself and its property, to the exclusive jurisdiction of the Chancery Court of the State of Delaware and any state appellate court therefrom within the State of Delaware (or, if the Chancery Court of the State of Delaware declines to accept jurisdiction over a particular matter, any state or federal court within the State of Delaware), in any action or proceeding arising out of or relating to this Agreement or the Transactions or for recognition or enforcement of any judgment relating thereto, and each Party hereby irrevocably and unconditionally (i) agrees not to commence any such action or proceeding except in such courts; (ii) agrees that any claim in respect of any such action or proceeding may be heard and determined in such Chancery Court of the State of Delaware or any state appellate court therefrom; (iii) waives, to the fullest extent it may legally and effectively do so, any objection which it may now or hereafter have to the laying of venue of any such action or proceeding in any such Delaware Chancery or state appellate court; and (iv) waives, to the fullest extent permitted by Law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such Delaware Chancery or state appellate court.  Each Party agrees that (i) this Agreement involves at least $100,000 and (ii) this

 

100



 

Agreement has been entered into by the Parties in express reliance upon 6 Del. C. § 2708.  Each Party agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by Law.  Each Party irrevocably consents to service of process in the manner provided for notices in Section 10.2 .  Nothing in this Agreement will affect the right of any Party to serve process in any other manner permitted by Law.  Notwithstanding anything in this Agreement to the contrary, each of the parties hereto agrees that it (i) will not bring or support any action or proceeding, cross-claim or third party claim of any kind or description, whether in law or equity, whether in contract or tort or otherwise against the Financing Sources arising out of or relating to this Agreement, including any dispute arising out of or relating in any way to the Financing, in any forum other than a court of competent jurisdiction located within the Borough of Manhattan in the City of New York, New York, whether a state or federal court and (ii) the provisions of Section 10.13 relating to the waiver of jury trial shall apply to any such action or proceeding, cross-claim or third party claim.

 

10.15      Specific Performance .

 

(a)           Each Party acknowledges and agrees that the other Party may be irreparably damaged in the event that any of the terms or provisions of this Agreement are not performed in accordance with their specific terms or otherwise are breached.  Therefore, notwithstanding anything to the contrary set forth in this Agreement and subject to Section 10.15(b) , each Party hereby agrees that the other Party shall be entitled to seek an injunction or injunctions to prevent breaches of any of the terms or provisions of this Agreement, and to enforce specifically the performance by such Party under this Agreement, including without limitation, Purchaser’s obligation to consummate the transactions contemplated hereby upon satisfaction or waiver by the applicable party of the conditions set forth in ARTICLE VII hereof (except those conditions that may only be satisfied at the Closing, provided that such conditions are capable of being satisfied if the Closing were to occur at such time) and each Party hereby agrees to waive the defense in any such suit that the other Party has an adequate remedy at law and to interpose no opposition, legal or otherwise, as to the propriety of injunction or specific performance as a remedy, and hereby agrees to waive any requirement to post any bond in connection with obtaining such relief.  The equitable remedies described in this Section 10.15 shall be in addition to, and not in lieu of, any other remedies at law or in equity that the Parties may elect to pursue.

 

(b)           Notwithstanding anything to the contrary in this Agreement, it is explicitly agreed that the Company shall be entitled to seek specific performance of the Purchaser’s obligation to consummate the transactions contemplated hereby and fund the Transaction Consideration only in the event that (i) the conditions set forth in Section 7.1 and 7.2 have been satisfied or with respect to Section 7.2 , waived as of the date of the Closing should the Closing be consummated pursuant to the terms of this Agreement (other than those conditions that by their terms are to be satisfied at the Closing, but subject to the satisfaction or waiver of those conditions assuming a Closing would occur), (ii) the Company has irrevocably confirmed to the Purchaser in writing that (A) all of the conditions set forth in Section 7.1 , Section 7.2 and Section 7.3 have been satisfied or waived (other than those conditions that by their terms are to be satisfied at the Closing, but subject to the satisfaction or waiver of those conditions assuming a

 

101



 

Closing would occur), and (B) the Company is prepared to consummate the Closing, and, regardless of whether  the Debt Financing is funded, the Company stands ready, willing and able to consummate the Closing, (iii) the Debt Financing is, or at the Closing, will be funded in accordance with the terms of the Financing Letters and (iv) Purchaser fails to consummate the Closing within three Business Days following the receipt of such certification from the Company.  For the avoidance of doubt, under no circumstances will the Company, the Blocker Sellers, or any of their respective Affiliates be entitled to monetary damages in excess of the Reverse Termination Fee, specific performance or any other equitable remedies in the event that the Reverse Termination Fee becomes payable in accordance with the terms of this Agreement.  Notwithstanding anything contained herein, and for the avoidance of doubt, in no event shall the Company and/or its Affiliates be entitled to, or be permitted to seek, specific performance in respect of any Financing Sources in connection with the Debt Financing. Subject to the limitations set forth in this Section 10.15 , if the Sellers are entitled to seek specific performance of the Purchaser’s obligations as set forth in this Section 10.15 , the Sellers and the Target Companies may seek specific performance of Purchaser’s obligations in Section 6.12(a)  in connection with the Debt Financing.

 

10.16      Non-Recourse .  Notwithstanding anything to the contrary provided in this Agreement, (i) in no event may the Sellers, the Target Companies or any other Person seek or permit to be sought on behalf of the Sellers, the Company or any of their Affiliates or any other Person, any damages or any other recovery or judgment of any kind, in law or in equity, from any Purchaser Related Party in connection with this Agreement or the transactions contemplated hereby; provided, that in no event shall either of Purchaser or Merger Sub be considered a Purchaser Related Party for purposes of this Agreement, notwithstanding anything to the contrary contained herein, and (ii) the Target Companies and each Seller acknowledge and agree that they have no right of recovery against, and no personal Liability shall attach to any such Purchaser Related Party, whether by or through attempted piercing of the corporate, limited partnership or limited liability company veil, by or through a claim by or on behalf of the Sellers or the Target Companies against Purchaser or any Purchaser Related Party, by the enforcement of any assessment or by any legal or equitable proceeding, by virtue of any statute, regulation or applicable Law in connection with this Agreement.  For the avoidance of doubt, notwithstanding anything to the contrary herein, in no event shall the Financing Sources have any liability or obligation to Seller, Target Companies or their respective Affiliates in connection with this Agreement or the transactions contemplated hereby (including any Financing),  whether at law or equity, in contract, in tort or otherwise.

 

10.17      No Third Party Beneficiaries .  No provision of this Agreement is intended to or shall be deemed to confer any rights or remedies upon any Person other than the Parties, except for Sections 10.8 , 10.12 , 10.13 , 10.14 , 10.15 , 10.16 and this 10.17 (in each case, solely to the extent relating to the Financing Sources) and Section 6.8 as set forth therein.

 

10.18      Cumulative Remedies .  Except as expressly provided otherwise in this Agreement, all rights and remedies of either Party are cumulative of each other and of every other right or remedy such Party may otherwise have at law or in equity, and the exercise of one or more rights or remedies shall not prejudice or impair the concurrent or subsequent exercise of other rights or remedies.

 

102



 

10.19      Expenses .  Except as otherwise expressly provided herein (including Section 6.2 , Section 8.1 and Section 6.8 hereof), all costs and expenses, including fees and disbursements of counsel, financial advisors and accountants, incurred in connection with this Agreement and the Transactions shall be paid by the party incurring such costs and expenses, whether or not the Closing shall have occurred; provided , however , that the Purchaser shall pay (or reimburse the Company) and be fully responsible for (i) all filing and other similar fees payable in connection with any filings or submissions under the HSR Act and any comparable non-U.S. Laws, (ii) fifty percent (50%) of any fees and expenses charged by the Escrow Agent, and (iii) all fees and expenses charged by the Paying Agent.

 

10.20      Waiver of Conflicts; Privilege .

 

(a)           Each of the Parties hereto acknowledges and agrees that Goodwin Procter LLP (“ Goodwin ”) has acted as counsel to the Company, the Subsidiary, the Blockers, the Blocker Sellers, the Securityholders and the Securityholder Representative (in its capacity as both the Securityholder Representative and as a Securityholder) in connection with the negotiation of this Agreement and consummation of the Transaction, and that Goodwin has not acted as counsel for any other Person in connection with the Transactions and that no other Party or Person has the status of a client of Goodwin for conflict of interest or any other purposes as a result thereof.

 

(b)           The Purchaser hereby consents and agrees to, and agrees to cause the Company and the Subsidiary to consent and agree to, Goodwin representing the Blocker Sellers, the Securityholder Representative and Securityholders after the Closing, including with respect to disputes in which the interests of the Blocker Sellers, the Securityholder Representative and/or the Securityholders may be directly adverse to the Purchaser and its Affiliates (including the Company and the Subsidiary), and even though Goodwin may have represented any of the Target Companies in a matter substantially related to any such dispute, or may be handling ongoing matters for the Target Companies.

 

(c)           In connection with the foregoing, the Purchaser hereby irrevocably waives and agrees not to assert, and agrees to cause the Company and the Subsidiary to irrevocably waive and not to assert, any conflict of interest arising from or in connection with (a) Goodwin’s prior representation of the Target Companies and (b) Goodwin’s representation of the Blocker Sellers, the Securityholder Representative and the Securityholders prior to and after the Closing.

 

(d)           The Purchaser further agrees, on behalf of itself and, after the Closing, on behalf of the Company and the Subsidiary, that all communications occurring on or prior to the Closing in any form or format whatsoever between or among any of Goodwin, Blocker Sellers, the Securityholder Representative, the Securityholders, the Company, the Subsidiary, or any of their respective directors, officers, employees or other Representatives that relate in any way to the negotiation, documentation and consummation of the transactions contemplated by this Agreement or any dispute arising under this Agreement (collectively, the “ Deal Communications ”) shall be deemed to be retained and owned by the Blocker Sellers, the Securityholders and controlled by the Securityholder Representative, and shall not pass to or be claimed by the Purchaser, the Company or the Subsidiary.  All Deal Communications that are

 

103



 

attorney-client privileged (the “ Privileged Deal Communications ”) shall remain privileged after the Closing and the privilege and the expectation of client confidence relating thereto shall belong solely to the Blocker Sellers and the Securityholders and be controlled by the Securityholder Representative and shall not pass to or be claimed by Purchaser, the Company or the Subsidiary .

 

(e)           Notwithstanding the foregoing, in the event that a dispute arises between the Purchaser, the Company or a Subsidiary, on the one hand, and a third party other than the Blocker Sellers, the Securityholder Representative and/or the Securityholders, on the other hand, the Purchaser, the Company or such Subsidiary may assert the attorney-client privilege to prevent the disclosure of the Privileged Deal Communications to such third party; provided , however , that none of the Purchaser, the Company or any subsidiary may waive such privilege without the prior written consent of the Securityholder Representative.  In the event that the Purchaser, the Company or any subsidiary is legally required by Order or otherwise to access or obtain a copy of all or a portion of the Deal Communications, the Purchaser shall immediately (and, in any event, within two (2) Business Days) notify the Securityholder Representative in writing (including by making specific reference to this Section) so that the Securityholder Representative can seek a protective order at its expense and the Purchaser agrees to use all commercially reasonable efforts to assist therewith.

 

(f)            To the extent that files or other materials maintained by Goodwin constitute property of its clients, only the Blocker Sellers, the Securityholders and the Securityholder Representative shall hold such property rights and Goodwin shall have no duty to reveal or disclose any such files or other materials or any Deal Communications by reason of any attorney-client relationship between Goodwin, on the one hand, and a Target Company, on the other hand.

 

(g)           Except with respect to post-Closing dispute with a Person that is not a Seller or a Securityholder Representative or their respective Affiliates and except as provided in Section 10.20(e) , the Purchaser agrees that it will not, and that it will cause the Company and the Subsidiary not to, (i) access or use the Deal Communications, including by way of review of any electronic data, communications or other information, or by seeking to have the Securityholder Representative waive the attorney-client or other privilege, or by otherwise asserting that the Purchaser, the Target Companies have the right to waive the attorney-client or other privilege or (ii) seek to obtain the Deal Communications from Goodwin.  In furtherance of the foregoing, it shall not be a breach of any provision of this Agreement if prior to the Closing, the Blocker Sellers, the Securityholders, the Securityholder Representative, the Blockers, the Company, the Subsidiary or any of their respective Affiliates or Representatives takes any action to protect from access or remove from the premises of the Company or the Subsidiary (or any offsite back-up or other facilities) any Deal Communications, including without limitation by segregating, encrypting, copying, deleting, erasing, exporting or otherwise taking possession of any Deal Communications.  In the event that any copy, backup, image, or other form or version or electronic vestige of any portion of such Deal Communication remains accessible to or discoverable or retrievable by the Purchaser, the Company or the Subsidiary (each, a “ Residual Communication ”), the Purchaser agrees that it will not, and that it will cause the Blockers, the Company, the Subsidiary and their respective directors, officers, employees or other

 

104



 

Representatives not to use or attempt to use any means to access, retrieve, restore, recreate, unarchive or otherwise gain access to or view any Residual Communication in a manner that would be adverse to a Seller or a Securityholder Representative or their respective Affiliates.

 

(h)           This Section 10.18 shall not be terminated or modified without Goodwin’s prior written consent, it being expressly agreed that Goodwin is a third party beneficiary of this Section 10.18 .

 

10.21      Time of the Essence .  Time is of the essence in this Agreement.  If the date specified for giving any notice or taking any action is not a Business Day (or if the period during which any notice is required to be given or any action taken expires on a date which is not a Business Day), then the date for giving such notice or taking such action (and the expiration date of such period during which notice is required to be given or action taken) shall be the next date which is a Business Day.

 

10.22      Counterparts .  This Agreement may be executed in one or more counterparts (including by facsimile, . pdf or other means of electronic file delivery), each of which when executed shall be deemed an original and all of which together shall constitute one and the same instrument.

 

[Signature Page Follows]

 

105



 

IN WITNESS WHEREOF , the Parties have caused this Agreement to be executed and delivered as of the date first written above.

 

 

THE PURCHASER:

 

 

 

 

DIPLOMAT PHARMACY, INC.

 

 

 

 

 

By:

/s/ Philip R. Hagerman

 

Name:

Philip R. Hagerman

 

Title:

Chief Executive Officer

 

 

 

 

 

 

 

MERGER SUB:

 

 

 

 

LEEWARD MERGER SUB LLC

 

 

 

 

 

 

By:

/s/ Philip R. Hagerman

 

Name:

Philip R. Hagerman

 

Title:

Chief Executive Officer

 

 

 

 

 

 

 

THE COMPANY:

 

 

 

 

LDI HOLDING COMPANY, LLC

 

 

 

 

 

 

 

By:

/s/ Leonard S. Dino, Jr.

 

Name:

Leonard S. Dino, Jr.

 

Title:

Chief Executive Officer

 

106



 

IN WITNESS WHEREOF , the Parties have caused this Agreement to be executed and delivered as of the date first written above.

 

 

 

BLOCKER SELLERS:

 

 

 

 

NAUTIC PARTNERS VII, L.P.

 

 

 

 

By: Nautic Partners VII, L.P., its general partner

 

 

 

 

By: Nautic Associates VII, LLC, its general partner

 

 

 

 

 

 

By:

/s/ Christopher Corey

 

Name:

Christopher Corey

 

Title:

Managing Director

 

 

 

 

 

 

 

NAUTIC PARTNERS VII-A, L.P.

 

 

 

 

By: Nautic Partners VII, L.P., its general partner

 

 

 

 

By: Nautic Associates VII, LLC, its general partner

 

 

 

 

 

 

By:

/s/ Christopher Corey

 

Name:

Christopher Corey

 

Title:

Managing Director

 

 

 

 

 

 

 

NAUTIC PARTNERS VIII-A, L.P.

 

 

 

 

By: Nautic Partners VIII, L.P., its general partner

 

 

 

 

By: Nautic Associates VIII, LLC, its general partner

 

 

 

 

 

 

 

By:

/s/ Christopher Corey

 

Name:

Christopher Corey

 

Title:

Managing Director

 

 

 

 

 

 

 

OAK HC/FT PARTNERS, L.P.

 

 

 

 

By: Oak HC/FT Associates, LLC, its general partner

 

 

 

 

 

 

 

By:

/s/ Andrew W. Adams

 

Name:

Andrew W. Adams

 

Title:

Managing Member

 

107



 

IN WITNESS WHEREOF , the Parties have caused this Agreement to be executed and delivered as of the date first written above.

 

 

Solely for purposes of its obligations under Section 6.4:

 

 

 

NAUTIC PARTNERS VIII, L.P.

 

 

 

By: Nautic Capital VIII, L.P., its general partner

 

By: Nautic Management, LLC, its general partner

 

 

 

 

By:

/s/ Christopher Corey

 

Name:

Christopher Corey

 

Title:

Managing Director

 

108



 

IN WITNESS WHEREOF , the Parties have caused this Agreement to be executed and delivered as of the date first written above.

 

 

THE SECURITYHOLDER REPRESENTATIVE:

 

 

 

Solely in its capacity as the Securityholder Representative

 

 

 

 

NAUTIC CAPITAL VIII, L.P.

 

By: Nautic Management, LLC, its general partner

 

 

 

 

By:

/s/ Christopher Corey

 

Name:

Christopher Corey

 

Title:

Managing Director

 

109


Exhibit 10.1

 

Execution Version

 

JPMORGAN CHASE BANK, N.A.
383 Madison Avenue
New York, New York 10179

 

CAPITAL ONE, NATIONAL
ASSOCIATION
299 Park Avenue
New York, NY 10171

 

CONFIDENTIAL
November 15, 2017

 

Diplomat Pharmacy, Inc.

4100 S. Saginaw St.

Flint, Michigan 48507

 

Attention:  Mr. Atul Kavthekar, Chief Financial Officer

 

Project Duke
$795,000,000 Senior Secured Credit Facilities

Commitment Letter

 

Ladies and Gentlemen:

 

You have advised each of JPMorgan Chase Bank, N.A. (“ JPMorgan ”) and Capital One, National Association (“ Capital One and, together with JPMorgan, the “ Commitment Parties ”, “ we ” or “ us ”) that you intend to consummate the Transactions (such term and each other capitalized term used but not defined herein having the meanings assigned to them in the Term Sheet (as defined below)).

 

In connection with the Transactions, JPMorgan and Capital One each are pleased to advise you of their commitment, on a several and not joint basis, to provide 65% and 35%, respectively, of the principal amount of the Facilities, upon the terms and subject to the conditions set forth in this commitment letter (this “ Commitment Letter ”) and in the Summary of Principal Terms and Conditions attached hereto as Exhibit A (the “ Senior Facilities Term Sheet ” and, together with the Summary of Additional Conditions Precedent attached hereto as Exhibit B (the “ Conditions Exhibit ”), the “ Term Sheet ”).

 

You hereby appoint each of JPMorgan and Capital One to act, and JPMorgan and Capital One hereby agree to act, as joint lead arrangers and joint bookrunners for the Facilities, upon the terms and subject to the conditions set forth in this Commitment Letter and in the Term Sheet.  You also hereby appoint (i) JPMorgan to act, and JPMorgan hereby agrees to act, as sole and exclusive administrative agent and collateral agent for the Facilities, in each case upon the terms and subject to the conditions set forth in this Commitment Letter and in the Term Sheet. JPMorgan, in such capacity, will perform the duties and exercise the authority customarily performed and exercised by it in such roles; provided that you agree that JPMorgan may perform its responsibilities hereunder as a joint lead arranger and joint bookrunner through its affiliate, J.P. Morgan Securities LLC and (ii) Capital One to act, and Capital One hereby agrees to act, as sole and exclusive syndication agent for the Facilities, upon the terms and subject to the conditions set forth in this Commitment Letter and in the

 



 

Term Sheet. JPMorgan and Capital One, each in such capacity, will perform the duties and exercise the authority customarily performed and exercised by it in such roles. It is understood and agreed that (a) no additional agents, co-agents, arrangers, co-arrangers, managers, co-managers, bookrunners or co-bookrunners will be appointed and no other titles will be awarded in connection with the Facilities and (b) no compensation (other than as expressly contemplated by the Term Sheet or the Fee Letters referred to below) will be paid in connection with the Facilities, in each case unless you and we so agree in writing.  It is further agreed that JPMorgan will have “left” placement on and will appear on the top left of any Information Materials (as defined below) and all other offering or marketing materials in respect of the Facilities (with Capital One immediately to the “right” of JPMorgan), and JPMorgan will perform the roles and responsibilities conventionally understood to be associated with such “left” placement.

 

The Commitment Parties reserve the right, prior to or after the execution of definitive documentation for the Facilities (the “ Facilities Documentation ”), to, after consultation with you, syndicate all or a portion of its commitments hereunder to one or more financial institutions reasonably satisfactory to you that will become parties to such definitive documentation pursuant to syndications to be managed by the Commitment Parties (the financial institutions becoming parties to such definitive documentation being collectively referred to herein as the “ Lenders ”); provided , however , that notwithstanding the Commitment Parties’ right to syndicate the Facilities and receive commitments with respect thereto, other than with respect to the commitments of any additional agent, co-agent or joint bookrunner appointed in accordance with the immediately preceding paragraph, unless otherwise agreed in writing by you, (a) the Commitment Parties shall not be relieved, released or novated from their obligations hereunder (including their respective obligations to fund the Facilities on the Closing Date) in connection with any syndication, assignment or participation of the Facilities, including their commitment in respect thereof, until after the initial funding under the Facilities on the Closing Date has occurred, (b) no assignment or novation shall become effective with respect to all or any portion of the Commitment Parties’ commitments in respect of the Facilities until after the initial funding under the Facilities on the Closing Date has occurred and (c) the Commitment Parties shall retain exclusive control over all rights and obligations with respect to its commitments in respect of the Facilities, including all rights with respect to consents, modifications, supplements, waivers and amendments, until after the initial funding under the Facilities on the Closing Date has occurred.  You understand that each of the Facilities may be separately syndicated.  The Commitment Parties may decide to commence syndication efforts promptly, and you agree, until the earlier of (x) the date upon which a Successful Syndication (as defined in the Arranger Fee Letter) of the Facilities is achieved and (y) the date that is 60 days after the Closing Date (such earlier date, the “ Syndication Date ”), to assist (and, to the extent provided in the Purchase Agreement, to use your commercially reasonable efforts to cause the Target to actively assist) the Commitment Parties in completing satisfactory syndications.  Such assistance shall include (a) your using commercially reasonable efforts to ensure that the syndication efforts benefit from your existing banking relationships, (b) direct contact during the syndications between your senior management, representatives and advisors and the proposed Lenders (and, to the extent provided in the Purchase Agreement, using your commercially reasonable efforts to ensure such contact between senior management of the Target and the proposed Lenders), (c) your assistance (and, to the extent provided in the Purchase Agreement, using commercially

 

2



 

reasonable efforts to cause the Target to assist) in the preparation of a Confidential Information Memorandum for the Facilities and other marketing materials to be used in connection with the syndications (collectively, the “ Information Materials ”), (d) the hosting, with the Commitment Parties, of one or more meetings with prospective Lenders at times and locations to be mutually agreed upon, (and, to the extent provided in the Purchase Agreement, using your commercially reasonable efforts to cause the officers of the Target to be available for such meetings) and (e) prior to the Syndication Date, there being no competing issues, offerings, placements or arrangements of debt securities or commercial bank or other credit facilities of you or your subsidiaries being issued, offered, placed or arranged (other than the Facilities) without the consent of JPMorgan if such issuance, offering, placement or arrangement would reasonably be expected to materially impair the primary syndications of the Facilities.  Notwithstanding anything to the contrary contained in this Commitment Letter or the Fee Letters or any other letter agreement or undertaking concerning the financing of the Transactions to the contrary, none of the compliance with the foregoing provisions of this paragraph or any syndications of the Facilities shall constitute a condition to the commitments hereunder or the funding of the Facilities on the Closing Date.

 

It is understood and agreed that the Commitment Parties will, after consultation with and in a manner reasonably acceptable to you, manage all aspects of the syndications, including but not limited to selection of Lenders, the determination of when the Commitment Parties will approach potential Lenders and the time of acceptance of the Lenders’ commitments and the final allocations of the commitments among the Lenders; provided that the selection of Lenders and the final allocations of the commitments among the Lenders shall be subject to your consent (not to be unreasonably withheld).  In acting as the joint lead arrangers and joint bookrunners, the Commitment Parties will have no responsibility other than to arrange the syndications as set forth herein and shall in no event be subject to any fiduciary or other implied duties.  To assist the Commitment Parties in their syndication efforts, you agree to promptly prepare and provide to the Commitment Parties (and, to the extent provided in the Purchase Agreement, use commercially reasonable efforts to cause the Target to prepare and provide) all information with respect to you, the Target and your and its respective subsidiaries, the Transactions and the other transactions contemplated hereby, including financial information and projections (the “ Projections ”) as the Commitment Parties may reasonably request in connection with the structuring, arrangement and syndications of the Facilities. At the request of the Commitment Parties, you agree to assist the Commitment Parties in preparing an additional version of the Information Materials (the “ Public Side Version ”) to be used by prospective Lenders’ public-side employees and representatives (“ Public-Siders ”) who do not wish to receive material non-public information (within the meaning of the United States Federal or State securities laws) with respect to you, the Target, your and its respective affiliates and any of your or its respective securities (such material non-public information, “ MNPI ”) and who may be engaged in investment and other market-related activities with respect to your, the Target’s or your and its respective affiliates’ securities or loans.  Before distribution of any Information Materials, (a) you agree to execute and deliver to the Commitment Parties (i) a customary letter in which you authorize distribution of the Information Materials to a prospective Lender’s employees willing to receive MNPI (“ Private-Siders ”) and (ii) a separate customary letter in which you authorize distribution of the Public Side Version to Public-Siders and represent that no MNPI is contained therein and (b) you agree to identify that portion of the Information Materials that

 

3



 

may be distributed to Public-Siders as not containing MNPI, which, at a minimum, shall mean that the word “PUBLIC” shall appear prominently on the first page thereof (and you agree that, by marking Information Materials as “PUBLIC”, you shall be deemed to have authorized the Commitment Parties and the prospective Lenders to treat such Information Materials as not containing MNPI (it being understood that you shall not be under any obligation to mark the Information Materials as “PUBLIC”)).  You acknowledge that the Commitment Parties will make available the Information Materials on a confidential basis to the proposed syndicate of Lenders by posting such information on Intralinks, Debt X or SyndTrak Online or by similar electronic means.  You agree that the following documents may be distributed to both Private-Siders and Public-Siders, unless you advise the Commitment Parties within a reasonable time after receipt of such materials for review that such materials should only be distributed to Private-Siders: (1) administrative materials prepared by the Commitment Parties for prospective Lenders (such as a lender meeting invitation, bank allocation, if any, and funding and closing memoranda), (2) the Term Sheet and notification of changes in the Facilities’ terms and conditions and (3) drafts and final versions of the Facilities Documentation.  If you so advise the Commitment Parties that any of the foregoing should be distributed only to Private-Siders, then Public-Siders will not receive such materials without further discussions with you. You acknowledge that the Commitment Parties’ public-side employees and representatives who are publishing debt analysts may participate in any meetings held pursuant to clause (d) of the second preceding paragraph; provided that such analysts shall not publish any information obtained from such meetings (i) until the syndication of the Facilities has been completed upon the making of allocations by JPMorgan and JPMorgan freeing the Facilities to trade or (ii) in violation of any confidentiality agreement between you and any other party hereto.

 

You hereby represent and warrant that (but the accuracy of such representation and warranty shall not be a condition to the commitment hereunder or the funding of the Facilities on the Closing Date) (with respect to any information or data relating to the Target, the following representations and warranties shall be made solely to your knowledge) (a) all written information and written data (other than the Projections and other forward-looking information and other than information of a general economic or industry specific nature) (such information and data, the “ Information ”) that has been or will be made available to the Commitment Parties or their representatives by or on behalf of you or your representatives, when taken as a whole, is or will be, when furnished, correct in all material respects and does not or will not, when furnished, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements contained therein not materially misleading in light of the circumstances under which such statements are made (giving effect to all supplements and updates provided thereto from time to time) and (b) the Projections that have been or will be made available to the Commitment Parties or their representatives by or on behalf of you or your representatives have been and will be prepared in good faith based upon assumptions that are believed by you to be reasonable at the time made (it being understood that (i) the Projections are as to future events and are not to be viewed as facts, (ii) the Projections are subject to significant uncertainties and contingencies, many of which are beyond your control, (iii) no assurance can be given that any particular Projections will be realized and (iv) actual results during the period or periods covered by any such Projections may differ significantly from the projected results and such differences may be material).  You agree that if at any time from and including the date hereof until the later of the Closing

 

4



 

Date and the Syndication Date you become aware that the representation and warranty in the immediately preceding sentence would not be satisfied if the Information and Projections were being furnished, and such representations were being made, at such time, then you will (or with respect to Information and Projections relating to the Target, use commercially reasonable efforts to) promptly supplement the Information and the Projections so that such representation and warranty would be correct (prior to the Closing Date, to your knowledge with respect to Information and Projections relating to the Target) under those circumstances.  In arranging the Facilities, including the syndications of the Facilities, the Commitment Parties (A) will be entitled to use and rely primarily on the Information and the Projections without responsibility for independent verification thereof and (B) do not assume responsibility for the accuracy or completeness of the Information or the Projections.

 

As consideration for the Commitment Parties’ commitments hereunder and agreement to structure, arrange and syndicate the Facilities, you agree to pay the fees as set forth in the Term Sheet, the Arranger Fee Letter dated the date hereof and delivered herewith with respect to the Facilities (the “ Arranger Fee Letter ”) and the Administrative Agent Fee Letter dated the date hereof and delivered herewith with respect to the Facilities (the “ Agent Fee Letter ” and, together with the Arranger Fee Letter, the “ Fee Letters ”).  Once paid, except as expressly provided in the Fee Letters, such fees shall not be refundable under any circumstances.

 

The Commitment Parties’ commitments hereunder to fund the Facilities on the Closing Date and the agreement of the Commitment Parties to perform the services described herein are subject solely to the express conditions set forth under the headings “Conditions Precedent to Initial Borrowing” and “Conditions Precedent to All Borrowings” in the Senior Facilities Term Sheet and the conditions set forth in the Conditions Exhibit, and upon satisfaction (or waiver by the Commitment Parties) of such conditions, the initial funding of the Facilities shall occur.

 

Notwithstanding anything in this Commitment Letter, the Term Sheet, the Fee Letters, the Facilities Documentation or any other letter agreement or other undertaking concerning the financing of the Transactions to the contrary, (a) the only representations and warranties the accuracy of which shall be a condition to the availability of the Facilities on the Closing Date shall be (i) such of the representations and warranties made by the Seller, the Target or their affiliates with respect to the Target in the Purchase Agreement as are material to the interests of the Lenders, but only to the extent that you have (or an affiliate of yours has) the right to terminate your (or its) obligations under the Purchase Agreement or decline to consummate the Acquisition as a result of a breach of such representations and warranties in the Purchase Agreement (the “ Specified Purchase Agreement Representations ”) and (ii) the Specified Representations (as defined below) made by you in the Facilities Documentation and (b) the terms of the Facilities Documentation shall be in a form such that they do not impair the availability or funding of the Facilities on the Closing Date if the conditions described in the immediately preceding paragraph are satisfied or waived by the Commitment Parties (it being understood that, to the extent any security interest in any Collateral is not or cannot be provided and/or perfected on the Closing Date (other than the creation of and perfection (including by delivery of stock or other equity certificates, if any) of security interests (i) in the equity interests in any of your material domestic subsidiaries (to the extent constituting Collateral under the Senior Facilities Term Sheet) and (ii) in other assets located

 

5



 

in the United States with respect to which a lien may be perfected by the filing of a financing statement under the Uniform Commercial Code) after your use of commercially reasonable efforts to do so or without undue burden or expense, then the provision and/or perfection of a security interest in such Collateral shall not constitute a condition precedent to the availability of the Facilities on the Closing Date, but instead shall be required to be provided or delivered after the Closing Date pursuant to arrangements and timing to be mutually agreed by the Administrative Agent and the Borrower acting reasonably).  For purposes hereof, “ Specified Representations ” means the representations and warranties of you relating to the Borrower and the Guarantors set forth in the Facilities Documentation relating to organization and powers (as to execution, delivery and performance of the Facilities Documentation); authorization, due execution and delivery and enforceability; no conflicts between the Facilities Documentation and organizational documents immediately after giving effect to the Transactions; sanctions and anti-corruption; solvency on a consolidated basis as of the Closing Date (after giving effect to the Transactions) of you and your subsidiaries on a consolidated basis; the Investment Company Act of 1940; Federal Reserve margin regulations; and subject to the parenthetical statement in the immediately preceding sentence, creation, perfection and priority (subject to permitted liens) of security interests in the Collateral.  This paragraph, and the provisions herein, shall be referred to as the “ Limited Conditionality Provisions ”.

 

By executing this Commitment Letter, you agree (a) to indemnify and hold harmless each Commitment Party, their respective affiliates and each of their respective Related Parties (as defined below) (each, an “ indemnified person ”) from and against any and all losses, claims, damages, liabilities and expenses, joint or several, to which any such indemnified person may become subject arising out of or in connection with this Commitment Letter, the Term Sheet, the Fee Letters, the Transactions, the Facilities or any related transaction or any claim, litigation, investigation or proceeding relating to any of the foregoing (any of the foregoing, a “ Proceeding ”), regardless of whether any such indemnified person is a party thereto or whether a Proceeding is initiated by or on behalf of a third party or you or any of your affiliates, and to reimburse each such indemnified person upon demand for any reasonable and documented out-of-pocket legal expenses of one firm of counsel for all such indemnified persons, taken as a whole, and, if necessary, of a single firm of local counsel in each appropriate jurisdiction (which may include a single firm of special counsel acting in multiple jurisdictions) for all such indemnified persons, taken as a whole (and, in the case of an actual or perceived conflict of interest where the indemnified person affected by such conflict informs you of such conflict and thereafter retains its own counsel, of another firm of counsel for such affected indemnified person and, if necessary, of a single firm of local counsel in each appropriate jurisdiction (which may include a single firm of special counsel acting in multiple jurisdictions) for such affected indemnified person) and other reasonable and documented out-of-pocket fees and expenses, in each case incurred in connection with investigating or defending any of the foregoing; provided that the foregoing indemnity will not, as to any indemnified person, apply to losses, claims, damages, liabilities or related expenses to the extent they (i) are found in a final and non-appealable judgment of a court of competent jurisdiction to have resulted from the bad faith, willful misconduct or gross negligence of such indemnified person, (ii) result from a claim brought by you or any of your subsidiaries against such indemnified person for material breach of such indemnified person’s obligations hereunder, the Fee Letters or the Facilities Documentation if you or such

 

6



 

subsidiary has obtained a final and non-appealable judgment in your or its favor on such claim as determined by a court of competent jurisdiction or (iii) result from a proceeding that does not involve an act or omission by you or any of your affiliates and that is brought by an indemnified person against any other indemnified person (other than claims against any arranger, bookrunner or agent in its capacity or in fulfilling its roles as an arranger, bookrunner or agent hereunder or any similar role with respect to the Facilities), and (b) to reimburse each Commitment Party upon presentation of a summary statement for all reasonable and documented out-of-pocket expenses (including but not limited to the expenses of each Commitment Party’s due diligence investigation, consultants’ fees and expenses, syndication expenses, travel expenses and reasonable fees, disbursements and other charges of counsel (such charges and disbursements limited to one firm of counsel to JPMorgan and one firm of counsel to Capital One (with such fees of Capital One’s counsel not required to be reimbursed to the extent in excess of $20,000), and, if necessary, one firm of local counsel in each appropriate jurisdiction)) incurred in connection with the Facilities and the preparation of this Commitment Letter, the Term Sheet, the Fee Letters, the Facilities Documentation and any security arrangements in connection therewith; provided that you shall not be required to reimburse any of the foregoing expenses in clause (b) in excess of $250,000 (plus, if applicable, such fees of Capital One’s counsel to the extent not in excess of $20,000) in the event the Closing Date does not occur.  Notwithstanding any other provision of this Commitment Letter, (1) no indemnified person shall be liable for any damages directly or indirectly arising from the use by others of information or other materials obtained through electronic, telecommunications or other information transmission systems (except to the extent that any such damages have resulted from the willful misconduct or gross negligence of such indemnified person (as determined by a court of competent jurisdiction in a final non-appealable judgment)) and (2) none of the indemnified persons, you or the Target or your or its respective subsidiaries or affiliates shall be liable for any special, indirect, consequential or punitive damages in connection with the Facilities or the Transactions; provided that nothing contained in this paragraph shall limit your indemnity and reimbursement obligations to the extent set forth in this paragraph. You shall not be liable for any settlement, compromise or consent to the entry of any judgment in any Proceeding effected without your prior written consent (which consent shall not be unreasonably withheld or delayed), but if settled with your written consent or if there is a final judgment in any such Proceeding, you agree to indemnify and hold harmless each indemnified person from and against any and all losses, claims, damages, liabilities and expenses by reason of such settlement or judgment in accordance with, and to the extent required by, this paragraph.  Notwithstanding the foregoing, each indemnified person shall be obligated to refund and return promptly any and all amounts paid by you or any of your affiliates under this paragraph to such indemnified persons for any loss, claim, expense, damage or liability with respect to which such indemnified person was not entitled to payment in accordance with the terms hereof (as determined by a court of competent jurisdiction in a final non-appealable judgment). You shall not, without the prior written consent of an indemnified person (which consent shall not be unreasonably withheld or delayed), effect any settlement or consent to the entry of any judgment of any pending or threatened Proceeding in respect of which indemnity could have been sought hereunder by such indemnified person unless such settlement (i) includes an unconditional release of such indemnified person, in form and substance reasonably satisfactory to such indemnified person, from all liability on claims that are the subject matter

 

7



 

of such Proceeding, (ii) does not include any statement as to or any admission of fault, culpability or a failure to act by or on behalf of such indemnified person and (iii) contains customary confidentiality and non-disparagement provisions. For purposes hereof, “ Related Parties ” means, with respect to any person, the directors, officers, employees, agents, advisors, representatives and controlling persons of such person.

 

You acknowledge that the Commitment Parties and their respective affiliates may be providing debt financing, equity capital or other services (including but not limited to financial advisory services) to other companies in respect of which you may have conflicting interests regarding the transactions described herein and otherwise. Neither the Commitment Parties or any of their respective affiliates will use confidential information obtained from you by virtue of the transactions contemplated by this Commitment Letter or its other relationships with you in connection with the performance by the Commitment Parties or any of their respective affiliates of services for other companies, and none of the Commitment Parties or any of their respective affiliates will furnish any such information to other companies.  You also acknowledge that neither the Commitment Parties or any of their respective affiliates has any obligation to use in connection with the transactions contemplated by this Commitment Letter, or to furnish to you, the Target or your or their respective subsidiaries or representatives, confidential information obtained by the Commitment Parties or any of their respective affiliates from any other company or person.

 

You further acknowledge and agree that (a) no fiduciary, advisory or agency relationship between you, on the one hand, and the Commitment Parties, on the other hand, is intended to be or has been created in respect of any of the transactions contemplated by this Commitment Letter and the Term Sheet, irrespective of whether the Commitment Parties have advised or are advising you on other matters, (b) each Commitment Party, on the one hand, and you, on the other hand, have an arms-length business relationship that does not directly or indirectly give rise to, nor do you rely on, any fiduciary duty on the part of the Commitment Parties, (c) you are capable of evaluating and understanding, and you understand and accept, the terms, risks and conditions of the transactions contemplated by this Commitment Letter and the Term Sheet, (d) you have been advised that each Commitment Party is engaged in a broad range of transactions that may involve interests that differ from your interests and that the Commitment Parties do not have an obligation to disclose such interests and transactions to you by virtue of any fiduciary, advisory or agency relationship, (e) the Commitment Parties are not advising you as to any legal, regulatory, tax, accounting or investment matters in any jurisdiction (including, without limitation, with respect to any consents needed in connection with the transactions contemplated hereby) and that you shall consult your own advisors with respect to such matters to the extent you deem appropriate in connection with the transactions contemplated hereby and (f) you agree not to assert, to the fullest extent permitted by law, any claims against the Commitment Parties for alleged breach of fiduciary duty in connection with the Transactions.

 

You further acknowledge that each Commitment Party is a full service securities firm engaged in securities trading and brokerage activities as well as providing investment banking and other financial services.  In the ordinary course of business, each Commitment Party may provide investment banking and other financial services to, and/or acquire, hold or sell, for its own accounts and the accounts of customers, equity, debt and

 

8



 

other securities and financial instruments (including bank loans) and other obligations of, you, the Target and other companies with which you or the Target may have commercial or other relationships.  With respect to any securities and/or financial instruments so held by the Commitment Parties or any of their respective customers, all rights in respect of such securities and financial instruments, including any voting rights, will be exercised by the holder of the rights, in its sole discretion.

 

This Commitment Letter and the commitments hereunder shall not be assignable by any party hereto, and such party’s obligations hereunder may not be delegated, without the prior written consent of the Commitment Parties (in the case of any such assignment or delegation by the Borrower) or the Borrower (in the case of any such assignment or delegation by the Commitment Parties), and any attempted assignment without such consent shall be null and void.  This Commitment Letter may not be amended or any provision hereof waived or modified except by an instrument in writing signed by each Commitment Party and you.  This Commitment Letter may be executed in any number of counterparts, each of which shall be deemed an original and all of which, when taken together, shall constitute one agreement.  Delivery of an executed counterpart of a signature page of this Commitment Letter by facsimile transmission or other electronic transmission (in “pdf” or “tif” format) shall be effective as delivery of a manually executed counterpart of this Commitment Letter.  This Commitment Letter, the Term Sheet and the Fee Letters are the only agreements that have been entered into among us with respect to the Facilities and set forth the entire understanding of the parties with respect thereto.  This Commitment Letter, the Term Sheet and the Fee Letters supersede all prior understandings, whether written or oral, between us with respect to the Facilities.  This Commitment Letter is intended to be solely for the benefit of the parties hereto and the indemnified persons and is not intended to confer any benefits upon, or create any rights in favor of, any person other than the parties hereto and the indemnified persons.  THIS COMMITMENT LETTER AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS COMMITMENT LETTER AND THE TRANSACTIONS CONTEMPLATED HEREBY SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK; PROVIDED THAT, (A) THE INTERPRETATION OF THE DEFINITION OF A COMPANY MATERIAL ADVERSE EFFECT (AS DEFINED IN EXHIBIT B) AND THE DETERMINATION AS TO WHETHER THERE SHALL HAVE OCCURRED A COMPANY MATERIAL ADVERSE EFFECT, (B) WHETHER THE ACQUISITION HAS BEEN CONSUMMATED AS CONTEMPLATED BY THE PURCHASE AGREEMENT AND (C) WHETHER THE REPRESENTATIONS AND WARRANTIES MADE BY THE SELLER OR THE TARGET IN THE PURCHASE AGREEMENT ARE ACCURATE AND WHETHER AS A RESULT OF ANY INACCURACY THEREOF YOU (OR YOUR APPLICABLE AFFILIATES) HAVE THE RIGHT TO TERMINATE YOUR OBLIGATIONS UNDER THE PURCHASE AGREEMENT, OR TO DECLINE TO CONSUMMATE THE ACQUISITION (IN EACH CASE, IN ACCORDANCE WITH THE TERMS THEREOF), SHALL, IN EACH CASE, BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF DELAWARE.  The Commitment Parties may perform the duties and activities described hereunder through any of their respective affiliates and the provisions of the fourth

 

9



 

preceding paragraph shall apply with equal force and effect to any of such affiliates so performing any such duties or activities.

 

Subject to the last sentence of this paragraph, each of the parties hereto irrevocably and unconditionally agrees that it will not commence any action, litigation or proceeding of any kind or description, whether in law or equity, whether in contract or in tort or otherwise, against any other party hereto or any of their respective affiliates or any of their respective officers, directors, employees, agents and controlling persons in any way relating to the Transactions, this Commitment Letter, the Term Sheet or the Fee Letters or the performance of services hereunder or thereunder, in any forum other than any Federal court for the Southern District of New York sitting in the Borough of Manhattan in the City of New York (or in the event such court lacks subject matter jurisdiction, in any State court for the State of New York sitting in the Borough of Manhattan in the City of New York) or any appellate court from any thereof, and each of the parties hereto irrevocably and unconditionally submits to the jurisdiction of such courts and agrees that all claims in respect of any such action, litigation or proceeding may be heard and determined in such court.  Each of the parties hereto hereby agrees that service of any process, summons, notice or document by registered mail addressed to such party shall be effective service of process for any suit, action or proceeding brought in any such court.  Each party hereto hereby irrevocably and unconditionally waives any objection to the laying of venue of any such action, litigation or proceeding brought in any such court and any claim that any such action, litigation or proceeding has been brought in any inconvenient forum.  Each party hereto hereby agrees that a final judgment in any such action, litigation or proceeding brought in any such court shall be conclusive and binding upon such party and may be enforced in any other courts to whose jurisdiction such party is or may be subject, by suit upon judgment.  Nothing in this Commitment Letter, the Term Sheet or the Fee Letters shall affect any right that the Commitment Parties may have to bring any action, litigation or proceeding relating to the Transactions, this Commitment Letter, the Term Sheet or the Fee Letters or the performance of services hereunder or thereunder against you or your property in the courts of any other jurisdiction.

 

EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS COMMITMENT LETTER, THE TERM SHEET, THE FEE LETTERS OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY OR THE PERFORMANCE OF SERVICES HEREUNDER OR THEREUNDER (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY).  EACH PARTY HERETO HERBY (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PERSON HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PERSON WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS COMMITMENT LETTER AND THE FEE LETTERS BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS PARAGRAPH.

 

10



 

Each of the parties hereto agrees that this Commitment Letter is a binding and enforceable agreement with respect to the subject matter contained herein, including an agreement to negotiate in good faith the Facilities Documentation by the parties hereto in a manner consistent with this Commitment Letter and the Term Sheet, it being acknowledged and agreed that the commitment provided hereunder is subject to conditions precedent as provided herein.

 

You agree that you will not disclose, directly or indirectly, this Commitment Letter, the Term Sheet, the Fee Letters, the contents of any of the foregoing or the activities of the Commitment Parties pursuant hereto or thereto to any person without the prior approval of the Commitment Parties, except that you may disclose (a) this Commitment Letter, the Term Sheet, the Fee Letters and the contents hereof and thereof (i) to the Seller, the Target and your and the Seller’s and the Target’s directors, officers, employees, attorneys, accountants and advisors directly involved in the consideration of this matter on a confidential and need-to-know basis ( provided that any disclosure of the Fee Letters or their terms or substance to the Seller, the Target or their directors, officers, employees, attorneys, accountants and advisors shall be redacted in a manner reasonably satisfactory to the Commitment Parties), (ii) pursuant to the order of any court or administrative agency or in any legal, judicial or administrative proceeding or other compulsory process or otherwise as required by applicable law or regulations (in which case you shall promptly notify us, in advance, to the extent lawfully permitted to do so), (iii) in connection with the exercise of remedies to the extent relating to this Commitment Letter, the Term Sheet or the Fee Letters and (iv) to the extent this Commitment Letter, the Term Sheet, the Fee Letters or the contents hereof and thereof become publicly available other than by reason of disclosure by you, the Seller, the Target or your, the Seller’s or the Target’s directors, officers, employees, attorneys, accountants and advisors in breach of this Commitment Letter, (b) this Commitment Letter, the Term Sheet and the contents hereof and thereof (but not the Fee Letters or the contents thereof) (i) to S&P and Moody’s in connection with the Transactions and on a confidential and need-to-know basis and (ii) in any syndication or other marketing materials in connection with the Facilities (including the Information Materials) or, to the extent required by law, in connection with any public filing and (c) the aggregate fee amount contained in the Fee Letters as part of Projections, pro forma information or a generic disclosure of aggregate sources and uses related to fee amounts in connection with the Transactions in marketing materials for the Facilities or, to the extent required by applicable law, in any public filing.

 

Each Commitment Party shall use all non-public information received by them in connection with the Facilities and the Transactions solely for the purposes of providing the services that are the subject of this Commitment Letter, the Term Sheet and the Fee Letters and shall treat confidentially all such information; provided , however , that nothing herein shall prevent the Commitment Parties from disclosing any such information (a) to ratings agencies on a confidential basis and in consultation with you, (b) to any Lenders or participants or prospective Lenders or prospective participants, (c) pursuant to the order of any court or administrative agency or in any legal, judicial or administrative proceeding or other compulsory process or otherwise as required by applicable law or regulations (in which case the Commitment Parties shall promptly notify you, in advance, to the extent lawfully permitted to do so), (d) upon the request or demand of any regulatory authority having jurisdiction over the Commitment Parties or any of their respective affiliates (in which case

 

11



 

the Commitment Parties shall, except with respect to any audit or examination conducted by bank accountants or any governmental bank regulatory authority exercising examination or regulatory authority, promptly notify you, in advance, to the extent lawfully permitted to do so), (e) to its affiliates and the respective Related Parties of the Commitment Parties and its affiliates who are informed of the confidential nature of such information and are or have been advised of their obligation to keep all such information confidential or are otherwise under a professional or employment duty of confidentiality, (f) to any direct or indirect contractual counterparties to any swap or derivatives transaction relating to the Borrower or the transactions under the Facilities, (g) to the extent any such information becomes publicly available other than by reason of disclosure by the Commitment Parties, their affiliates or any of their respective Related Parties in breach of this Commitment Letter, (h) to the extent such information is received by the Commitment Parties from a third party that is not, to the Commitment Parties’ knowledge, subject to a confidentiality obligation to you with respect to such information and (i) in connection with the exercise of remedies to the extent relating to this Commitment Letter, the Term Sheet or the Fee Letters; provided that the disclosure of any such information to any Lenders, prospective Lenders, participants, prospective participants or derivatives counterparties referred to in clauses (b) or (f) above shall be made subject to the acknowledgment and acceptance by such recipient that such information is being disseminated on a confidential basis in accordance with the standard syndication processes of the Commitment Parties or customary market standards for dissemination of such type of information. The obligations of the Commitment Parties under this paragraph shall automatically terminate and be superseded by the confidentiality provisions of the Facilities Documentation upon the initial funding thereunder; provided that if not previously terminated, the provisions of this paragraph shall automatically terminate two years following the date of this Commitment Letter.

 

The Commitment Parties hereby notify you that pursuant to the requirements of the USA PATRIOT Act (Title III of Pub. L. 107 56 (signed into law October 26, 2001), as subsequently amended and reauthorized) (the “ Patriot Act ”), that they and each of the Lenders may be required to obtain, verify and record information that identifies you, which information may include your name and address, the name and address of each of the Guarantors and other information that will allow the Commitment Parties and each of the Lenders to identify you and each of the Guarantors in accordance with the Patriot Act.  This notice is given in accordance with the requirements of the Patriot Act and is effective for the Commitment Parties and each of the Lenders.

 

Please indicate your acceptance of the terms hereof and of the Fee Letters by signing in the appropriate space below and in the Fee Letters and returning to JPMorgan (or its counsel) executed original copies (or facsimiles or other electronic copies in “pdf” or “tif” format thereof) of this Commitment Letter and the Fee Letters not later than 11:59 p.m., New York City time, on November 15, 2017.  The commitments and agreements of the Commitment Parties hereunder will expire at such time in the event that JPMorgan has not received such executed original copies (or facsimiles or other electronic copies in “pdf” or “tif” format thereof) in accordance with the immediately preceding sentence.  In the event that (i) the initial borrowing under the Facilities does not occur on or before December 31, 2017; provided that if the termination date is extended under the Purchase Agreement pursuant to the second proviso to Section 9.1(a) thereof (as in effect on the date hereof), such December 

 

12



 

31, 2017 date shall automatically be extended to such extended date under the Purchase Agreement; provided further that in no event shall such extended date be later than January 14, 2018, (ii) the Purchase Agreement is terminated without consummation of the Acquisition and the funding of the Facilities or (iii) the consummation of the Acquisition occurs with or without the use of the Facilities, then this Commitment Letter and the commitments hereunder shall automatically terminate unless the Commitment Parties shall, in their sole discretion, agree to an extension.  The syndication (including information), compensation, reimbursement, indemnification, jurisdiction, governing law, waiver of jury trial, no fiduciary relationship and, except as expressly set forth above, confidentiality provisions contained herein and in the Fee Letters shall remain in full force and effect regardless of whether Facilities Documentation shall be executed and delivered and notwithstanding the termination of this Commitment Letter or the commitments hereunder.  You may terminate this Commitment Letter and/or the commitments hereunder with respect to the Facilities (or a portion thereof, ratably among any parties hereto) at any time subject to the provisions of the immediately preceding sentence.

 

[The remainder of this page intentionally left blank]

 

13



 

We are pleased to have been given the opportunity to assist you in connection with this important financing.

 

 

Very truly yours,

 

 

 

 

 

JPMORGAN CHASE BANK, N.A.

 

 

 

By:

/s/ Diane D. Forrest

 

 

Name: Diane D. Forrest

 

 

Title: Authorized Officer

 

[Signature Page to Commitment Letter]

 



 

 

CAPITAL ONE, NATIONAL ASSOCIATION

 

 

 

By:

/s/ Karen M. Dahlquist

 

 

Name: Karen M. Dahlquist

 

 

Title: Duly Authorized Signatory

 

 

CAPITAL ONE, NATIONAL ASSOCIATION

 

 

 

By:

/s/ Joe Lee

 

 

Name: Joe Lee

 

 

Title: Duly Authorized Signatory

 

[Signature Page to Commitment Letter]

 



 

Accepted and agreed to as of the date first above written:

 

 

 

 

 

DIPLOMAT PHARMACY, INC.

 

 

 

By:

/s/ Philip R. Hagerman

 

 

Name: Philip R. Hagerman

 

 

Title: Chief Executive Officer

 

 

[Signature Page to Commitment Letter]

 



 

Execution Version

 

EXHIBIT A

 

CONFIDENTIAL

 

Project Duke
$795,000,000 Senior Secured Credit Facilities
Summary of Principal Terms and Conditions(1)

 

Borrower:

 

The borrower under the Facilities (as defined below) will be Diplomat Pharmacy, Inc., a Michigan corporation (the “ Borrower ”).

 

 

 

Transactions:

 

The Borrower intends to acquire all of the outstanding equity interests of the entity previously identified to JPMorgan as “Duke” (the “ Target ”) pursuant to, and subject to the conditions set forth in, the Securities Purchase Agreement and Plan of Merger (together with the schedules, annexes, exhibits and other attachments thereto, the “ Purchase Agreement ”) dated as of November 15, 2017 and among the Borrower, the Target, the Sellers (as defined in the Purchase Agreement) (the “ Seller ”) and the other parties thereto (the “ Acquisition ”).

 

 

 

 

 

Upon consummation of the Acquisition, the Seller shall receive cash consideration (the “ Cash Consideration ”) and consideration in the form of common equity interests of the Borrower (the “ Equity Issuance to Seller ”), in each case in an aggregate amount and in the manner provided for in the Purchase Agreement.

 

 

 

 

 

In connection with the Acquisition, (a) the Borrower will obtain the senior secured credit facilities (the “ Facilities ”) described below under the heading “Facilities” on the date on which the Acquisition is consummated (the “ Closing Date ”), (b) the Borrower’s Second Amended and Restated Credit Agreement dated as of April 1, 2015 among the Borrower, General Electric Capital Corporation as agent and the other parties thereto (including any amendments, increases replacements, refinancings or modifications thereof), certain other existing indebtedness of the Borrower and its subsidiaries and all material

 


(1)  Capitalized terms used herein but not otherwise defined have the meanings assigned thereto in the Commitment Letter to which this Exhibit A is attached (the “ Commitment Letter ”), including the other exhibits thereto.

 



 

 

 

indebtedness of the Target and its subsidiaries (the “ Existing Indebtedness ”) will be repaid, repurchased, redeemed or otherwise retired and all existing commitments, guarantees, obligations and security interests in respect of the Existing Indebtedness will be terminated in full (collectively, the “ Existing Indebtedness Refinancing ”) and (c) fees and expenses incurred in connection with the Transactions (the “ Transaction Costs ”) will be paid. The transactions described in clauses (a) through (c) of this paragraph, together with the Acquisition, are collectively referred to herein as the “ Transactions ”.

 

 

 

Administrative Agent:

 

JPMorgan Chase Bank, N.A. (“ JPMorgan ”) will act as sole and exclusive administrative agent and collateral agent for the Facilities (in such capacities, the “ Administrative Agent ”) for a syndicate of financial institutions (the “ Lenders ”) and will perform the duties customarily performed by persons acting in such capacities.

 

 

 

Syndication Agent :

 

Capital One, National Association (“ Capital One ”) will act as sole and exclusive syndication agent for the Facilities.

 

 

 

Joint Lead Arrangers and Joint Bookrunners:

 

Each of JPMorgan and Capital One will act as a joint lead arranger and joint bookrunner for the Facilities (each in such capacities, the “ Arrangers ”) and will manage the syndication of the Facilities.

 

 

 

Facilities:

 

(a)   A senior secured term loan facility denominated in U.S. Dollars in an aggregate principal amount equal to $545,000,000 (the “ Term Loan Facility ”).

 

 

 

 

 

(b)   A senior secured revolving credit facility available in U.S. Dollars with aggregate commitments in an amount equal to $250,000,000 (the “ Revolving Credit Facility ”). Up to an amount equal to $10,000,000 of the Revolving Credit Facility will be available for the issuance of letters of credit.

 

 

 

 

 

In connection with the Revolving Credit Facility, JPMorgan, in its capacity as the maker of swingline loans (in such capacity, the “ Swingline Lender ”), may, in its sole discretion, make available to the Borrower a swingline facility in an amount equal to $20,000,000

 

2



 

 

 

under which the Borrower may make same-day short-term borrowings. Any such swingline loans will reduce availability under the Revolving Credit Facility on a dollar-for-dollar basis, except for purposes of calculating the commitment fee described in Annex I. Each Lender under the Revolving Credit Facility will, promptly upon request by the Administrative Agent, fund to the Administrative Agent its pro rata share of any swingline borrowings.

 

 

 

Incremental Facility:

 

The Facilities Documentation will permit the Borrower (pursuant to procedures to be mutually agreed upon and set forth in the credit agreement with respect to the Facilities (the “ Credit Agreement ”)) to add one or more incremental term loan facilities to the Facilities (each, an “ Incremental Term Loan Facility ”) and/or increase the commitments under the Revolving Credit Facility (each such increase, a “ Revolving Credit Facility Increase ” and, together with the Incremental Term Loan Facilities, the “ Incremental Facilities ”) in an aggregate principal amount not to exceed for all such increases and incremental facilities the sum of (x) $125,000,000 plus (y) the amount of any voluntary prepayments of the Term Loan Facility or any Incremental Term Loan Facility, plus (z) an amount of Incremental Facilities such that, after giving effect to the incurrence of any Incremental Facilities pursuant to clauses (x) and (y) (and after giving effect to any acquisition consummated concurrently therewith and any other acquisition, disposition, debt incurrence, debt retirement and other appropriate pro forma adjustment events, including any debt incurrence or retirement subsequent to the end of the applicable test period and on or prior to the date of such incurrence, all to be further defined in the Credit Agreement), on a pro forma basis (but excluding the cash proceeds of such incurrence and assuming, in the case of any Revolving Credit Facility Increase, that the commitments in respect thereof are fully drawn) the First Lien Net Leverage Ratio (to be defined in a manner to be agreed and in any event to permit netting of Unrestricted Cash (as defined below)) would not exceed 3.75 to 1.00; provided that (a) no default or event of default exists or would exist after giving effect to such Incremental Facility (or if agreed by the lenders providing such Incremental Facility in connection with any acquisition or investment permitted under the Credit Agreement, no payment or bankruptcy event of default),

 

3



 

 

 

(b)   all fees and expenses owing in respect of such Incremental Facility to the Administrative Agent have been paid and (c) no Lender shall be required to participate in any such Incremental Facility; provided further that the loans under any Incremental Term Loan Facility (i) will rank pari passu in right of payment and security with the other Facilities, (ii) will mature no earlier than the final maturity of the Term Loan Facility and (iii) will have a weighted average life to maturity no shorter than the remaining weighted average life to maturity of the Term Loan Facility. If the “yield” (which, for this purpose, shall be deemed to include all upfront or similar fees or original issue discount payable to the lenders in respect of such Incremental Term Loan Facility and any pricing “floor” applicable to such Incremental Term Loan Facility but excluding customary arrangement and commitment fees paid to arrangers thereof) applicable to any Incremental Term Loan Facility incurred prior to the 12 month anniversary of the Closing Date exceeds the “yield” applicable to the Term Loan Facility by more than 0.50%, then the interest rate spread applicable to the Term Loan Facility shall be increased so that the “yield” on the Term Loan Facility is equal to the “yield” applicable to such Incremental Term Loan Facility less 0.50%. Any Incremental Term Loan Facility will have terms and conditions substantially identical to the Term Loan Facility (other than with respect to pricing, amortization and maturity) and will be otherwise on terms and subject to conditions reasonably satisfactory to the Administrative Agent.

 

 

 

 

 

The Borrower will be permitted to utilize the above available incremental credit capacity in the form of (in addition to Incremental Term Loan Facilities and Revolving Credit Facility Increases) senior unsecured notes or loans or senior secured notes or loans that are secured by the Collateral, in the case of notes, on a pari passu or junior basis or, in the case of loans, a junior basis (“ Alternative Incremental Indebtedness ”); provided that, subject to clause (f) below, in addition to the requirements with respect to the amount, incurrence and maturity of any such incremental credit extensions set forth above, (a) in the case of any such Alternative Incremental Indebtedness in the form of notes, such Alternative Incremental Indebtedness is not required to be repaid, prepaid, redeemed, repurchased or defeased, whether on one or

 

4



 

 

 

more fixed dates, upon the occurrence of one or more events or at the option of any holder thereof (except, in each case, upon the occurrence of an event of default, a change in control, an event of loss or an asset disposition) prior to the date that is 91 days after the latest maturity date of the Term Loan Facility and revolving credit commitments existing under the Credit Agreement at the time of such incurrence, (b) if such Alternative Incremental Indebtedness is secured, (i) such indebtedness shall not be secured by any assets or property other than the Collateral and (ii) all security therefor shall be granted pursuant to documentation substantially similar to the applicable collateral documents, and the secured parties thereunder, or a trustee or collateral agent on their behalf, shall have become a party to a first lien intercreditor agreement or a junior lien intercreditor agreement, in each case in form and substance reasonably satisfactory to the Administrative Agent, (c) such Alternative Incremental Indebtedness is not guaranteed by any subsidiaries of the Borrower other than the Guarantors, (d) any Alternative Incremental Indebtedness does not have a shorter weighted average life than the remaining weighted average life of the Term Loan Facility, (e) the other terms and conditions of such Alternative Incremental Indebtedness (excluding pricing) are no more favorable to the investors providing such Alternative Incremental Indebtedness than those applicable to the Term Loan Facility (except for covenants or other provisions applicable only to periods after the latest final maturity date of the Term Loan Facility existing under the Credit Agreement at the time of incurrence of such Alternative Incremental Indebtedness) and (f) in lieu of the First Lien Net Leverage Ratio test applicable to Incremental Facilities pursuant to clause (z) under the heading “Incremental Facility” such test with respect to Alternative Incremental Indebtedness shall instead be: (1) in the case of such indebtedness secured on a pari passu basis with the Facilities, a First Lien Net Leverage Ratio not to exceed 3.75 to 1.00, (2) in the case of such indebtedness secured on a junior basis to the Facilities, a Secured Net Leverage Ratio (to be defined in a manner to be agreed and in any event to permit netting of Unrestricted Cash) not to exceed 4.25 to 1.00 or (3) in the case of such unsecured indebtedness, a Total Net Leverage Ratio (as defined below) not to exceed 5.00 to

 

5



 

 

 

1.00.

 

 

 

Refinancing Term Loans and Revolving Credit Commitments:

 

With the consent of the Borrower, the Administrative Agent and the lenders providing the refinancing term loans or refinancing revolving credit commitments, one or more tranches of term loans or any revolving credit commitments can be refinanced from time to time, in whole or part, with one or more new tranches of term loans, senior secured notes (which may rank pari passu or junior in right of security to the Term Loan Facility) or senior unsecured notes (“ Refinancing Debt ”) or new revolving credit commitments (“ Refinancing Commitments ”), respectively, under the Credit Agreement; provided that (i) any Refinancing Debt does not mature prior to the maturity date of, or have a shorter weighted average life than, the term loans being refinanced, (ii) any Refinancing Commitments do not mature prior to the maturity date of the revolving credit commitments being refinanced and (iii) the other terms and conditions of such Refinancing Debt or Refinancing Commitments (excluding pricing and optional prepayment terms) are no more favorable to the lenders or investors, as the case may be, providing such Refinancing Debt or Refinancing Commitments, as applicable, than those applicable to the term loans or revolving credit commitments being refinanced (except for covenants or other provisions applicable only to periods after the latest final maturity date of the Term Loan Facility and revolving credit commitments existing under the Credit Agreement at the time of such refinancing).

 

 

 

Purpose:

 

(a)   The proceeds of the loans under the Term Loan Facility will be used by the Borrower on the Closing Date solely (i)  first , to pay the Transaction Costs, (ii)  second , to consummate the Existing Indebtedness Refinancing, (iii)  third , to pay the Cash Consideration and (iv)  fourth , for working capital and other general corporate purposes.

 

 

 

 

 

(b)   The proceeds of loans under the Revolving Credit Facility will be used by the Borrower for working capital and other general corporate purposes.

 

 

 

 

 

(c)   Letters of credit will be used to support obligations of the Borrower and its subsidiaries incurred in the

 

6



 

 

 

ordinary course of business.

 

 

 

 

 

(d)   The proceeds of loans under any Incremental Term Loan Facility will be used by the Borrower for the purposes specified in the definitive documentation relating thereto.

 

 

 

Availability:

 

(a)   The Term Loan Facility must be drawn in a single drawing on the Closing Date. Amounts borrowed under the Term Loan Facility that are repaid or prepaid may not be reborrowed.

 

 

 

 

 

(b)   Loans under the Revolving Credit Facility will be available on and after the Closing Date at any time prior to the final maturity of the Revolving Credit Facility, in minimum principal amounts to be mutually agreed upon; provided that extensions of credit under the Revolving Credit Facility made on the Closing Date shall be subject to a requirement that the unutilized Revolving Credit Facility commitments plus the amount of Unrestricted Cash shall be at least $100,000,000 on a pro forma basis after giving effect to the Transactions (provided any amounts under the Revolving Credit Facility utilized to fund “flex” original issue discount and upfront fees in respect of the Facilities pursuant to the terms of the Arranger Fee Letter shall not be deemed a utilization of the Revolving Credit Facility solely for purposes of this test). Amounts repaid under the Revolving Credit Facility may be reborrowed.

 

 

 

Interest Rates and Fees:

 

As set forth on Annex I hereto.

 

 

 

Default Rate:

 

The applicable interest rate plus 2.0% per annum.

 

 

 

Letters of Credit:

 

Letters of credit under the Revolving Credit Facility will be made available by JPMorgan and Capital One (or their applicable banking affiliate) in respect of the Facilities and any other Lender under the Revolving Credit Facility that is acceptable to the Borrower and the Administrative Agent (each, an “ Issuing Bank ”). Each letter of credit shall expire not later than the earlier of (a) 12 months after its date of issuance and (b) the fifth business day prior to the final maturity of the Revolving Credit Facility; provided that any letter of credit having a 12-month tenor may provide for the renewal of such letter of credit for

 

7



 

 

 

additional 12-month periods (which shall, in no event, extend beyond the date referred to in clause (b) of this paragraph). The Letter of credit sublimit shall be shared ratably among JPMorgan and Capital One based on the amount of their commitments in respect of the Revolving Credit Facility, and such institution may in its discretion, but shall not be required to, issue letters of credit in an aggregate amount in excess of its individual sub-limit.

 

 

 

 

 

Each drawing under any letter of credit shall be reimbursed by the Borrower not later than one business day after such drawing. To the extent that the Borrower does not reimburse the applicable Issuing Bank on such business day, the Lenders under the Revolving Credit Facility shall be irrevocably obligated to reimburse such Issuing Bank pro rata based upon their respective Revolving Credit Facility commitments.

 

 

 

 

 

The issuance of all letters of credit shall be subject to the customary procedures of the applicable Issuing Bank. Letters of credit shall be denominated in U.S. Dollars.

 

 

 

Maturity and Amortization:

 

(a)   The Term Loan Facility will mature on the date that is seven years after the Closing Date and will amortize in equal quarterly installments in an amount equal to 1.00% per annum beginning with the first full fiscal quarter after the Closing Date, with the balance due at maturity.

 

 

 

 

 

(b)   The Revolving Credit Facility will mature on the date that is five years after the Closing Date.

 

 

 

Guarantees:

 

All obligations of the Borrower under the Facilities and all obligations of the Borrower and the other Guarantors (as defined below) under any interest rate protection or other hedging arrangements entered into with the Administrative Agent or a Lender (or an affiliate of the Administrative Agent or a Lender) and all obligations of the Borrower and the other Guarantors in respect of overdrafts and related liabilities owed to a Lender (or an affiliate of a Lender) arising from treasury, depository or other cash management services, will be unconditionally guaranteed (the “ Guarantees ”) by the Borrower and each existing or subsequently acquired or organized material domestic subsidiary of the Borrower (including the Target and its material domestic subsidiaries) (the “ Guarantors ”),

 

8



 

 

 

subject to restrictions imposed by applicable law or otherwise agreed in the Facilities Documentation.

 

 

 

Security:

 

All obligations of the Borrower under the Facilities, all obligations of the Borrower and the other Guarantors under any interest rate protection and other hedging arrangements entered into with the Administrative Agent or a Lender (or an affiliate of the Administrative Agent or a Lender) and all obligations of the Borrower and the other Guarantors in respect of overdrafts and related liabilities owed to the Administrative Agent or a Lender (or an affiliate of the Administrative Agent or a Lender) arising from treasury, depository or cash management services, including credit card and merchant card programs, and all Guarantees will be secured by substantially all the assets of the Borrower and each other Guarantor (collectively, the “ Collateral ”), including but not limited to (a) a perfected first-priority pledge of all the capital stock held by the Borrower or any other Guarantor of each existing or subsequently acquired or organized subsidiary of the Borrower (which pledge, in the case of stock of any foreign subsidiary of the Borrower, shall not include more than 65% of the voting stock of such foreign subsidiary) and (b) perfected first-priority security interests in, and mortgages on, substantially all tangible and intangible assets of the Borrower and each other Guarantor (including but not limited to accounts, inventory, equipment, commercial tort claims, investment property, intellectual property, intercompany indebtedness (which shall be evidenced by a note), general intangibles, licensing agreements, real property, letter of credit rights and proceeds of the foregoing), subject to exceptions and thresholds to be mutually agreed upon and, at closing, to the Limited Conditionality Provisions (as defined in the Commitment Letter).

 

 

 

 

 

Notwithstanding anything to the contrary, the Collateral shall exclude the following: (a) any fee-owned real property with a fair market value of less than $5,000,000 and all leasehold interests; (b) motor vehicles and other assets subject to certificates of title (other than to the extent a security interest in such assets can be perfected by filing a Uniform Commercial Code financing statement); (c) equity interests in any non-wholly owned subsidiaries of the Borrower or any Guarantor to the extent not permitted by such person’s organizational or

 

9



 

 

 

joint-venture documents ( provided the Borrower shall have taken commercially reasonable efforts to obtain a waiver of such restriction); (d) commercial tort claims with a value of less than an amount to be mutually agreed upon; (e) any lease, license or other agreement or any property subject to a purchase money security interest or similar arrangement to the extent that a grant of a security interest therein would violate or invalidate such lease, license or agreement or purchase money security interest or similar arrangement or create a right of termination in favor of any other party thereto (other than the Borrower or any subsidiary thereof) after giving effect to the applicable anti-assignment provisions of the Uniform Commercial Code, other than proceeds and receivables thereof, the assignment of which is expressly deemed effective under the Uniform Commercial Code notwithstanding such prohibition; (f) those assets as to which the Administrative Agent and the Borrower reasonably agree that the cost of obtaining such a security interest or perfection thereof are excessive in relation to the benefit to the Lenders of the security to be afforded thereby; (g) “intent-to-use” trademark applications; and (h) other exceptions to be mutually agreed upon. In addition, in no event shall (a) control agreements or control or similar arrangements be required with respect to cash deposit or securities accounts, (b) notice be required to be sent to account debtors or other contractual third parties prior to the occurrence and absent the continuance of an event of default, (c) perfection be required with respect to letter of credit rights and commercial tort claims (except to the extent perfected through the filing of Uniform Commercial Code financing statements) and (d) security documents governed by the laws of a jurisdiction other than the United States or any State thereof or the District of Columbia be required.

 

 

 

 

 

All the above-described pledges, security interests and mortgages shall be created on terms, and pursuant to documentation, reasonably satisfactory to the Administrative Agent (including, in the case of real property, by customary items such as satisfactory title insurance and surveys) and, subject to exceptions permitted under the Facilities Documentation, none of the Collateral shall be subject to any other pledges, security interests or mortgages.

 

10



 

Mandatory Prepayments:

 

Loans under the Term Loan Facility shall be prepaid with:

 

 

 

 

 

(a)   100% of the net cash proceeds of all non-ordinary course asset sales or other dispositions of property by the Borrower and its restricted subsidiaries, subject to thresholds and reinvestment rights to be mutually agreed upon (with a reinvestment period equal to 12 months) and other exceptions to be mutually agreed upon;

 

 

 

 

 

(b)   Starting with the first full fiscal year of the Borrower ended after the Closing Date (or if the Closing Date occurs in 2018, starting with the fiscal year of the Borrower ended in 2018 based on the Excess Cash Flow from the Closing Date to the last day of such fiscal year), 50%, with step-downs to 25% and 0% at Secured Net Leverage Ratios of 3.75 to 1.00 and 3.25 to 1.00, respectively, of annual Excess Cash Flow in excess of $1.0 million (to be defined in a manner to be agreed) of the Borrower and its restricted subsidiaries; provided that any voluntary prepayments of Loans under the Term Loan Facility, any Incremental Term Loan Facility, any Incremental Alternative Facility secured on a pari passu basis with the Term Loan Facility or of loans under the Revolving Credit Facility (including any Revolving Credit Facility Increase) accompanied by an equivalent permanent termination of such applicable revolving commitment, made during such fiscal year (or, without duplication for any deductions in future periods, thereafter but prior to the date such Excess Cash Flow prepayment is due) other than prepayments funded with the proceeds of long term indebtedness, shall be credited against excess cash flow prepayment obligations for such fiscal year on a dollar-for-dollar basis; and

 

 

 

 

 

(c)  100% of the net cash proceeds of issuances of indebtedness of the Borrower and its restricted subsidiaries (other than indebtedness permitted under the Credit Agreement).

 

 

 

 

 

Notwithstanding the foregoing, each Lender under the Term Loan Facility shall have the right to reject its pro rata share of any mandatory prepayments described in clause (a) above, in which case the amounts so rejected may be retained by the Borrower.

 

11



 

 

 

The above-described mandatory prepayments shall be applied to the remaining amortization payments under the Term Loan Facility as follows: (a) in direct order of maturity to the amortization repayments occurring in the eight quarters following the date of such prepayment and (b)  pro rata to the remaining amortization payments.

 

 

 

 

 

Loans under the Revolving Credit Facility will be required to be prepaid if the aggregate revolving credit exposure under the Revolving Credit Facility exceeds the aggregate commitments thereunder. Any unused portion of the commitment in respect of the Term Loan Facility shall terminate in full immediately after the funding thereof on the Closing Date.

 

 

 

Voluntary Prepayments/Reductions in Commitments:

 

Voluntary prepayments of borrowings under the Facilities and voluntary reductions of the unutilized portion of the Revolving Credit Facility commitments will be permitted at any time, in minimum principal amounts to be mutually agreed upon, without premium or penalty (except as described below), subject to reimbursement of the Lenders’ redeployment costs in the case of a prepayment of Adjusted LIBOR borrowings other than on the last day of the relevant Interest Period (to be defined).

 

 

 

 

 

Any (a) voluntary prepayment of the loans under the Term Loan Facility that is made on or prior to the date that is six months after the Closing Date with the proceeds from a Repricing Transaction (as defined below) and (b) amendment or other modification of the Credit Agreement on or prior to the date that is six months after the Closing Date, the effect of which is a Repricing Transaction, in each case shall be accompanied by a prepayment premium equal to 1.00% of (i) the aggregate principal amount of the loans under the Term Loan Facility so prepaid, in the case of a voluntary prepayment, and (ii) the aggregate principal amount of the loans under the Term Loan Facility affected by such amendment or modification, in the case of an amendment or other modification of the Credit Agreement. For the avoidance of doubt, any Lender that has its loans under the Term Loan Facility prepaid as a result of the “yank-a-bank” provisions of the Facilities Documentation due to failure to consent to an amendment described in clause (b) above shall be entitled to such prepayment premium. “ Repricing Transaction ” means the prepayment or refinancing (other than in

 

12



 

 

 

connection with a change of control) of all or a portion of the loans under the Term Loan Facility concurrently with the incurrence by the Borrower or its subsidiaries of any term loan financing, in each case having a lower all-in yield (taking into account any original issue discount and upfront fees in respect of such financing and any pricing “floor” applicable thereto but excluding customary arrangement and commitment fees paid to arrangers thereof) than the all-in yield applicable to such loans.

 

 

 

 

 

All voluntary prepayments under the Term Loan Facility shall be applied to the remaining amortization payments under the Term Loan Facility as directed by the Borrower.

 

 

 

Facilities Documentation:

 

The definitive documentation for the Facilities (the “ Facilities Documentation ”) will be consistent with this Term Sheet and will contain only those conditions precedent, mandatory prepayments, representations and warranties, affirmative and negative covenants, financial covenants and events of default expressly set forth herein (subject only to the exercise of any “market flex” expressly provided in the Arranger Fee Letter) and, to the extent such terms are not expressly set forth herein, such terms will be negotiated in good faith.

 

 

 

Representations and Warranties:

 

Limited to the following (to be applicable to the Borrower and its restricted subsidiaries (or in the case of certain representations and warranties customarily applicable to all subsidiaries, all subsidiaries)): organization and powers; authorization, due execution and delivery and enforceability; governmental approvals and no conflicts (including no creation of liens); accuracy of financial statements; no material adverse change; ownership of properties; intellectual property; absence of actions, suits or proceedings; environmental matters; compliance with laws; sanctions and anti-corruption; Investment Company Act of 1940; Federal Reserve regulations; payment of taxes; compliance with ERISA; accuracy of information; subsidiaries; insurance; labor matters; solvency on a consolidated basis; delivery of certain documents; validity, perfection and priority of security interests in the Collateral (subject to the Limited Conditionality Provisions); and neither the Borrower nor any Guarantor is an EEA Financial Institution, in each case subject to customary qualifications and exceptions to be mutually

 

13



 

 

 

agreed upon.

 

 

 

Conditions Precedent to Initial Borrowing:

 

Limited to those set forth in the Conditions Exhibit and those under the heading “Conditions Precedent to All Borrowings” below.

 

 

 

Conditions Precedent to All Borrowings:

 

The making of each extension of credit shall be conditioned upon (a) the accuracy in all material respects (or, if already qualified by materiality, in all respects) of all representations and warranties (which, for purposes of the initial extensions of credit on the Closing Date and, in the case of any extension of credit under any Incremental Facility in connection with any acquisition or investment permitted under the Credit Agreement, if agreed by the lenders providing such Incremental Facility, shall be limited to the Specified Representations and the Specified Purchase Agreement Representations), (b) solely for extensions of credit after the Closing Date, there being no default or event of default in existence at the time of, or immediately after giving effect to the making of, such extension of credit (or, in the case of any extension of credit under any Incremental Facility in connection with any acquisition or investment permitted under the Credit Agreement, if agreed by the lenders providing such Incremental Facility, no payment or bankruptcy event of default) and (c) the delivery of a borrowing notice.

 

 

 

Affirmative Covenants:

 

Limited to the following (to be applicable to the Borrower and its restricted subsidiaries (or in the case of certain affirmative covenants customarily applicable to all subsidiaries, all subsidiaries): delivery of audited annual consolidated financial statements for the Borrower, unaudited quarterly consolidated financial statements for the Borrower and other financial information (including, to the extent the same is not already included in the Borrower’s public disclosure for an applicable fiscal period, customary management’s discussion and analysis with respect to such fiscal period) and other information; quarterly lender calls (provided such calls shall not be required to the extent the Borrower hosts a public call for its investors with respect to such quarter); delivery of notices of default, litigation, material adverse change and other material matters; maintenance of corporate existence and rights and conduct of business; payment of taxes; maintenance of properties; maintenance of customary insurance; maintenance and inspection by the

 

14



 

 

 

Administrative Agent of property and books and records; compliance with laws (including environmental laws); ERISA; use of proceeds and letters of credit; commercially reasonable efforts to maintain public ratings; sanctions and anti-corruption; additional subsidiaries; and further assurances, in each case subject to customary qualifications and exceptions to be mutually agreed upon.

 

 

 

Negative Covenants:

 

Limited to the following (to be applicable to the Borrower and its restricted subsidiaries):

 

 

 

 

 

(a) limitations on indebtedness;

 

 

 

 

 

(b) limitations on liens;

 

 

 

 

 

(c)  limitations on asset sales;

 

 

 

 

 

(d) limitations on mergers, consolidations and fundamental changes;

 

 

 

 

 

(e)  limitations on restricted payments (including with respect to certain indebtedness) and investments (including unlimited Permitted Acquisitions (to be defined in the Facilities Documentation) of entities that become Guarantors);

 

 

 

 

 

(f)  limitations on transactions with affiliates;

 

 

 

 

 

(g)  limitations on restrictions on liens and other restrictive agreements;

 

 

 

 

 

(h) limitations on amendments to certain agreements; and

 

 

 

 

 

(i)   limitation on changes in the fiscal year.

 

 

 

 

 

The negative covenants will be subject, in the case of each of the foregoing covenants, to exceptions, qualifications and “baskets” to be set forth in the Facilities Documentation which, in the case of certain monetary baskets, shall contain a “grower” component based on a percentage of Consolidated EBITDA equivalent to the initial monetary cap. Additionally, investments, acquisitions, redemptions, prepayments of restricted debt and other restricted payments shall include an exception based on an available basket amount (the “ Available

 

15



 

 

 

Amount Basket ”) equal to the following: (a) $25,000,000, plus (b) retained Excess Cash Flow plus (c) the net cash proceeds of equity issuances and capital contributions (other than disqualified equity) received by the Borrower and cash distributions received by the Borrower or a restricted subsidiary from any unrestricted subsidiary, plus (d) the net cash proceeds of debt and disqualified equity of the Borrower, in each case issued after the Closing Date, which have been exchanged or converted into qualified equity of the Borrower, plus (e) the net cash proceeds of sales of investments made under the Available Amount Basket (in an amount, together with amounts added pursuant to clause (f) below, not to exceed the amount of such investment made under the Available Amount Basket), plus (f) returns, profits, distributions and similar amounts received in cash or cash equivalents on investments made under the Available Amount Basket (in an amount, together with amounts added pursuant to clause (e) above, not to exceed the amount of such investment made under the Available Amount Basket). The Available Amount Basket may be used for, among other things, investments, acquisitions, redemptions or prepayments of restricted debt and other restricted payments; provided that, no default or event of default under the Facilities Documentation shall exist or result therefrom. Usage of the Available Amount Basket for redemptions or prepayments of restricted debt and other restricted payments shall be subject to the Total Net Leverage Ratio (as defined below), on a pro forma basis, not exceeding 5.00:1.00 (provided that this Total Net Leverage Ratio test shall not apply to the redemption or prepayment of any junior secured indebtedness funded with the proceeds of any common equity offering of the Borrower).

 

 

 

Financial Covenants:

 

Limited to the following:

 

 

 

 

 

With respect to the Term Loan Facility: None.

 

 

 

 

 

With respect to the Revolving Credit Facility:

 

 

 

 

 

(a) a maximum ratio of total consolidated indebtedness less Unrestricted Cash (as defined below) to Consolidated EBITDA (to be defined in a manner to be agreed) (the “ Total Net Leverage Ratio ”) of 6.00x to 1.00; provided such ratio shall step down to (i) 5.75 to 1.00 on and after

 

16



 

 

 

March 31, 2019; (ii) 5.50 to 1.00 on and after September 30, 2019; (iii) 5.00 to 1.00 on and after March 31, 2020; (iv) 4.50 to 1.00 on and after September 30, 2020; and (v) 4.00 to 1.00 on and after March 31, 2021. For purposes of this paragraph, “Unrestricted Cash” shall mean the lesser of (x) any unrestricted cash or cash equivalents of the Borrower and the Guarantors and (y) $50,000,000; and

 

 

 

 

 

(b) a minimum ratio of Consolidated EBITDA to cash interest expense (the “ Interest Coverage Ratio ”) of 2.75 to 1.00, stepping up to 3.00 to 1.00 on the last day of the first fiscal quarter ended on or after the date that is 24 months after the Closing Date.

 

 

 

 

 

Lenders holding more than 50% of the aggregate amount of the commitments under the Revolving Credit Facility (excluding the commitments of defaulting Lenders, the “ Requisite Revolving Lenders ”) may amend the definitions related to such covenants, amend or waive the terms of such covenants and waive, amend, terminate or otherwise modify such covenants with respect to the occurrence of an event of default.

 

 

 

 

 

Consolidated EBITDA will include an addback for factually supportable cost savings and synergies in connection with the Transactions as certified in good faith by the chief financial officer of the Borrower to the extent reasonably expected to be achieved within 18 months of the Closing Date (without duplication of achieved cost savings); provided that such amount added back in any period shall not exceed a percentage of Consolidated EBITDA to be agreed for such period (prior to giving effect to such addback).

 

 

 

Unrestricted Subsidiaries:

 

The Credit Agreement will contain provisions pursuant to which, subject to limitations to be agreed (including on loans, advances, guarantees and other investments in unrestricted subsidiaries, and transactions with affiliates), the Borrower will be permitted to designate any existing or subsequently acquired or organized subsidiary as an “unrestricted subsidiary” and subsequently re-designate any such unrestricted subsidiary as a restricted subsidiary so long as (w) no default or event of default then exists or would result therefrom, (x) after giving effect to any such designation or re-designation the Borrower shall be in pro forma compliance with the financial covenants

 

17



 

 

 

recomputed as of the last day of the most recently ended fiscal quarter of the Borrower for which financial statements have been delivered, (y) the designation of any unrestricted subsidiary as a restricted subsidiary shall constitute the incurrence at the time of designation of any indebtedness or liens of such subsidiary existing at such time and (z) the fair market value of such subsidiary at the time it is designated as an “unrestricted subsidiary” shall be treated as an investment by the Borrower at such time. Unrestricted subsidiaries will not be subject to the representation and warranties, affirmative or negative covenant or event of default provisions of the Credit Agreement (other than certain representation and warranties and affirmative covenants customarily applicable to all subsidiaries) and the results of operations and indebtedness of unrestricted subsidiaries will not be taken into account for purposes of determining compliance with any financial ratio or financial covenant contained in the Credit Agreement.

 

 

 

Events of Default:

 

Limited to the following (to be applicable to the Borrower and its restricted subsidiaries): nonpayment of principal, interest, fees or other amounts; inaccuracy of representations and warranties; violation of covenants ( provided that, with respect to the financial covenants described under the heading “Financial Covenants” above, a breach thereof shall only result in an event of default under the Term Loan Facility after the Requisite Revolving Lenders have terminated the Revolving Credit Facility and accelerated any loans outstanding thereunder); cross default; voluntary and involuntary bankruptcy or insolvency proceedings; inability to pay debts as they become due; material judgments; ERISA events; actual or asserted invalidity of the Guarantees or the documentation in respect of the Collateral; and Change in Control (to be defined in a manner to be mutually agreed upon), in each case with customary grace periods, qualifications and exceptions to be mutually agreed upon.

 

 

 

Voting:

 

Except as provided above with respect to the financial covenants, amendments and waivers of the Credit Agreement and the other Facilities Documentation will require the approval of Lenders holding more than 50% of the aggregate amount of the extensions of credit and unused commitments under the Facilities, except that

 

18



 

 

 

(a) the consent of each Lender directly and adversely affected thereby shall be required with respect to, among other things, (i) increases in commitments, (ii) reductions of principal (it being understood that a waiver of any condition precedent or the waiver of any default, event of default or mandatory prepayment shall not constitute a reduction in principal), interest (other than a waiver of default interest) or fees, (iii) extensions of scheduled amortization, final maturity or reimbursement dates or postponement of any payment dates and (iv) modifications to the pro-rata sharing and “waterfall” provisions and (b) the consent of 100% of the Lenders shall be required with respect to (i) modifications to any of the voting percentages, (ii) releases of all or substantially all the Collateral (other than in connection with any sale of the applicable Collateral permitted by the Credit Agreement) and (iii) releases of all or substantially all the value of the guarantees provided by the subsidiaries of the Borrower (other than in connection with any sale of the applicable Guarantor permitted by the Credit Agreement). Notwithstanding the foregoing and for the avoidance of doubt, changes to the Facilities Documentation as a result of the exercise of the “flex” provisions of the Arranger Fee Letter shall only require the consent of the Borrower and the Administrative Agent.

 

 

 

 

 

The Credit Agreement will contain customary amend and extend and “yank-a-bank” provisions to be mutually agreed upon.

 

 

 

Cost and Yield Protection:

 

Usual for facilities and transactions of this type (it being agreed that the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines or directives promulgated thereunder or issued in connection therewith, and all requests, rules, guidelines or directives promulgated by the Bank for International Settlement, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States of America or foreign regulatory authorities, in each case pursuant to Basel III, in each case will be deemed to be a “change in law”, regardless of the date enacted, adopted, promulgated or issued, for purposes of such cost and yield protections).

 

 

 

Assignments and

 

The Lenders will be permitted to assign all or a portion of

 

19



 

Participations:

 

their loans and commitments (other than to a natural person) with the consent (such consent not to be unreasonably withheld or delayed) of (a) the Borrower (unless an event of default has occurred and is continuing or such assignment is to a Lender, an affiliate of a Lender or an Approved Fund (to be defined in a manner to be mutually agreed upon)); provided that the Borrower shall be deemed to have consented to a proposed assignment of loans or commitments if the Borrower has not responded to such proposal within seven business days after the Borrower has received notice thereof, (b) the Administrative Agent (unless such assignment is an assignment of a loan under the Term Loan Facility to a Lender, an affiliate of a Lender or an Approved Fund) and (c) the Swingline Lender and each Issuing Bank (unless such assignment is an assignment of a loan under the Term Loan Facility), in each case which consent shall not be unreasonably withheld. Each assignment (except to other Lenders or their affiliates) will be in a minimum amount of (a) $5,000,000 in respect of loans and commitments under the Revolving Credit Facility and (b) $1,000,000 in respect of loans and commitments under the Term Loan Facility, unless otherwise agreed by the Borrower (unless an event of default has occurred and is continuing) and the Administrative Agent. The Administrative Agent will receive a processing and recordation fee of $3,500, payable by the assignor and/or the assignee, with each such assignment. Assignments will be by novation and will not be required to be pro rata among the Facilities.

 

 

 

 

 

Assignments of loans under the Term Loan Facility to the Borrower and its subsidiaries shall be permitted so long as:

 

 

 

 

 

(i) any offer to purchase or take by assignment any loans under the Term Loan Facility by the Borrower and its subsidiaries shall have been made to all Lenders pro rata (with buyback mechanics to be mutually agreed upon);

 

 

 

 

 

(ii) no default or event of default has occurred and is continuing or would result therefrom;

 

 

 

 

 

(iii) the loans purchased are immediately canceled (with customary restrictions on increasing EBITDA

 

20



 

 

 

by any non-cash gains associated with such cancellation of debt); and

 

 

 

 

 

(iv) no proceeds from any extensions of credit under the Revolving Credit Facility shall be used to fund such assignments.

 

 

 

 

 

The Lenders will be permitted to sell participations in loans and commitments without restriction. Participants shall have the same benefits as the Lenders with respect to yield protection and increased cost provisions. Voting rights of participants shall be limited to matters that require the consent of all Lenders or all affected Lenders.

 

 

 

 

 

Pledges of loans in accordance with applicable law shall be permitted without restriction. Promissory notes shall be issued under the Facilities only upon request.

 

 

 

Expenses and Indemnification:

 

All reasonable and documented out-of-pocket expenses of the Administrative Agent, the Syndication Agent, the Arrangers and their respective affiliates (including, without limitation, the reasonable fees, charges and disbursements of counsel for any of the foregoing) associated with the structuring, arrangement and syndication of the Facilities and the preparation, negotiation, execution, delivery and administration of the Credit Agreement and the other Facilities Documentation and any amendments, modifications and waivers thereof (which, in the case of preparation, negotiation, execution, delivery and administration of the Credit Agreement and other Facilities Documentation shall be limited to a single counsel for such persons and one local counsel in each jurisdiction as the Administrative Agent shall deem advisable in connection with the creation and perfection of security interests in the Collateral), as well as all reasonable and documented out-of-pocket expenses incurred by the Issuing Banks in connection with the issuance, amendment, renewal or extension of letters of credit or any demand for payment thereunder, are to be paid by the Borrower. In addition, all out-of-pocket expenses of the Administrative Agent, the Issuing Banks and the Lenders (including, without limitation, the reasonable and documented out-of-pocket fees, charges and disbursements of counsel for any of the foregoing) for enforcement costs associated with the Facilities are to be

 

21



 

 

 

paid by the Borrower.

 

 

 

 

 

The Borrower will indemnify the Arrangers, the Administrative Agent, the Syndication Agent, the Issuing Banks, the Lenders and their respective affiliates and each of their respective Related Parties (each, an “ indemnified person ”) and hold them harmless from and against all losses, claims, damages, liabilities and related expenses (including, without limitation, the fees, charges and disbursements of one firm of counsel for all such indemnified persons, taken as a whole, and, if necessary, of a single firm of local counsel in each appropriate jurisdiction (which may include a single firm of special counsel acting in multiple jurisdictions) for all such indemnified persons, taken as a whole (and, in the case of an actual or perceived conflict of interest where the indemnified person affected by such conflict informs the Borrower of such conflict and thereafter retains its own counsel, of another firm of counsel for such affected indemnified person and, if necessary, of a single firm of local counsel in each appropriate jurisdiction (which may include a single firm of special counsel acting in multiple jurisdictions) for such affected indemnified person)) of any such indemnified person arising out of, in connection with or as a result of the Transactions, including, without limitation, the financings contemplated thereby, or any transactions connected therewith or any claim, litigation, investigation or proceeding (regardless of whether any such indemnified person is a party thereto and regardless of whether such claim, litigation, investigation or proceeding is brought by a third party or by the Borrower or any of its subsidiaries) that relate to any of the foregoing; provided that the foregoing indemnity will not, as to any indemnified person, apply to losses, claims, damages, liabilities and related expenses to the extent they (a) are found in a final and non-appealable judgment of a court of competent jurisdiction to have resulted from the bad faith, willful misconduct or gross negligence of such indemnified person, (b) result from a claim brought by the Borrower or any of its subsidiaries against such indemnified person for material breach of such indemnified person’s obligations hereunder if the Borrower or such subsidiary has obtained a final and non-appealable judgment in its or its subsidiary’s favor on such claim as determined by a court of competent jurisdiction or (c) result from a proceeding that does not

 

22



 

 

 

involve an act or omission by the Borrower or any of its affiliates and that is brought by an indemnified person against any other indemnified person (other than claims against any arranger, bookrunner or agent in its capacity or in fulfilling its roles as an arranger, bookrunner or agent hereunder or any similar role with respect to the Facilities). No party to the Facilities Documentation shall be liable for any special, indirect, consequential or punitive damages in connection with the Facilities or the Transactions; provided that, nothing contained in this sentence shall limit the Borrower’s indemnity and reimbursement obligations to the extent set forth in this paragraph. Notwithstanding the foregoing, each indemnified person shall be obligated to refund and return promptly any and all amounts paid by the Borrower for any loss, claim, expense, damage or liability with respect to which such indemnified person was not entitled to payment in accordance with the terms of the Credit Agreement (in a final and non-appealable judgment of a court of competent jurisdiction). “ Related Parties ” means, with respect to any person, the directors, officers, employees, agents, advisors, representatives and controlling persons of such person.

 

 

 

Defaulting Lenders:

 

The Credit Agreement shall contain customary provisions relating to “defaulting” Lenders (including, without limitation, provisions relating to providing cash collateral to support letters of credit and swingline loans, the suspension of voting rights and rights to receive interest and fees, and assignment of commitments or loans of such Lenders).

 

 

 

Bail-In:

 

The Facilities Documentation shall contain customary “EU-Bail In” provisions.

 

 

 

Governing Law and Forum:

 

New York.

 

 

 

Counsel to Administrative Agent and Arrangers:

 

Simpson Thacher & Bartlett LLP.

 

23



 

ANNEX I

 

Interest Rates:

 

The interest rates under the Facilities will be as follows:

 

 

 

 

 

Revolving Credit Facility

 

 

 

 

 

At the option of the Borrower, a per annum rate of Adjusted LIBOR plus 2.25% or ABR plus 1.25%, subject to two Total Net Leverage Ratio based step-downs to be agreed; provided , however , that all swingline loans shall bear interest based upon the ABR.

 

 

 

 

 

Term Loan Facility

 

 

 

 

 

At the option of the Borrower, the Term Loans shall accrue interest at either Adjusted LIBOR plus 4.00% or ABR plus 3.00%.

 

 

 

 

 

All Facilities

 

 

 

 

 

The Borrower may elect interest periods of 1, 2, 3 or 6 months (or, to the extent available to the applicable Lenders, 12 months) for Adjusted LIBOR borrowings.

 

 

 

 

 

Calculation of interest shall be on the basis of actual days elapsed in a year of 360 days (or 365 or 366 days, as applicable, in the case of ABR loans based on the Prime Rate) and interest shall be payable at the end of each interest period and, in any event, at least every 3 months.

 

 

 

 

 

ABR is the Alternate Base Rate, which is the highest of (i) JPMorgan’s prime rate, (ii) the greater of the federal funds effective rate and the overnight bank funding rate published by the Federal Reserve Bank  of New York plus ½ of 1.00% and (iii) the Adjusted LIBOR for a one-month interest period plus 1.00%.  For the avoidance of doubt, if ABR shall be less than zero, such rate shall be deemed to be zero; provided , however , that notwithstanding the rate calculated in accordance with the foregoing, at no time shall the ABR for the Term Loan Facility be less than 2.00% per annum.

 

 

 

 

 

Adjusted LIBOR will at all times include statutory reserves and if LIBOR shall be less than zero, such rate shall be deemed to be zero; provided , however , that notwithstanding the foregoing, at no time shall LIBOR with respect to the Term Loan Facility be less than 1.00% per annum.

 

 

 

Letter of Credit Fee:

 

A per annum fee equal to the spread over Adjusted LIBOR under the Revolving Credit Facility will accrue on the aggregate face amount of outstanding letters of credit under

 



 

 

 

the Revolving Credit Facility, payable in arrears at the end of each quarter and upon the termination of the Revolving Credit Facility, in each case for the actual number of days elapsed over a 360-day year.  Such fees shall be distributed to the Lenders participating in the Revolving Credit Facility pro rata in accordance with the amount of each such Lender’s Revolving Credit Facility commitment.  In addition, the Borrower shall pay to each Issuing Bank, for its own account, (a) a fronting fee of 0.125% per annum on the aggregate face amount of outstanding letters of credit issued by such Issuing Bank, payable in arrears at the end of each quarter and upon the termination of the Revolving Credit Facility, in each case for the actual number of days elapsed over a 360-day year, and (b) customary issuance and administration fees.

 

 

 

Commitment Fees:

 

0.40% per annum, subject to two Total Net Leverage Ratio based step-downs to be agreed, on the undrawn portion of the commitments in respect of the Revolving Credit Facility, commencing to accrue on the Closing Date and payable quarterly in arrears after the Closing Date.  For purposes of calculating the commitment fee, outstanding swingline loans will be deemed not to utilize the Revolving Credit Facility commitments.

 

 

 

 

 

For the avoidance of doubt, all calculations of interest and fees in respect of the Facilities will be calculated on the basis of their full stated principal amount.

 

2



 

EXHIBIT B

 

Project Duke
Summary of Additional Conditions Precedent(2)

 

The initial borrowings under the Facilities shall be subject to the following conditions precedent:

 

1.                                       The Acquisition shall have been consummated in compliance with the Purchase Agreement prior to or substantially simultaneously with the closing of the Facilities in accordance with applicable law and the Purchase Agreement and all other related documentation shall not have been amended, consented to or waived in any manner materially adverse to the Lenders unless consented to in writing by the Arrangers (such consent not to be unreasonably withheld or delayed); provided that, (i) any reduction in purchase price by not more than 10% will not be deemed to be materially adverse to the interests of the Lenders if such purchase price reduction shall ratably reduce the equity issuance to Seller and funded debt on the Closing Date under the Facilities; (ii) any amendment or waiver to the terms of the Purchase Agreement that has the effect of increasing the cash consideration required to be paid thereunder on the Closing Date will not be deemed to be materially adverse to the Lenders if such increase is funded with an increase in the aggregate amount of the equity issuance required by the terms thereof; (iii) any amendment, modification or waiver to the definition of “Material Adverse Effect” or “Material Adverse Change” in the Purchase Agreement will be deemed materially adverse to the Lenders; (iv) any amendment, modification or waiver to Sections 10.8, 10.12, 10.13, 10.14, 10.15, 10.16 or 10.17 of the Purchase Agreement will be deemed materially adverse to the Lenders; and (v) decreases in purchase price by more than 10% will be deemed materially adverse to the Lenders.  The Specified Purchase Agreement Representations and the Specified Representations shall be true and correct in all material respects (or if already qualified by materiality,  material adverse effect or similar qualification, in all respects) on, or as of, the Closing Date (except in the case of any Specified Purchase Agreement Representation or Specified Representation which expressly relates to a given date or period, which such representation and warranty shall be true and correct in all material respects as of the respective date or for the respective period, as the case may be).

 

2.                                       Since November 15, 2017, there has not occurred, a Company Material Adverse Effect (as defined below, and with capitalized terms used in such definition having the meanings ascribed to them in the Purchase Agreement (as in effect on the date hereof)).

 

Company Material Adverse Effect ” shall mean any change, effect, event or occurrence that, individually or in the aggregate, (a) does, or would be reasonably expected to, prevent or materially impair, delay or affect the ability of the Company or the Blocker Sellers to consummate the Transactions or (b) has had or would reasonably be expected to have a material adverse effect on the business, assets, liabilities, condition (financial or

 


(2)  All capitalized terms used but not defined herein shall have the meanings set forth in the Commitment Letter to which this Exhibit B is attached, including the other exhibits thereto.

 



 

otherwise) or results of operations of the Company and the Subsidiary taken as a whole; provided, however, that in the case of this clause (b), none of the following shall be deemed in themselves to constitute a Material Adverse Effect and excluding any change, effect, event or occurrence arising from the following: (i) the announcement or pendency or consummation of the Transactions, including any related losses or threatened losses of employees, customers, suppliers, distributors or others having relationships with the Company; (ii) any change, effect, event or occurrence in any industry in which the Company participates, the U.S. economy or any other economy where the Company conducts business (in each case, as a whole) or the capital, banking or financing markets in general or the markets in which the Company operates or any geographical area in which the Company conducts its business; (iii) any “act of God” including weather, natural disasters and earthquakes, hostilities, acts of war, sabotage or terrorism or military actions or any escalation or material worsening of any such hostilities, acts of war, sabotage or terrorism or military actions; (iv) any change in global, national or regional political conditions; (v) changes after the date hereof in GAAP or any change in any applicable Laws, rules or regulations issued by any Governmental Entity; (vi) any failure, in and of itself, by the Company to meet any internal projections or forecasts for any period ending on or after the date of the Purchase Agreement (but not the change, effect, event or occurrence underlying, causing or contributing to such failure to the extent such change, effect, event or occurrence would otherwise constitute or contribute to a Material Adverse Effect under this definition); (vi) any existing event or occurrence or circumstance of which the Purchaser has actual knowledge on the date hereof as a result of such existing event or occurrence or circumstance having been expressly disclosed in reasonable detail in the Disclosure Schedules; or (vii) any action taken by a party hereto as expressly required by the Purchase; except, in the case of the foregoing clauses (ii) through (v), any change, effect, event or occurrence that has a material disproportionate effect on the Company or the Subsidiary or the business, assets, liabilities, condition (financial or otherwise) or results of operations of the Company or the Subsidiary as compared to other participants in the industry in which the Company or the Subsidiary operate.

 

3.                                       The Existing Indebtedness Refinancing and the Equity Issuance to Seller (in an aggregate amount at least equal to that set forth in the Purchase Agreement as in effect on the date hereof) shall have occurred or shall occur substantially simultaneously with the closing of the Facilities.

 

4.                                       The Lenders shall have received (a) audited consolidated balance sheets and related statements of income, stockholders’ equity and cash flows of the Borrower for the three most recently completed fiscal years ended at least 90 days prior to the Closing Date and (b) unaudited consolidated balance sheets and related statements of income, stockholders’ equity and cash flows of the Borrower for each subsequent fiscal quarter ended at least 45 days before the Closing Date (and comparable periods for the prior fiscal year), provided that if requested by the Arrangers and solely to the extent available to the Borrower, such unaudited quarterly financial statements for the fourth fiscal quarter of 2017 of the Borrower shall also be required to be provided; provided further that the filing of the required financial statements on Form 10-K and Form 10-Q within such time periods by the Borrower will satisfy the requirements of this paragraph 4.

 

2



 

5.                                       The Lenders shall have received (a) audited consolidated financial statements of the Target consisting of a consolidated balance sheet as of December 31, 2016 and the related consolidated statements of income and retained earnings, shareholders’ equity and cash flows for the period beginning August 17, 2016 through December 31, 2016 and (b) unaudited consolidated financial statements of the Target consisting of (i) a consolidated balance sheet as of December 31, 2015 and the related financial statements for the fiscal year ended December 31, 2015, (ii) a consolidated balance sheet as of October 31, 2016 and the related financial statements for the ten month period beginning January 1, 2016 through October 31, 2016, and (iii) a consolidated balance sheet as of September 30, 2017 and the related financial statements for the nine month period beginning January 1, 2017 through September 30, 2017 (or, in lieu thereof, a quality of earnings report in form reasonably satisfactory to the Arranger for the Target’s fiscal year 2015, 2016 and the first three quarters of 2017).

 

6.                                       The Lenders shall have received a pro forma consolidated balance sheet of the Borrower and its subsidiaries as of the last day of the most recent fiscal period for which financial statements were delivered under paragraph 4 above, prepared after giving effect to the Transactions and the other transactions contemplated hereby.

 

7.                                       The Lenders shall have received a certificate from the chief financial officer of the Borrower in substantially the form of Annex II hereto confirming the solvency of the Borrower and its subsidiaries on a consolidated basis after giving effect to the Transactions and the other transactions contemplated hereby.

 

8.                                       The Administrative Agent shall have received, at least five business days prior to the Closing Date, all documentation and other information required by regulatory authorities under applicable “know your customer” and anti-money laundering rules and regulations, including, without limitation, the Patriot Act, in each case requested at least ten business days prior to the Closing Date.

 

9.                                       All fees required to be paid by the Borrower on the Closing Date pursuant to the Fee Letters and the Term Sheet and the reasonable and documented out-of-pocket expenses required to be reimbursed by the Borrower on the Closing Date pursuant to the Commitment Letter shall, upon the initial borrowing under the Facilities, have been paid (which amounts may be offset against the proceeds of the Facilities).

 

10.                                The Administrative Agent shall have received (a) copies of the Facilities Documentation executed by you and all documents and instruments required to create or perfect the Administrative Agent’s security interest, on behalf of the Lenders and the other Secured Parties (to be defined in a manner to be mutually agreed upon), in the Collateral (in proper form for filing), which shall, in each case, be consistent with the Commitment Letter and the Term Sheet and subject to the Limited Conditionality Provisions and (b) customary legal opinions, customary evidence of authorization, customary officer’s and secretary’s certificates, good standing certificates (to the extent applicable) and customary lien searches.

 

3



 

11.                                The Facilities shall have received a rating and the Borrower (on a pro forma basis for the Transactions) shall have received a public corporate credit rating and a public corporate family rating, in each case, from Standard & Poor’s Financial Services LLC and Moody’s Investors Service, Inc.

 

4



 

Annex I to EXHIBIT B

 

Form of Solvency Certificate

 

Date:                , 201[]

 

To the Administrative Agent and each of the Lenders party to the Credit Agreement referred to below:

 

I, the undersigned, the Chief Financial Officer of Diplomat Pharmacy, Inc. (the “ Borrower ”), in that capacity only and not in my individual capacity (and without personal liability), do hereby certify as of the date hereof, and based upon facts and circumstances as they exist as of the date hereof (and disclaiming any responsibility for changes in such facts and circumstances after the date hereof), that:

 

1.             This certificate is furnished to the Administrative Agent and the Lenders pursuant to Section [ · ] of the Credit Agreement, dated as of [ · ], 201[ ] (as the same may be amended, supplemented, amended and restated or otherwise modified from time to time, the “ Credit Agreement ”), among [ · ]. Unless otherwise defined herein, capitalized terms used in this certificate shall have the meanings set forth in the Credit Agreement.

 

2.             For purposes of this certificate, the terms below shall have the following definitions:

 

(a)           “Fair Value”

 

The amount at which the assets (both tangible and intangible), in their entirety, of the Borrower and its Subsidiaries taken as a whole would change hands between a willing buyer and a willing seller, within a commercially reasonable period of time, each having reasonable knowledge of the relevant facts, with neither being under any compulsion to act.

 

(b)           “Present Fair Salable Value”

 

The amount that could be obtained by an independent willing seller from an independent willing buyer if the assets (both tangible and intangible) of the Borrower and its Subsidiaries taken as a whole are sold on a going concern basis with reasonable promptness in an arm’s-length transaction under present conditions for the sale of comparable business enterprises insofar as such conditions can be reasonably evaluated.

 

(c)           “Stated Liabilities”

 

The recorded liabilities (including contingent liabilities that would be recorded in accordance with GAAP) of the Borrower and its Subsidiaries taken as a whole, as of the date hereof after giving effect to the consummation of the Transactions (including the execution and delivery of the Credit Agreement, the making of the Loans and the use of proceeds of such Loans on the date hereof), determined in accordance with GAAP consistently applied.

 



 

(d)           “Identified Contingent Liabilities”

 

The maximum estimated amount of liabilities reasonably likely to result from pending litigation, asserted claims and assessments, guaranties, uninsured risks and other contingent liabilities of the Borrower and its Subsidiaries taken as a whole after giving effect to the Transactions (including the execution and delivery of the Credit Agreement, the making of the Loans and the use of proceeds of such Loans on the date hereof) (including all fees and expenses related thereto but exclusive of such contingent liabilities to the extent reflected in Stated Liabilities), as identified and explained in terms of their nature and estimated magnitude by responsible officers of the Borrower.

 

(e)           “Can pay their Stated Liabilities and Identified Contingent Liabilities as they mature”

 

The Borrower and its Subsidiaries taken as a whole after giving effect to the Transactions (including the execution and delivery of the Credit Agreement, the making of the Loans and the use of proceeds of such Loans on the date hereof) have sufficient assets and cash flow to pay their respective Stated Liabilities and Identified Contingent Liabilities as those liabilities mature or (in the case of contingent liabilities) otherwise become payable.

 

(f)            “Do not have Unreasonably Small Capital”

 

The Borrower and its Subsidiaries taken as a whole after giving effect to the Transactions (including the execution and delivery of the Credit Agreement, the making of the Loans and the use of proceeds of such Loans on the date hereof) have sufficient capital to ensure that it is a going concern.

 

3.             For purposes of this certificate, I, or officers of the Borrower under my direction and supervision, have performed the following procedures as of and for the periods set forth below.

 

(a)           I have reviewed the financial statements (including the pro forma financial statements) referred to in Section [ · ] of the Credit Agreement.

 

(b)           I have knowledge of and have reviewed to my satisfaction the Credit Agreement.

 

(c)           As chief financial officer of the Borrower, I am familiar with the financial condition of the Borrower and its Subsidiaries.

 

4.             Based on and subject to the foregoing, I hereby certify on behalf of the Borrower that after giving effect to the consummation of the Transactions (including the execution and delivery of the Credit Agreement, the making of the Loans and the use of proceeds of such Loans on the date hereof), (i) each of the Fair Value and the Present Fair Salable Value of the assets of the Borrower and its Subsidiaries taken as a whole exceed their Stated Liabilities and Identified Contingent Liabilities; (ii) the Borrower and its Subsidiaries taken as a whole do not have Unreasonably Small Capital; and (iii) the Borrower and its Subsidiaries taken as a whole can pay their Stated Liabilities and Identified Contingent Liabilities as they mature.

 

2



 

IN WITNESS WHEREOF, the Borrower has caused this certificate to be executed on its behalf by the Chief Financial Officer as of the date first written above.

 

 

DIPLOMAT PHARMACY, INC.

 

 

 

By:

 

 

Name:

 

 

 

Title:

Chief Financial Officer

 


Exhibit 99.1

 

 

FOR IMMEDIATE RELEASE:

 

INVESTOR CONTACT

Nov. 15, 2017

 

Bob East, Westwicke Partners

 

 

443.213.0500 | diplomat@westwicke.com

 

 

 

 

 

MEDIA CONTACT

 

 

Jenny Cretu, Senior Vice President,

 

 

Pharma Services and Marketing

 

 

810.768.9370 | jcretu@diplomat.is

 

Diplomat to Acquire LDI Integrated Pharmacy Services

 

The nation’s largest independent provider of specialty pharmacy services will add a pharmacy benefit manager, accelerating its evolution to a broader health care company.

 

FLINT, Mich. — Diplomat Pharmacy, Inc. (NYSE: DPLO), has entered into a definitive agreement to acquire Leehar Distributors, LLC, doing business as LDI Integrated Pharmacy Services (LDI). The transaction is expected to close in 30—60 days.

 

For more information about the transaction, click here.

 

Diplomat will discuss its acquisition on a conference call at 5 p.m. ET Wednesday, Nov. 15. Listen to a live broadcast by calling 833.286.5805 (647.689.4450 for international callers) and using participant code 1788088. A recording of the conference call will be available for approximately 90 days on the investor relations section of Diplomat’s website at ir.diplomat.is.

 

LDI Integrated Pharmacy Services is a full-service pharmacy benefit manager (PBM) based in St. Louis, Missouri. LDI’s service offering includes URAC—accredited mail-order and specialty pharmacies, a national network of retail pharmacies, and comprehensive clinical programs.

 

Diplomat announced its first PBM acquisition of National Pharmaceutical Services (NPS) on Nov. 6. The acquisition of NPS gives Diplomat a proprietary claims-processing system, as well as PBM capabilities. The acquisition of LDI positions Diplomat to take a strategic leap forward, becoming a highly differentiated specialty company and giving health care payors access to a robust specialty platform to manage this high-cost, fast-growing component of pharmacy benefits.

 

“Bringing on LDI is an even bigger step as Diplomat evolves from a specialty pharmacy provider to a broader health care company,” said Phil Hagerman, CEO and chairman of Diplomat.

 



 

“LDI expands Diplomat’s ability to meet growing demand from small and midsize health insurers, third-party administrators, and self-insured organizations. We can give payors access to a robust specialty platform to manage this high-cost, fast-growing component of pharmacy benefits.”

 

LDI dramatically increases the scope of Diplomat’s PBM capabilities, Hagerman said.

 

“We now field a leadership team with decades of PBM and specialty experience,” he said. “The combined company will have the enhanced ability to serve middle-market payors hungry for a service model that helps patients achieve optimal well-being with complex therapies while delivering cost-containment strategies that impact pharmacy costs under both the medical and pharmacy benefit.”

 

Len Dino, CEO of LDI, said LDI’s strong clinical foundation and long commitment to providing high-quality patient care align nicely with Diplomat.

 

“We see further opportunities to help health care payors rein in rising pharmacy costs,” Dino said. “With the added resources of Diplomat, LDI can make a dramatic impact for our clients while increasing members’ access to life-saving therapies. We’ll continue to build upon our 50-year legacy of transforming how pharmacy care is delivered.”

 

Cost management within pharmacy benefits has evolved considerably over the past 10 years, said Diplomat President Joel Saban.

 

“With 90 percent of traditional medications now filled as generics, it’s specialty pharmacy costs that are driving pharmacy spend for payors,” Saban said. “To offer real solutions to today’s challenges, a new model with a diverse set of assets is needed. The need for specialty benefit management solutions has never been more urgent. Deep clinical expertise across therapeutic categories, a network of home infusion providers, advanced data analytics platforms, and trusted industry relationships are all critical.”

 

Saban said Diplomat has rights to dispense more limited-distribution drugs—approximately 100—than any other independent specialty pharmacy.

 

“This access positions us to provide an enhanced breadth of service to the LDI client base,” he said. “Authority to distribute these drugs requires extensive data collection and monitoring capabilities, proven patient support programs, and strong relationships with pharmaceutical manufacturers—all strengths of Diplomat.”

 

Albert Thigpen, chief operating officer of LDI, added, “Today’s pharmacy benefit market is underserved and in need of new solutions. The combined company will fill these gaps—creating synergy across specialty pharmacy, pharmacy benefits, and infusion therapy—and we’re excited to provide the missing link. With LDI’s leading-edge technology platform, we will educate and empower patients to better manage these complex therapies while bringing clients innovative approaches in specialty benefit management.”

 



 

Under the terms of the agreement, Diplomat will pay LDI $515 million cash and approximately $80 million in Diplomat common stock. LDI is expected to generate approximately $388 million in revenue and $41 million in adjusted EBITDA in 2017. The cash portion of the acquisition is expected to be funded by Diplomat’s new $795 million senior secured credit facility, the proceeds of which will also be used to terminate Diplomat’s outstanding credit facility.

 

Honigman Miller Schwartz and Cohn, LLP, and Quarles & Brady, LLP, acted as legal counsel to Diplomat. J.P. Morgan Securities LLC acted as Diplomat’s financial advisor and JPMorgan Chase Bank, N.A. and Capital One, National Association have provided committed financing for the transaction. Houlihan Lokey served as the exclusive financial adviser to LDI. Goodwin Procter, LLP, acted as LDI’s legal counsel.

 

Forward-Looking Statements

 

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance and may include the Company’s expectations regarding: the closing of the acquisition and the timing thereof; expected benefits of the acquisition; financing of the acquisition; developments and business strategies, and the financial and operational performance of the combined entities. The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. These risks and uncertainties include: the ability of the parties to consummate the acquisition on the terms set forth in the purchase agreement in a timely manner or at all; the ability to obtain governmental approvals; the occurrence of any event, change or other circumstances that could give rise to the termination of the purchase agreement; delays or difficulties in integrating the combined businesses; potential disruption of management’s attention from the Company’s ongoing business operations due to the acquisition; the effect of the announcement of the acquisition on the ability of the Company to maintain relationships with its customers, suppliers and others with whom it does business; the ability to achieve cost savings and operating synergies and the timing thereof. The foregoing transaction risks should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included herein and elsewhere, including “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended Dec. 31, 2016, and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.

 

Non-GAAP Information

 

We define Adjusted EBITDA as net income (loss) before interest expense, income taxes, depreciation and amortization, share-based compensation, change in fair value of contingent consideration and other merger and acquisition-related expenses, restructuring and impairment charges, and certain other items that we do not consider indicative of our ongoing operating performance.  Adjusted EBITDA is not in accordance with, or an alternative to, accounting principles generally accepted in the United States (“GAAP”).  In addition, this non-GAAP

 



 

measure is not based on any comprehensive set of accounting rules or principles.  You should be aware that in the future we may incur expenses that are the same as or similar to some of the adjustments in the press release, and we do not infer that our future results will be unaffected by unusual or non-recurring items.

 

We consider Adjusted EBITDA to be a supplemental measure of our operating performance.  We present Adjusted EBITDA because it is used by our Board of Directors and management to evaluate our operating performance.  Adjusted EBITDA is also used as a factor in determining incentive compensation, for budgetary planning and forecasting overall financial and operational expectations, for identifying underlying trends, and for evaluating the effectiveness of our business strategies.  Further, we believe it assists us, as well as investors, in comparing performance from period-to-period on a consistent basis.  Other companies in our industry may calculate Adjusted EBITDA differently than we do and these calculations may not be comparable to our Adjusted EBITDA metrics.

 

About Diplomat

 

Diplomat (NYSE: DPLO) is the nation’s largest independent provider of specialty pharmacy services—helping patients and providers in all 50 states. The company offers medication management programs for people with complex chronic diseases and delivers unique solutions for manufacturers, hospitals, payors, providers, and more. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information, visit diplomat.is.

 

About LDI Integrated Pharmacy Services

 

LDI Integrated Pharmacy Services was founded by pharmacists in 1967 and is a trusted partner for pharmacy benefit management. We serve hundreds of payor clients, including health insurers, third-party administrators, and self-insured organizations. LDI offers specialty and mail-order pharmacy dispensing; an extensive retail network; and comprehensive clinical programs to help plan members achieve their treatment goals. For more information, visit ldirx.com.

 

About Nautic Partners, LLC

 

Nautic is a middle-market private equity firm that focuses on three industries: healthcare, industrial products, and outsourced services. Nautic has completed 131 platform transactions over its 31-year history. Nautic’s strategy is to partner with management teams to accelerate the growth trajectory of its portfolio companies via add-on acquisitions, targeted operating initiatives, and increased management team depth. Nautic generally makes equity investments of $25 to $100 million. For more information, please visit www.nautic.com.

 

About OAK HC/FT

 

Oak HC/FT (http://oakhcft.com) is the premier venture growth-equity fund investing in Healthcare Information & Services (“HC”) and Financial Services Technology (“FT”). We are

 



 

focused on driving transformation in these industries by providing entrepreneurs and companies with strategic counsel, board-level participation, business plan execution and access to our extensive network of industry leaders.

 


Exhibit 99.2

Diplomat’s Acquisition of LDI Integrated Pharmacy Services Nov. 15, 2017

GRAPHIC

 


Proprietary and Confidential of Diplomat Pharmacy Inc. DISCLAIMERS

GRAPHIC

 


A COMPELLING COMBINATION LDI supports Diplomat’s long-term strategic priorities: Proprietary and Confidential of Diplomat Pharmacy Inc. Enables our payor partners to more effectively manage pharmacy cost trends Pharmacy benefit management is a natural extension of our core capabilities Addresses needs of growing middle-market segments Creates new earnings stream and further diversifies our business Combined companies accelerate our growth We believe this combination enables us to better support emerging trends in health care.

GRAPHIC

 


Proprietary and Confidential of Diplomat Pharmacy Inc. Target Purchase Price Consideration Anticipated Closing LDI TRANSACTION SUMMARY LDI Integrated Pharmacy Services (“LDI”) Full-service PBM with 2017E revenue of $388 million and 2017E adjusted EBITDA of $41 million $595 million gross purchase price Represents ~14.5x on gross purchase price $540 million adjusted purchase price ~$94 million tax shield (NPV ~$55 million) Represents ~13.2x post tax shield benefit $4-6 million of synergies in Year 1 Represents ~11.7x post synergies and post tax shield $515 million in cash Committed cash financing from a new $795 million credit facility provided by JPMorgan and Capital One ~$80 million in common stock, representing ~4.15 million shares Pro forma total leverage of ~4.6x LTM adjusted 2017 EBITDA; Expected to be between 2.0x-3.0x by mid 2019 Expected to be accretive to adjusted EPS in 2018 Expected to close in 30–60 days Subject to regulatory approval and other customary closing conditions

GRAPHIC

 


LDI VALUE PROPOSITION Proprietary and Confidential of Diplomat Pharmacy Inc. 1 Leading full-service middle-market PBM with 380,000 member lives 2 Founded and run by pharmacists since 1967 (recapitalized by Nautic Partners in 2016) 3 Dedicated book of commercial business primarily focused on self-funded employers and unions 4 Highly-diversified base of 300-plus clients, with no single client representing >4% of gross profits 5 Long track record of high client retention and robust financial growth 6 Full-service mail-order pharmacy, retail network, and specialty pharmacy 7 Seasoned management team with decades of PBM industry experience

GRAPHIC

 


STRONG RATIONALE FOR DIPLOMAT TO EXPAND IN THE PBM SECTOR Allows Diplomat to expand its specialty product offering using PBM levers Well-positioned with multiple service lines for evolving market needs in the middle-market space Strengthens Diplomat’s financial profile and substantially diversifies Diplomat’s EBITDA LDI and NPS combine to create a robust full-service middle-market PBM offering Complementary products, services, and solutions offer full platform for future scale and growth Well-defined integration strategy with early synergies Proprietary and Confidential of Diplomat Pharmacy Inc. Expanded capabilities accelerate growth and drive shareholder value.

GRAPHIC

 


LARGE AND GROWING MARKET OPPORTUNITY Proprietary and Confidential of Diplomat Pharmacy Inc. Source IGS $20B market opportunity in SME segment alone

GRAPHIC

 


DIFFERENTIATED TOTAL PHARMACY SOLUTION Specialty Pharmacy Full-Service PBM Cost-constant capability aligned with broader PBM theme Access to rebates and retail network PBM / specialty pharmacy cross-sell opportunities Specialty Infusion Expertise across broad range of specialty therapeutic categories Specialty infusion market has significant projected growth and higher margins Manufacturer Services Proven track record as a partner of choice for biotechnology and pharmaceutical manufacturers Superior services driven by unique clinical expertise Aligned Scaled High-Growth / Margin Diversified Access to 100+ LDDs High-touch, high-services solution in growth category Payor partnerships Proprietary and Confidential of Diplomat Pharmacy Inc.

GRAPHIC

 


STRONG TRACK RECORD OF GROWTH Proprietary and Confidential of Diplomat Pharmacy Inc. Revenue ($M) $296 $338 2015A 2016A ~$388 2017E CAGR +15% Member Lives (000s) $311 $366 2015A 2016A ~$388 2017E CAGR ~11% Adj. Scripts (millions) 3.5M 4.0M 2015A 2016A ~4.4M 2017E CAGR ~12% Adj. EBITDA ($M) $19 $26 2015A 2016A $41 2017E CAGR +47%

GRAPHIC

 


DIPLOMAT, NPS, AND LDI GENERATE REAL AND IMMEDIATE COST AND SALES SYNERGIES Near-term cost synergies YR 1 $4–6M 3 YR COMBINED $20–25M Substantial long-term revenue synergies Proprietary and Confidential of Diplomat Pharmacy Inc. NPS proprietary claims-processing platform will reduce ongoing processing fees Cross-leverage existing infrastructure to improve efficiencies Drug-purchasing efficiencies Increased access to LD drugs carried by Diplomat for immediate revenue increase Diplomat improved ability to deliver new integrated care model Specialty, mail-order, retail, and PBM services offer plan members more options Complementary service offerings of the combined business will help drive both specialty pharmacy and PBM customer wins

GRAPHIC

 


Scaled asset in middle market Serving all key customer types +855k lives 700+ customers Bringing best-in-class specialty pharmacy capabilities to underserved market Attractive partnership approach to manage formulary and drug costs High-touch/high-service DNA consistent with Diplomat Differentiated clinically, leveraging proprietary technology platform PBM PLATFORM WITH FULL SUITE OF CAPABILITIES Self-Funded Employers / Unions Medicare Part D / Managed Medicaid Workers’ Comp Transparent Pricing Traditional Pricing Owned Adjudication Platform Comprehensive/Competitive Network Direct Manufacturer Rebates High-Touch Services CUSTOMER EXPERIENCE KEY CAPABILITIES/ BUSINESS MODEL EXPERTISE LDI NPS DPLO’s PBM Capabilities Proprietary and Confidential of Diplomat Pharmacy Inc.

GRAPHIC

 


COMBINED NEW DIPLOMAT FINANCIAL SUMMARY Diplomat’s New PBM Deal Value $47M $540M1 $587M1 2017E Revenue $32M $388M $420M 2017E Adjusted EBITDA $5M $41M $46M Deal Multiple / Post Synergies2 9.4x 13.23x/11.74x 12.83x/11.54x Proprietary and Confidential of Diplomat Pharmacy Inc. Adjusted purchase price for present value of tax shield Assuming $5 million synergy Year 4 Multiple at adjusted price (includes tax shield) Multiple at adjusted price with synergy and present value of tax shield Mid-point of Diplomat 2017 guidance Summary Transaction Value For NPS and LDI Combined Pro Forma 2017E (excludes synergies) New Diplomat Revenues $4.5B5 $32M $388M $4.9B Adjusted EBITDA $100.5M5 $5M $41M $146.5M

GRAPHIC